Fungicidal azocyclic amides

ABSTRACT

Disclosed are compounds of Formulae 1, 1A, 1B and 1C including all geometric and stereoisomers, N-oxides, and salts thereof, 
     
       
         
         
             
             
         
       
     
     wherein
         R 1 , R 2 , R 4a1 , R 4a2 , A, A a , G, M, W, Z 1 , Z 3 , X, J, J 1  and n are as defined in the disclosure.       

     Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

FIELD OF THE INVENTION

This invention relates to certain carboxamides, their N-oxides, salts and compositions, and methods of their use as fungicides.

BACKGROUND OF THE INVENTION

The control of plant diseases caused by fungal plant pathogens is extremely important in achieving high crop efficiency. Plant disease damage to ornamental, vegetable, field, cereal, and fruit crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. Many products are commercially available for these purposes, but the need continues for new compounds which are more effective, less costly, less toxic, environmentally safer or have different sites of action.

World Patent Publication WO 05/003128 discloses thiazolylpiperidine derivatives of Formula i as MTP (Microsomal Triglyceride transfer Protein) inhibitors.

wherein

A is a radical selected from the radicals a1 and a2 below

and R¹, R², R^(2′), R³, R⁴ and R⁵ are as defined in the disclosure.

World Patent Publication WO 04/058751 discloses piperidinyl-thiazole carboxamide derivatives for altering vascular tone.

SUMMARY OF THE INVENTION

This invention relates to compounds of Formula 1 including all geometric and stereoisomers, N-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides:

wherein

-   -   R¹ is an optionally substituted phenyl, naphthalenyl or 5- or         6-membered heteroaromatic ring;     -   A is CHR¹⁵ or NR¹⁶;     -   R¹⁵ is H, halogen, cyano, hydroxy, —CHO, C₁-C₄ alkyl, C₂-C₄         alkenyl, C₂-C₄ alkynyl, C₁-C₄ haloalkyl, C₂-C₄ haloalkenyl,         C₂-C₄ haloalkynyl, C₂-C₄ alkoxyalkyl, C₂-C₄ alkylthioalkyl,         C₂-C₄ alkylsulfinylalkyl, C₂-C₄ alkylsulfonylalkyl, C₂-C₄         alkylcarbonyl, C₂-C₄ haloalkylcarbonyl, C₂-C₅ alkoxycarbonyl,         C₃-C₅ alkoxycarbonylalkyl, C₂-C₅ alkylaminocarbonyl, C₃-C₅         dialkylaminocarbonyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄         alkylthio, C₁-C₄ haloalkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄         haloalkylsulfinyl, C₁-C₄ alkylsulfonyl or C₁-C₄         haloalkylsulfonyl;     -   R¹⁶ is H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄         haloalkyl, C₂-C₄ haloalkenyl, C₂-C₄ haloalkynyl, C₂-C₄         alkoxyalkyl, C₂-C₄ alkylthioalkyl, C₂-C₄ alkylsulfinylalkyl,         C₂-C₄ alkylsulfonylalkyl, C₂-C₄ alkylcarbonyl, C₂-C₄         haloalkylcarbonyl, C₂-C₅ alkoxycarbonyl, C₃-C₅         alkoxycarbonylalkyl, C₂-C₅ alkylaminocarbonyl, C₃-C₅         dialkylaminocarbonyl, C₁-C₄ alkylsulfonyl or C₁-C₄         haloalkylsulfonyl;     -   W is O or S;     -   X is a radical selected from

-   -   wherein the bond of X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸ or X⁹ which         is identified with “t” is connected to the carbon atom         identified with “q” of Formula 1, the bond which is identified         with “u” is connected to the carbon atom identified with “r” of         Formula 1, and the bond which is identified with “v” is         connected to G;     -   each R² is independently C₁-C₄ alkyl, C₁-C₄ alkenyl, C₁-C₄         haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy; or     -   two R² are taken together as C₁-C₄ alkylene or C₂-C₄ alkenylene         to form a bridged bicyclic or fused bicyclic ring system; or     -   two R² attached to adjacent ring carbon atoms joined by a double         bond are taken together as —CH═CH—CH═CH— optionally substituted         with 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, halogen, hydroxy,         amino, cyano and nitro;     -   G is an optionally substituted 5-membered heteroaromatic ring or         5-membered saturated or partially saturated heterocyclic ring;     -   J is a 5-, 6- or 7-membered ring, a 8- to 11-membered bicyclic         ring system or a 7- to 11-membered spirocyclic ring system, each         ring or ring system containing ring members selected from carbon         and optionally 1 to 4 heteroatoms selected from up to 2 O, up to         2 S and up to 4 N, and optionally including 1 to 3 ring members         selected from the group consisting of C(═O), C(═S), S(O), S(O)₂         and SiR¹⁷R¹⁸, each ring or ring system optionally substituted         with 1 to 5 substituents independently selected from R⁵;     -   each R⁵ is independently H, halogen, cyano, hydroxy, amino,         nitro, —CHO, —C(═O)OH, —C(═O)NH₂, —NR²⁵R²⁶, C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl,         C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl,         C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₆-C₁₄         cycloalkylcycloalkyl, C₄-C₁₀ halocycloalkylalkyl, C₅-C₁₀         alkylcycloalkylalkyl, C₃-C₈ cycloalkenyl, C₃-C₈         halocycloalkenyl, C₂-C₆ alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl,         C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆ alkylthioalkyl, C₂-C₆         alkylsulfinylalkyl, C₂-C₆ alkylsulfonylalkyl, C₂-C₆         alkylaminoalkyl, C₃-C₈ dialkylaminoalkyl, C₂-C₆         haloalkylaminoalkyl, C₄-C₁₀ cycloalkylaminoalkyl, C₂-C₆         alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₄-C₈         cycloalkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₄-C₈         cycloalkoxycarbonyl, C₅-C₁₀ cycloalkylalkoxycarbonyl, C₂-C₆         alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₄-C₈         cycloalkylaminocarbonyl, C₂-C₆ haloalkoxyalkyl, C₁-C₆         hydroxyalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy,         C₃-C₈ halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy, C₂-C₆         alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆         haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy,         C₂-C₆ haloalkylcarbonyloxy, C₄-C₈ cycloalkylcarbonyloxy, C₃-C₆         alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈         cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl,         C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈         cycloalkylsulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆         alkylsulfonylamino, C₁-C₆ haloalkylsulfonylamino or —Z²Q;     -   R²⁵ is H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₁-C₆         alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆ alkoxycarbonyl or         C₂-C₆ haloalkoxycarbonyl;     -   R²⁶ is C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₂-C₆         alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆ alkoxycarbonyl,         C₂-C₆ haloalkoxycarbonyl or —Z⁴Q;     -   each R¹⁷ and R¹⁸ is independently C₁-C₅ alkyl, C₂-C₅ alkenyl,         C₂-C₅ alkynyl, C₃-C₅ cycloalkyl, C₃-C₆ halocycloalkyl, C₄-C₁₀         cycloalkylalkyl, C₄-C₇ alkylcycloalkyl, C₅-C₇         alkylcycloalkylalkyl, C₁-C₅ haloalkyl, C₁-C₅ alkoxy or C₁-C₅         haloalkoxy;     -   each Q is independently phenyl, benzyl, naphthalenyl, a 5- or         6-membered heteroaromatic ring or an 8- to 11-membered         heteroaromatic bicyclic ring system, each optionally substituted         with 1 to 5 substituents independently selected from R⁷ on         carbon atom ring members and R¹² on nitrogen atom ring members;         or     -   each Q is independently a 3- to 7-membered nonaromatic         carbocyclic ring, a 5-, 6- or 7-membered nonaromatic         heterocyclic ring or an 8- to 11-membered nonaromatic bicyclic         ring system, each optionally including ring members selected         from the group consisting of C(═O), C(═S), S(O), S(O)₂ and         SiR¹⁷R¹⁸, and optionally substituted with 1 to 5 substituents         independently selected from R⁷ on carbon atom ring members and         R¹² on nitrogen atom ring members;     -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀         alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,         C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,         halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄         haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄         alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,         C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,         C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,         C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆         alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆         alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆         trialkylsilyl; or     -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to         form an optionally substituted 5- to 7-membered ring containing         ring members selected from carbon and optionally 1 to 3         heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and         optionally including 1 to 3 ring members selected from the group         consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸;     -   R¹² is H, C₁-C₃ alkyl, C₁-C₃ alkylcarbonyl, C₁-C₃ alkoxy or         C₁-C₃ alkoxycarbonyl;     -   each Z¹ and Z² is independently a direct bond, O, C(═O),         S(O)_(m), CHR²⁰ or NR²¹;     -   each Z⁴ is independently O, C(═O), S(O)_(m) or CHR²⁰;     -   each R²⁰ is independently H, C₁-C₄ alkyl or C₁-C₄ haloalkyl;     -   each R²¹ is independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈         cycloalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆         alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl;     -   each m is independently 0, 1 or 2; and n is 0, 1 or 2;         provided that:     -   (a) when R¹ is unsubstituted thienyl, X is X¹ and the ring         containing X is saturated, G is an unsubstituted thiazole ring         connected at its 2-position to X and at its 4-position to Z¹ in         Formula 1, A is CHR¹⁵, R¹⁵ is H, and J is an isoxazole ring         connected at its 4-position to Z¹ and substituted at its         5-position with methyl and at its 3-position with         meta-substituted phenyl, then Z¹ is O, C(═O), S(O)_(m), CHR²⁰ or         NR²¹.

More particularly, this invention pertains to compounds of Formula 1 including all geometric and stereoisomers, N-oxides, and salts thereof; provided that (b) when A is NR¹⁶, X is X¹ or X², Z¹ is a direct bond, and J is phenyl, then J is substituted with at least one R⁵ other than H, F, Cl, CN, OCH₃, CF₃ and CH₃, and (c) when A is CHR¹⁵, R¹⁵ is H, W is O, X is X¹, n is 0, G is a thiazole ring connected at its 2-position to X, and at its 4-position to Z¹ in Formula 1, and bonded at its 5-position to H, F, Cl or Br, Z¹ is a direct bond, and R¹ is

then when J is a substituted phenyl or substituted pyrimidin-4-yl, it is substituted with at least one R⁵ other than H, SCF₃, OCF₃, C(CH₃)₃, S(O)₂CF₃, OCH₃, CF₃, Br, cyclopropyl, 1-methylcyclopropyl, OH or CF₂CH₃, and when J is a 2,3-dihydro-1H-inden-4-yl or 5,6,7,8-tetrahydronaphthalen-2-yl, it is substituted with at least one R⁵ other than H, CH₃ or C(CH₃)₃.

This invention also relates to a compound of Formula 1A

wherein

-   -   each R^(4a1) and R^(4a2) is independently C₁-C₃ alkyl, C₂-C₃         alkenyl, C₂-C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃         haloalkenyl, C₂-C₃ haloalkynyl, halocyclopropyl, halogen, cyano,         nitro, C₁-C₂ alkoxy, C₁-C₂ haloalkoxy, C₁-C₂ alkylthio, C₁-C₂         haloalkylthio, C₂-C₃ alkoxyalkyl, C₂-C₃ alkylcarbonyl, C₂-C₃         alkoxycarbonyl, C₂-C₃ alkylaminocarbonyl or C₃-C₄         dialkylaminocarbonyl;

A^(a) is H, CH₂CO₂H, CH₂CO₂R³⁰ or CH₂C(═O)Cl; and R³⁰ is C₁-C₃ alkyl.

This invention also relates to a compound of Formula 1B

wherein

-   -   each R^(4a1) and R^(4a2) is independently C₁-C₃ alkyl, C₂-C₃         alkenyl, C₂-C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃         haloalkenyl, C₂-C₃ haloalkynyl, halocyclopropyl, halogen, cyano,         nitro, C₁-C₂ alkoxy, C₁-C₂ haloalkoxy, C₁-C₂ alkylthio, C₁-C₂         haloalkylthio, C₂-C₃ alkoxyalkyl, C₁-C₃ alkylcarbonyl, C₂-C₃         alkoxycarbonyl, C₂-C₃ alkylaminocarbonyl or C₃-C₄         dialkylaminocarbonyl; and     -   Z³ is CN or C(═S)NH₂.

This invention further relates to a compound of Formula 1C

wherein

-   -   M is C₁-C₃ alkyl, C₁-C₃ haloalkyl, hydroxy, C₁-C₄ alkoxy, C₁-C₂         haloalkoxy, C₁-C₄ alkylamino, C₂-C₈ dialkylamino, 1-piperidinyl,         1-pyrrolidinyl or 4-morpholinyl; and     -   J¹ is J-29-1 through J-29-58 depicted in Exhibit A as described         below.

More particularly, this invention pertains to compounds of Formulae 1A, 1B and 1C, including all geometric and stereoisomers, an N-oxide or salt thereof (except that the compounds of Formula 1C of this invention are limited to those stereoisomer embodiments depicted for J¹ in the Summary of Invention above).

This invention also relates to a fungicidal composition comprising a fungicidally effective amount of a compound of Formula 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.

This invention also relates to a fungicidal composition comprising a mixture of a compound of Formula 1 (including all geometric and stereoisomers, N-oxides, and salts thereof) and at least one other fungicide (e.g., at least one other fungicide having a different site of action).

This invention further relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of Formula 1 (including all geometric and stereoisomers, N-oxides, and salts thereof) (e.g., as a composition described herein).

This invention additionally relates to fungicidal compositions and methods of controlling plant diseases as described above, except that proviso (a) is removed from the definition of the scope of Formula 1.

DETAILS OF THE INVENTION

As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has.” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus. Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and Both A and B are true (or present).

Also, use of “a” or “an” are employed to describe elements and components of the invention. This is done merely for convenience and to give a general sense of the invention. This description should be read to include one or at least one and the singular also includes the plural unless it is obvious that it is meant otherwise.

As referred to in the present disclosure and claims, “plant” includes members of Kingdom Plantae, particularly seed plants (Spermatopsida), at all life stages, including young plants (e.g., germinating seeds developing into seedlings) and mature, reproductive stages (e.g., plants producing flowers and seeds). Portions of plants include geotropic members typically growing beneath of the surface of the growing medium (e.g., soil), such as roots, tubers, bulbs and corms, and also members growing above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds.

In the above recitations, the term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, n-propyl, i-propyl, or the different butyl, pentyl or hexyl isomers. “Alkenyl” includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. “Alkynyl” includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. “Alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. “Alkylene” denotes a straight-chain or branched alkanediyl. Examples of “alkylene” include CH₂, CH₂CH₂, CH(CH₃), CH₂CH₂CH₂, CH₂CH(CH₃) and the different butylene isomers. “Alkenylene” denotes a straight-chain or branched alkenediyl containing one olefinic bond. Examples of“alkenylene” include CH═CH, CH₂CH═CH, CH═C(CH₃), CH₂CH═CH and CH₂CH═CHCH₂. “Alkoxy” includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers. “Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH₃OCH₂, CH₃OCH₂CH₂, CH₃CH₂OCH₂, CH₃CH₂CH₂CH₂OCH₂ and CH₃CH₂OCH₂CH₂. “Alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. “Alkylsulfinyl” includes both enantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl” include CH₃S(O), CH₃CH₂S(O), CH₃CH₂CH₂S(O), (CH₃)₂CHS(O) and the different butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers. Examples of “alkylsulfonyl” include CH₃S(O)₂, CH₃CH₂S(O)₂, CH₃CH₂CH₂S(O)₂, (CH₃)₂CHS(O)₂ and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers. Examples of “alkylcarbonyl” include C(O)CH₃, C(O)CH₂CH₂CH₃ and C(O)CH(CH₃)₂. Examples of “alkoxycarbonyl” include CH₃OC(═O), CH₃CH₂OC(═O), CH₃CH₂CH₂OC(═O), (CH₃)₂CHOC(═O) and the different butoxy- or pentoxycarbonyl isomers. Examples of “alkylaminocarbonyl” include CH₃NHC(═O)—, CH₃CH₂NHC(═O)—, CH₃CH₂CH₂NHC(═O)—, (CH₃)₂CHNHC(═O)— and the different butylamino- or pentylaminocarbonyl isomers. Examples of “dialkylaminocarbonyl” include (CH₃)₂NC(═O)—, (CH₃CH₂)₂NC(═O)—, CH₃CH₂(CH₃)NC(═O)—, (CH₃)₂CHN(CH₃)C(═O)— and CH₃CH₂CH₂(CH₃)NC(═O)—. “Alkylamino”, “dialkylamino” and the like, are defined analogously to the above examples. “Trialkylsilyl” includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl. “Cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups. “Alkylcycloalkyl” denotes alkyl substitution on a cycloalkyl moiety. Examples include 4-methylcyclohexyl and 3-ethylcyclopentyl.

Unless otherwise indicated, a “ring” or “ring system” as a component of Formula 1 (e.g., substituent J and Q) is carbocyclic or heterocyclic. The term “ring system” denotes two or more connected rings. The term “spirocyclic ring system” denotes a ring system consisting of two rings connected at a single atom (so the rings have a single atom in commonality). Illustrative of a J¹ moiety that is a spirocyclic ring system is J-29-28 depicted in the definition of Formula 1C. The term “bicyclic ring system” denotes a ring system consisting of two rings sharing two or more common atoms. In a “fused bicyclic ring system” the common atoms are adjacent, and therefore the rings share two adjacent atoms and bond connecting them. In a “bridged bicyclic ring system” the common atoms are not adjacent (i.e. there is no bond between the bridgehead atoms). A “bridged bicyclic ring system” is conceptually formed by bonding a segment of one or more atoms to nonadjacent ring members of a ring.

A ring, a bicyclic ring system or spirocyclic ring system can be part of an extended ring system containing more than two rings wherein substituents on the ring, bicyclic ring system or spirocyclic are taken together to form the additional rings, which may be in bicyclic and/or spirocyclic relationships with other rings in the extended ring system. For example, the particular J¹ moiety J-29-26 depicted in the definition of Formula 1C consists of a dihydro isoxazoline ring having one R⁵ substituent as Z²Q, which is a cyclobutyl ring substituted with two methyl groups as R⁷ and also one R⁷ group taken together with another R⁵ substituent on the dihydro isoxazoline ring as —CH₂CH₂— to form the additional six-membered ring component in the ring system.

The term “ring member” refers to an atom (e.g., C, O, N or S) or other moiety (e.g., C(═O). C(═S), S(O) or S(O)₂) forming the backbone of a ring or ring system. The term “carbocyclic ring” denotes a ring wherein the atoms forming the ring backbone are selected only from carbon. The term “carbocyclic ring system” denotes two or more fused rings wherein the atoms forming the backbone of the rings are selected only from carbon. The term “heterocyclic ring” denotes a ring wherein at least one of the atoms forming the ring backbone is other than carbon. The term “heterocyclic ring system” denotes two or more fused rings wherein at least one of the atoms forming the backbone of the rings is other than carbon. “Aromatic” indicates that each of ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and in which (4n+2) π electrons, where n is a positive integer, are associated with the ring to comply with Hückel's rule. The term “heteroaromatic ring” refers to a heterocyclic ring that is aromatic. The term “saturated heterocyclic ring” denotes a heterocyclic ring containing only single bonds between ring members. The term “partially saturated heterocyclic ring” denotes a heterocyclic ring containing at least one double bond but which is not aromatic.

The dotted line in Formula 1 and in other rings depicted in the present description (e.g., J-44, J-45, J-48 and J-49 in Exhibit 3) represents that the bond indicated can be a single bond or double bond. Unless otherwise indicated, heterocyclic rings and ring systems are attached to the remainder of Formula 1 through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen, and all substituents on the heterocyclic rings and ring systems are attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.

As already described, J is a 5-, 6- or 7-membered ring, a 8- to 11-membered bicyclic ring system or a 7- to 11-membered spirocyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 4 heteroatoms selected from up to 2 O, up to 2 S and up to 4 N, and optionally including 1 to 3 ring members selected from the group consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R⁵. As the heteroatoms are optional, 0 to 4 heteroatoms may be present. In this description the heteroatoms selected from up to 2 S are atoms and not the moieties S(O) or S(O)₂. The heteroatoms selected from up to 4 N may be oxidized as N-oxides, because the present invention also relates to N-oxide derivatives of the compounds of Formula 1. Therefore the optional 1 to 3 ring members selected from the group consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸ are in addition to the optional 1 to 4 heteroatoms selected from up to 2 O, up to 2 S and up to 4 N. Of note is when the total number of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties (i.e. S(O) and S(O)₂) does not exceed 2, so that at most two ring members selected from S, S(O) and S(O)₂ are present in the ring or ring system. When none of the optional heteroatoms and none of the optional ring members selected from S(O), S(O)₂ and SiR¹⁷R¹⁸ are present, the ring or ring system is carbocyclic. The R⁵ substituents may be attached to carbon atom ring members and to nitrogen atom ring members having an available point of attachment. The carbon-based ring members C(═O) and C(═S) do not have available points of attachment. Furthermore in SiR¹⁷R¹⁸ ring members, the substituents R¹⁷ and R¹⁸ are otherwise separately defined, and these ring members cannot be further substituted with R⁵. As the R⁵ substituents are optional, 0 to 5 substituents may be present, limited by the number of available points of attachment.

Similarly, R⁵ and R⁷ may be taken together with the atoms linking R⁵ and R⁷ to form an optionally substituted 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and optionally including 1 to 3 ring members selected from the group consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸. As the heteroatoms are optional, 0 to 3 heteroatoms may be present. In this description the heteroatom selected from up to 1 S is an atom and not the moieties S(O) or S(O)₂. The heteroatom selected from up to 1 N may be oxidized as an N-oxide, because the present invention also relates to N-oxide derivatives of the compounds of Formula 1. Therefore the optional 1 to 3 ring members selected from the group consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸ are in addition to the optional 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N. Of note is when the total number of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties (i.e. S(O) and S(O)₂) does not exceed 1, so that at most one ring member selected from S, S(O) and S(O)₂ is present in the ring. When none of the optional heteroatoms and none of the optional ring members selected from S(O), S(O)₂ and SiR¹⁷R¹⁸ are present, the ring is carbocyclic. The 5- to 7-membered ring is optionally substituted. The substituents on the atoms linking R⁵ and R⁷ are described in the definition of the components linking R⁵ and R⁷. For example, when linking component Z² is CHR²⁰, the substituent R²⁰ is defined to be H, C₁-C₄ alkyl or C₁-C₄ haloalkyl. Regarding optional substituents attached to the portion of the ring consisting of R⁵ and R⁷ taken together, an optional substituent is a non-hydrogen substituent that does not extinguish fungicidal activity. Optional substituents may be attached to carbon atom ring members and to nitrogen atom ring members having an available point of attachment. The carbon-based ring members C(═-O) and C(═S) do not have available points of attachment. Furthermore in SiR¹⁷R¹⁸ ring members, the substituents R¹⁷ and R¹⁸ are otherwise separately defined, and these ring members cannot be further substituted.

The term “halogen”, either alone or in compound words such as “haloalkyl”, includes fluorine, chlorine, bromine or iodine. Furthermore, when used in compound words such as “haloalkyl”, said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” include F₃C, ClCH₂, CF₃CH₂ and CF₃CCl₂. The terms “haloalkenyl”, “haloalkynyl”, “halocycloalkyl”, “haloalkoxy”, “haloalkylthio”, and the like, are defined analogously to the term “haloalkyl”. Examples of “haloalkenyl” include (Cl)₂C═CHCH₂ and CF₃CH₂CH═CHCH₂. Examples of “haloalkynyl” include HC≡CCHCl, CF₃C≡C, CCl₃C≡C and FCH₂C═CCH₂. Examples of “haloalkoxy” include CF₃O, CCl₃CH₂O, HCF₂CH₂CH₂O and CF₃CH₂O. Examples of “haloalkylthio” include CCl₃S, CF₃S, CCl₃CH₂S and ClCH₂CH₂CH₂S. Examples of “haloalkylsulfinyl” include CF₃S(O), CCl₃S(O), CF₃CH₂S(O) and CF₃CF₂S(O). Examples of “haloalkylsulfonyl” include CF₃S(O)₂, CCl₃S(O)₂, CF₃CH₂S(O)₂ and CF₃CF₂S(O)₂.

The total number of carbon atoms in a substituent group is indicated by the “C_(i)-C_(j)” prefix where i and j are numbers from 1 to 10. For example, C₁-C₄ alkylsulfonyl designates methylsulfonyl through butylsulfonyl; C₂ alkoxyalkyl designates CH₃OCH₂; C₃ alkoxyalkyl designates, for example, CH₃CH(OCH₃), CH₃OCH₂CH₂ or CH₃CH₂OCH₂; and C₄ alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH₃CH₂CH₂OCH₂ and CH₃CH₂OCH₂CH₂.

When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can vary, then when the number of said substituents is greater than 1, said substituents are independently selected from the group of defined substituents. Furthermore when a range is indicated (e.g., i-j substituents), then the number of substituents may be selected from the integers between i and j inclusive. When a group (e.g., J) contains a substituent (e.g., R⁵) which can be hydrogen, then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for example (R²)_(n) wherein n may be 0, or as a further example (R⁴)_(k) wherein k may be 0 in Exhibit 1, then hydrogen may be at the position even if not recited in the definition of the variable group (e.g., R² and R⁴). When a position on a group is said to be “not substituted” or “unsubstituted”, then hydrogen atoms are attached to take up any free valency. The term “optionally substituted” in connection with groups listed for R¹, R², R⁵, R⁷ G, J and Q refers to groups that are unsubstituted or have at least 1 non-hydrogen substituent. Unless otherwise indicated, these groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, the number of optional substituents (when present) ranges from 1 to 3. When a range specified for the number of substituents (e.g., x being an integer from 0 to 5 in Exhibit 3) exceeds the number of positions available for substituents on a ring (e.g., 2 positions available for (R⁵)_(x) on J-1 in Exhibit 3), the actual higher end of the range is recognized to be the number of available positions. The term “optionally substituted” means that the number of substituents can be zero. For example, the phrase “optionally substituted with up to 2 substituents selected from R³ on carbon ring members and selected from R¹¹ on nitrogen ring members” means that 0, 1 or 2 substituents can be present (if number of potential connection points allows), and thus the number of R³ and R¹¹ substituents can be zero. Similarly, the phrase “optionally substituted with 1 to 5 substituents” means that 0, 1, 2, 3, 4 or 5 substituents can be present if the number of available connection points allows. The term “unsubstituted” in connection with a group such as a ring or ring system means the group does not have any substituents other than its one or more attachments to the remainder of Formula 1. The term “meta-substituted phenyl” means a phenyl ring substituted with a non-hydrogen substituent at a meta position relative to attachment of the phenyl ring to the remainder of Formula 1.

As noted above, R¹ is an optionally substituted phenyl, naphthalenyl or 5- or 6-membered heteroaromatic ring; G is an optionally substituted 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring; and R⁵ and R⁷ may be taken together with the atoms linking R⁵ and R⁷ to form an optionally substituted 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and optionally including 1 to 3 ring members selected from the group consisting of C(═O). C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸. The term “substituted” in connection with the definitions of R¹, G, R⁵ and R⁷ refers to groups that have at least one non-hydrogen substituent that does not extinguish fungicidal activity. Since these groups are optionally substituted, they need not have any non-hydrogen substituents. As these groups are “optionally substituted” without the number of substituents indicated, these groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom.

Naming of substituents in the present disclosure uses recognized terminology providing conciseness in precisely conveying to those skilled in the art the chemical structure. For sake of conciseness, locant descriptors may be omitted; “pyrazol-1-yl” means “1H-pyrazol-1-yl” according to the Chemical Abstracts system of nomenclature. The term “pyridyl” is synonymous with “pyridinyl”. The order of listing substituents may be different from the Chemical Abstracts system if the difference does not affect the meaning.

Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active form. For example, when J is J-29 (see Exhibit 3) bonded at the 3-position to the remainder of Formula 1 and J-29 has one R⁵ substituent other than H at the 5-position, then Formula 1 possesses a chiral center at the carbon atom to which R⁵ is bonded. The two enantiomers are depicted as Formula 1′ and Formula 1″ with the chiral center identified with an asterisk (*).

This invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1′ and 1″. In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1′ and Formula 1″.

When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess (“ee”), which is defined as (2x−1) 100%, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20% corresponds to a 60:40 ratio of enantiomers).

Preferably the compositions of this invention have at least a 50%/0 enantiomeric excess; more preferably at least a 75% enantiomeric excess; still more preferably at least a 90% enantiomeric excess; and the most preferably at least a 94% enantiomeric excess of the more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer.

Compounds of Formula 1 can comprise additional chiral centers. For example, substituents and other molecular constituents such as R⁴, R⁵, R⁷, G, J, Q and X¹ through X⁹ may themselves contain chiral centers. This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers.

Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about the amide bond (e.g., C(W)—N) in Formula 1. This invention comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others.

Some of the unsaturated rings and ring systems depicted in Exhibits 1, 2, 3 and 4 can have an arrangement of single and double bonds between ring members different from that depicted. Such differing arrangements of bonds for a particular arrangement of ring atoms correspond to different tautomers. For these unsaturated rings and ring systems, the particular tautomer depicted is to be considered representative of all the tautomers possible for the arrangement of ring atoms shown. The tables listing particular compounds incorporating the ring and ring systems depicted in the Exhibits may involve a tautomer different from the tautomer depicted in the Exhibits.

The compounds of the invention include N-oxide derivatives. One skilled in the art will appreciate that not all nitrogen-containing heterocycles can form N-oxides since the nitrogen requires an available lone pair of electrons for oxidation to the oxide; one skilled in the art will recognize those nitrogen containing heterocycles which can form N-oxides. One skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in Comprehensive Organic Synthesis, vol. 7, pp 748-750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in Comprehensive Heterocyclic Chemistry, vol. 3, pp 18-20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in Advances in Heterocyclic Chemistry, vol. 43, pp 149-161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry, vol. 9, pp 285-291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.

The present compounds of Formula 1 can be in the form of agriculturally suitable salts. One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of the compounds of Formula 1 are useful for control of plant diseases caused by fungal plant pathogens (i.e. are agriculturally suitable). The salts of the compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1 contains an acidic moiety such as a carboxylic acid or phenol, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formulae 1, 1A, 1B and 1C, N-oxides and salts thereof.

Embodiments of the present invention include:

-   -   Embodiment 1. A compound of Formula 1 wherein A is CHR¹⁵.     -   Embodiment 1a. A compound of Embodiment 1 wherein R¹⁵ is H,         halogen, cyano, hydroxy, —CHO, C₁-C₄ alkyl, C₁-C₄ haloalkyl or         C₂-C₅ alkoxycarbonyl.     -   Embodiment 1b. A compound of Embodiment 1a wherein R¹⁵ is H,         cyano, hydroxy, methyl or methoxycarbonyl.     -   Embodiment 1c. A compound of Embodiment 1b wherein R¹⁵ is H.     -   Embodiment 2. A compound of Formula 1 wherein A is NR¹⁶.     -   Embodiment 2a. A compound of Embodiment 2 wherein R¹⁶ is H,         C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkylcarbonyl, C₂-C₄         haloalkylcarbonyl or C₂-C₄ alkoxycarbonyl.     -   Embodiment 2b. A compound of Embodiment 2a wherein R¹⁶ is H,         methyl, methylcarbonyl or methoxycarbonyl.     -   Embodiment 2c. A compound of Embodiment 2b wherein R¹⁶ is H.     -   Embodiment 3. A compound of Formula 1 wherein W is O.     -   Embodiment 4. A compound of Formula 1 wherein W is S.     -   Embodiment 5. A compound of Formula 1 wherein each R² is         independently C₁-C₂ alkyl, C₁-C₂ haloalkyl, C₁-C₂ alkoxy,         halogen, cyano or hydroxy.     -   Embodiment 5a. A compound of Embodiment 5 wherein each R² is         independently methyl, methoxy, cyano or hydroxy.     -   Embodiment 5b. A compound of Embodiment 5a wherein each R² is         methyl.     -   Embodiment 6. A compound of Formula 1 wherein n is 0 or 1.     -   Embodiment 7. A compound of Embodiment 6 wherein n is 0.     -   Embodiment 7a. A compound of Embodiment 6 wherein n is 1.     -   Embodiment 8. A compound of Formula 1 wherein X is X¹, X² or X³.     -   Embodiment 9. A compound of Embodiment 8 wherein X is X¹ or X².     -   Embodiment 10. A compound of Embodiment 9 wherein X is X¹.     -   Embodiment 11. A compound of Formula 1 wherein the ring         comprising X is saturated (i.e. contains only single bonds).     -   Embodiment 12. A compound of Formula 1 wherein R¹ is a phenyl or         5- or 6-membered heteroaromatic ring optionally substituted with         substituents that do not link together to make R¹ a fused ring         system.     -   Embodiment 12a. A compound of Embodiment 12 wherein R¹ is a         phenyl or 5- or 6-membered heteroaromatic ring optionally         substituted with 1-3 substituents independently selected from         R^(4a) on carbon ring members and R^(4b) on nitrogen ring         members;         -   each R^(4a) is independently C₁-C₆ alkyl, C₂-C₆ alkenyl,             C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl,             C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₄             alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄             alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,             C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄             alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆             alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl or C₃-C₆ trialkylsilyl; and         -   each R^(4b) is independently C₁-C₆ alkyl, C₃-C₆ alkenyl,             C₃-C₆ alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkyl, C₃-C₆             haloalkenyl, C₃-C₆ haloalkynyl, C₃-C₆ halocycloalkyl or             C₂-C₄ alkoxyalkyl.     -   Embodiment 12b. A compound of Embodiment 12a wherein R¹ is a         phenyl or 5- or 6-membered heteroaromatic ring optionally         substituted with 1-2 substituents independently selected from         R^(4a) on carbon ring members and R^(4b) on nitrogen ring         members.     -   Embodiment 13. A compound of Embodiment 12b wherein R¹ is one of         U-1 through U-50 depicted in Exhibit 1;

wherein

-   -   when R⁴ is attached to a carbon ring member, said R⁴ is selected         from R^(4a), and when R⁴ is attached to a nitrogen ring member         (e.g., in U-4, U-11 through U-15, U-24 through U-26, U-31 or         U-35), said R⁴ is selected from R^(4b); and     -   k is 0, 1 or 2.     -   Embodiment 14. A compound of Embodiment 13 wherein R¹ is         selected from U-1 through U-5, U-8, U-11, U-13, U-15, U-20         through U-28, U-31, U-36 through U-39 and U-50.     -   Embodiment 15. A compound of Embodiment 14 wherein R¹ is         selected from U-1 through U-3, U-5, U-8, U-11, U-13, U-20, U-22,         U-23, U-25 through U-28, U-36 through U-39 and U-50.     -   Embodiment 16. A compound of Embodiment 15 wherein R¹ is         selected from U-1 through U-3, U-11, U-13, U-20, U-22, U-23,         U-36 through U-39 and U-50.     -   Embodiment 17. A compound of Embodiment 16 wherein R¹ is U-1 or         U-50.     -   Embodiment 18. A compound of Embodiment 17 wherein R¹ is U-1.     -   Embodiment 19. A compound of Embodiment 17 wherein R¹ is U-50.     -   Embodiment 20. A compound of any one of Embodiments 12 and 13         wherein each R^(4a) is independently C₁-C₃ alkyl, C₂-C₃ alkenyl,         C₂-C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃ haloalkenyl,         C₂-C₃ haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C₁-C₂         alkoxy, C₁-C₂ haloalkoxy, C₁-C₂ alkylthio, C₁-C₂ haloalkylthio,         C₁-C₃ alkoxyalkyl, C₂-C₃ alkylcarbonyl, C₂-C₃ alkoxycarbonyl,         C₂-C₃ alkylaminocarbonyl or C₃-C₄ dialkylaminocarbonyl.     -   Embodiment 21. A compound of Embodiment 20 wherein each R^(4a)         is independently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl,         cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃ haloalkenyl, C₁-C₃         haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C₁-C₂         alkoxy or C₁-C₂ haloalkoxy.     -   Embodiment 22. A compound of Embodiment 21 wherein each R^(4a)         is independently halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₂         alkoxy or C₁-C₂ haloalkoxy.     -   Embodiment 23. A compound of Embodiment 21 wherein each R^(4a)         is independently halogen, C₁-C₂, alkyl, C₁-C₂ haloalkyl or C₁-C₂         alkoxy.     -   Embodiment 24. A compound of Embodiment 23 wherein each R^(4a)         is independently C₁-C₂ alkyl, trifluoromethyl, Cl, Br, I or         methoxy.     -   Embodiment 25. A compound of Embodiment 24 wherein each R^(4a)         is independently C₁-C₂ alkyl, trifluoromethyl, Cl or Br.     -   Embodiment 26. A compound of any one of Embodiments 12 and 13         wherein each R^(4b) is independently C₁-C₃ alkyl, C₃ alkenyl         (e.g., allyl), C₃ alkynyl (e.g., propargyl), cyclopropyl, C₁-C₃         haloalkyl, C₃ haloalkenyl, C₃ haloalkynyl, halocyclopropyl or         C₂-C₃ alkoxyalkyl.     -   Embodiment 27. A compound of Embodiment 26 wherein each R^(4b)         is independently C₁-C₃ alkyl, C₃ alkenyl, C₃ alkynyl,         cyclopropyl, C₁-C₃ haloalkyl, C₃ haloalkenyl or halocyclopropyl.     -   Embodiment 28. A compound of Embodiment 27 wherein each R^(4b)         is independently C₁-C₂ alkyl or C₁-C₂ haloalkyl.     -   Embodiment 29. A compound of Embodiment 28 wherein each R^(4b)         is independently C₁-C₂ alkyl or trifluoromethyl.     -   Embodiment 30. A compound of Embodiment 29 wherein each R^(4b)         is independently C₁-C₂ alkyl.     -   Embodiment 31. A compound of Embodiment 13 wherein k is 1 or 2         and at least one R⁴ is Cl.     -   Embodiment 32. A compound of Embodiment 13 wherein k is 1 or 2         and at least one R⁴ is Br.     -   Embodiment 33. A compound of Embodiment 13 wherein k is 1 or 2         and at least one R⁴ is methyl.     -   Embodiment 34. A compound of Embodiment 13 wherein k is 1 or 2         and at least one R⁴ is ethyl.     -   Embodiment 35. A compound of Embodiment 13 wherein k is 1 or 2         and at least one R⁴ is trifluoromethyl.     -   Embodiment 36. A compound of Embodiment 13 wherein k is 1 or 2         and at least one R⁴ is methoxy.     -   Embodiment 37. A compound of Embodiment 18 wherein k is 1 and R⁴         is connected to the 3- or 5-position of U-1.     -   Embodiment 38. A compound of Embodiment 18 wherein k is 2 and         one R⁴ is connected to the 3-position and the other R⁴ is         connected to the 5-position of U-1.     -   Embodiment 39. A compound of Embodiment 19 wherein k is 1 and R⁴         is connected to the 2- or 3-position of U-50.     -   Embodiment 40. A compound of Embodiment 19 wherein k is 2 and         one R⁴ is connected to the 2-position and the other R⁴ is         connected to the 5-position of U-50.     -   Embodiment 41. A compound of Formula 1 wherein G is a 5-membered         heteroaromatic

ring or 5-membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R³ on carbon ring members and selected from R¹¹ on nitrogen ring members;

-   -   each R³ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or         halogen; and     -   each R¹¹ is independently C₁-C₃ alkyl.     -   Embodiment 42. A compound of Embodiment 41 wherein G is one of         G-1 through G-59 depicted in Exhibit 2:

-   -   -   wherein the bond projecting to the left is bonded to X, and             the bond projecting to the right is bonded to Z¹; each             R^(3a) is independently selected from H or R³; and R^(11a)             is selected from H and R¹¹;

    -   provided that:         -   when G is G-6, G-16 or G-42, and each R^(3a) is other than             H, then R^(11a) is H;         -   when G is G-25 or G-31, then at least one R^(3a) is H; and         -   when G is one of G-31 through G-35, then Z¹ is a direct bond             or CHR²⁰.

    -   Embodiment 43. A compound of Embodiment 42 wherein G is selected         from G-1 through G-3, G-7, G-8, G-10, G-11, G-14, G-15, G-23,         G-24, G-26 through G-28, G-30, G-36 through G-38 and G-49         through G-55.

    -   Embodiment 44. A compound of Embodiment 43 wherein G is selected         from G-1, G-2, G-7, G-8, G-14, G-15, G-23, G-24, G-26, G-27,         G-36, G-37, G-38, G-49, G-50 and G-55.

    -   Embodiment 45. A compound of Embodiment 44 wherein G is selected         from G-1, G-2, G-15. G-26, G-27, G-36, G-37 and G-38.

    -   Embodiment 46. A compound of Embodiment 45 wherein G is selected         from G-1, G-2, G-15, G-26 and G-36.

    -   Embodiment 47. A compound of Embodiment 46 wherein G is G-1. Of         note are embodiments of these compounds within Embodiments 1         through 40,

    -   Embodiments 52 through 83, and Embodiments A1 through A5.

    -   Embodiment 48. A compound of Embodiment 46 wherein G is G-2. Of         note are embodiments of these compounds within Embodiments 1         through 40, Embodiments 52 through 83, and Embodiments A1         through A5.

    -   Embodiment 49. A compound of Embodiment 46 wherein G is G-15. Of         note are embodiments of these compounds within Embodiments 1         through 40, Embodiments 52 through 83, and Embodiments A1         through A5.

    -   Embodiment 50. A compound of Embodiment 46 wherein G is G-26. Of         note are embodiments of these compounds within Embodiments 1         through 40, Embodiments 52 through 83, and Embodiments A1         through A5.

    -   Embodiment 51. A compound of Embodiment 46 wherein G is G-36. Of         note are embodiments of these compounds within Embodiments 1         through 40, Embodiments 52 through 83, and Embodiments A1         through A5.

    -   Embodiment 52. A compound of any one of Embodiments 41 through         51 wherein R^(3a) is H, C₁-C₃ alkyl or halogen.

    -   Embodiment 53. A compound of Embodiment 52 wherein R^(3a) is H         or methyl.

    -   Embodiment 54. A compound of any one of Embodiments 41 through         51 wherein R^(3a) is H and R^(11a) is H or methyl.

    -   Embodiment 55. A compound of any one of Formula 1 and         Embodiments 41 through 51 wherein G is unsubstituted.

    -   Embodiment 56. A compound of Formula 1 wherein J is one of J-1         through J-82 depicted in Exhibit 3;

-   -   -   wherein the bond shown projecting to the left is bonded to             Z¹; and x is an integer from 0 to 5.

    -   Embodiment 56a. A compound of Embodiment 56 wherein J is one of         J-29-1 through J-29-58 depicted in Exhibit A:

-   -   Embodiment 57. A compound of embodiment 56 wherein J is selected         from J-1, J-2, J-3, J-4, J-5, J-7, J-8, J-9, J-10, J-11, J-12,         J-14, J-15, J-16, J-20, J-24, J-25, J-26, J-29, J-30, J-37,         J-38, J-45 and J-69.     -   Embodiment 58. A compound of Embodiment 57 wherein J is selected         from J-4, J-5, J-8, J-11, J-15, J-16, J-20, J-29, J-30, J-37,         J-38, and J-69.     -   Embodiment 59. A compound of Embodiment 58 wherein J is selected         from J-4, J-5, J-11, J-20, J-29, J-37, J-38, and J-69.     -   Embodiment 60. A compound of Embodiment 59 wherein J is J-11.     -   Embodiment 61. A compound of Embodiment 59 wherein J is J-29.     -   Embodiment 61a. A compound of Embodiment 61 wherein J is any one         of J-29-1 to J-29-58 (depicted with Table 8).     -   Embodiment 62. A compound of Embodiment 59 wherein J is J-69.     -   Embodiment 63. A compound of Embodiment 60 wherein the         3-position of J-11 is connected to Z¹ and the 5-position of J-11         is connected to R⁵ other than H.     -   Embodiment 63a. A compound of Embodiment 63 wherein the         3-position of J-11 is connected to Z¹ and the 5-position of J-11         is connected to Z²Q.     -   Embodiment 64. A compound of Embodiment 61 wherein the         3-position of J-29 is connected to Z¹ and the 5-position of J-29         is connected to R⁵ other than H.     -   Embodiment 64a. A compound of Embodiment 65 wherein the         3-position of J-29 is connected to Z¹ and the 5-position of J-29         is connected to Z²Q.     -   Embodiment 65. A compound of Formula 1 or Embodiment 56 wherein         each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₂-C₆ alkenyl,         C₂-C₆ alkynyl. C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆         haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₄-C₁₀         alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₂-C₆ alkoxyalkyl,         C₄-C₁₀ cycloalkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆         alkylthioalkyl, C₂-C₆ alkoxycarbonyl, C₁-C₆ alkoxy, C₁-C₆         haloalkoxy, C₃-C₈ cycloalkoxy, C₃-C₈ halocycloalkoxy, C₄-C₁₀         cycloalkylalkoxy, C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆         alkynyloxy, C₂-C₆ haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆         alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₄-C₈         cycloalkylcarbonyloxy, C₃-C₆ alkylcarbonylalkoxy, C₁-C₆         alkylthio, C₁-C₆ haloalkylthio, C₃-C₈ cycloalkylthio, C₃-C₁₀         trialkylsilyl, —NR²⁵R²⁶ or Z²Q.     -   Embodiment 66. A compound of Embodiment 65 wherein each R⁵ is         independently H, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈         cycloalkyl, C₃-C₈ halocycloalkyl, C₂-C₆ alkoxyalkyl, C₁-C₆         alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₂-C₆ alkenyloxy,         C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆ alkoxyalkoxy,         C₂-C₆ alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₁-C₆         alkylthio, C₁-C₆ haloalkylthio, C₃-C₁₀ trialkylsilyl, —NR²⁵R²⁶         or Z²Q.     -   Embodiment 67. A compound of Embodiment 66 wherein each R⁵ is         independently H, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, C₁-C₆ haloalkoxy, —NR²⁵R²⁶ or Z²Q.     -   Embodiment 68. A compound of Formula 1 or Embodiment 56 wherein         one instance of R⁵ is Z²Q and other instances of R⁵ are         independently selected from H, cyano, C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₁-C₄ alkylcarbonyl and halogen.     -   Embodiment 69. A compound of Embodiment 68 wherein the other         instances of R⁵ are independently selected from H and C₁-C₃         alkyl.     -   Embodiment 70. A compound of Embodiment 56 wherein x is 1 or 2.     -   Embodiment 71. A compound of Embodiment 70 wherein x is 1.     -   Embodiment 72. A compound of Embodiment 71 wherein R⁵ is Z²Q.     -   Embodiment 73. A compound of Formula 1 wherein Z¹ is direct         bond.     -   Embodiment 74. A compound of Formula 1 wherein Z² is direct         bond.     -   Embodiment 75. A compound of Formula 1 wherein Q is one of Q-1         through Q-102 depicted in Exhibit 4;

-   -   -   wherein p is 0, 1, 2, 3, 4 or 5.

    -   Embodiment 76. A compound of Embodiment 75 wherein Q is selected         from Q-1, Q-20, Q-32 through Q-34, Q-45 through Q-47, Q-60         through Q-73, Q-76 through Q-79, Q-84 through Q-94 and Q-98         through Q-102.

    -   Embodiment 77. A compound of Embodiment 76 wherein Q is Q-1,         Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70, Q-71, Q-72, Q-73,         Q-76, Q-78, Q-79, Q-84, Q-85, Q-98. Q-99. Q-100. Q-101 or Q-102.

    -   Embodiment 78. A compound of Embodiment 77 wherein Q is Q-45,         Q-63, Q-64, Q-65, Q-68, Q-69, Q-70, Q-71, Q-72 or Q-85.

    -   Embodiment 78a. A compound of Embodiment 78 wherein Q is Q-45,         Q-63, Q-65, Q-70, Q-71, Q-72 or Q-85.

    -   Embodiment 78b. A compound of Embodiment 78 wherein Q is Q-45,         Q-63, Q-65 or Q-70.

    -   Embodiment 79. A compound of Formula 1 or Embodiment 75 wherein         each R⁷ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl, halogen,         hydroxy, amino, cyano, nitro, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.

    -   Embodiment 80. A compound of Embodiment 79 wherein each R⁷ is         independently C₁-C₃ alkyl, halogen, hydroxy, cyano or C₁-C₂         alkoxy.

    -   Embodiment 81. A compound of Embodiment 80 wherein each R⁷ is         independently methyl, F, Cl, Br, hydroxy, cyano or methoxy.

    -   Embodiment 82. A compound of Formula 1 wherein when R⁵ and R⁷         are taken together with the atoms linking R⁵ and R⁷ to form an         optionally substituted 5- to 7-membered ring, the ring members         are selected from carbon and optionally 1 to 3 heteroatoms         selected from up to 1 O, up to 1 S and up to 1 N and optionally         include 1 to 3 ring members selected from the group consisting         of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸.

    -   Embodiment 82a. A compound of Embodiment 82 wherein when R⁵ and         R⁷ are taken together with the atoms linking R⁵ and R⁷ to form         an optionally substituted 5- to 7-membered ring, then R⁵ and R⁷         are taken together with the atoms linking R⁵ and R⁷ to form a 5-         to 7-membered ring containing as ring members carbon atoms and         optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S         and up to 1 N, and optionally including 1 to 3 ring members         selected from the group consisting of C(═O), C(═S), S(O), S(O)₂         and SiR¹⁷R¹⁸, optionally substituted with up to 2 substituents         selected from R⁸; and each R⁸ is independently C₁-C₃ alkyl.

    -   Embodiment 82b. A compound of Formula 1 wherein when R⁵ and R⁷         are taken together with the atoms linking R⁵ and R⁷ to form an         optionally substituted 5- to 7-membered ring, then R⁵ and R⁷ are         taken together with the atoms linking R⁵ and R⁷ to form a 5- to         7-membered ring containing ring members selected from carbon and         optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S         and up to 1 N, and optionally including 1 to 3 ring members         selected from the group consisting of C(═O), C(═S), S(O), S(O)₂         and SiR¹⁷R¹⁸, the ring optionally substituted on ring members         other than the atoms linking R⁵ and R⁷ with substituents         selected from R⁸; and each R⁸ is independently C₁-C₆ alkyl,         C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀         cycloalkylalkyl, C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀         alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆         haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy, amino,         cyano, nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio,         C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio.         C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄         alkylamino. C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄         alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₁-C₆         alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio,         C₂-C₆ alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆         trialkylsilyl.

    -   Embodiment 82c. A compound of Formula 1 wherein when R⁵ and R⁷         are taken together with the atoms linking R⁵ and R⁷ to form an         optionally substituted 5- to 7-membered ring, then R⁵ and R⁷ are         taken together with the atoms linking R⁵ and R⁷ to form a 5- to         7-membered ring containing as ring members 2 to 7 carbon atoms         and optionally 1 to 3 heteroatoms selected from up to 1 O, up to         1 S, up to 1 Si and up to 1 N, the ring optionally substituted         on ring members other than the atoms linking R⁵ and R⁷ with         substituents selected from R⁸; and each R⁸ is independently         C₁-C₆ alkyl, C₁-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl,         C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀         alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆         haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy, amino,         cyano, nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio,         C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,         C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄         alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄         alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆         alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio,         C₂-C₆ alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆         trialkylsilyl.

    -   Embodiment 82d. A compound of Embodiment 82b or 82c wherein the         ring is optionally substituted on ring members other than the         atoms linking R⁵ and R⁷ with up to 4 substituents selected from         R⁸.

    -   Embodiment 82e. A compound of Embodiment 82d wherein the ring is         optionally substituted on ring members other than the atoms         linking R⁵ and R⁷ with up to 2 substituents selected from R⁸.

    -   Embodiment 82f. A compound of Embodiment 82b or 82c wherein each         R⁸ is independently C₁-C₃ alkyl.

    -   Embodiment 82g. A compound of Embodiment 82b wherein when R⁵ and         R⁷ are taken together with the atoms linking R⁵ and R⁷ to form         an optionally substituted 5- to 7-membered ring, then R⁵ and R⁷         are taken together with the atoms linking R⁵ and R⁷ to form a 5-         to 7-membered ring containing ring members selected from carbon         and optionally 1 to 3 heteroatoms selected from up to 1 O, up to         1 S and up to 1 N, and optionally including 1 to 3 ring members         selected from the group consisting of C(═O), C(═S), S(O), S(O)₂         and SiR¹⁷R¹⁸, optionally substituted with up to 2 substituents         selected from R⁸; and each R⁸ is C₁-C₃ alkyl.

    -   Embodiment 82h. A compound of Embodiment 82c wherein when R⁵ and         R⁷ are taken together with the atoms linking R⁵ and R⁷ to form         an optionally substituted 5- to 7-membered ring, then R⁵ and R⁷         are taken together with the atoms linking R⁵ and R⁷ to form a 5-         to 7-membered ring containing as ring members 2 to 7 carbon         atoms and optionally 1 to 3 heteroatoms selected from up to 1 O         up to 1 S and up to 1 N, optionally substituted with up to 2         substituents selected from R⁸; and each R⁸ is C₁-C₃ alkyl.

    -   Embodiment 83. A compound of Formula 1 or Embodiment 75 wherein         p is 0, 1, 2 or 3.

    -   Embodiment 84. A compound of Formula 1 wherein R¹ is an         optionally substituted phenyl or 5- or 6-membered heteroaromatic         ring.

    -   Embodiment 85. A compound of Formula 1 wherein A is CH₂ or NH.

    -   Embodiment 86. A compound of Formula 1 wherein X is selected         from X¹, X², X³, X⁴. X⁵, X⁶, X⁷ and X⁸.

    -   Embodiment 87. A compound of Formula 1 wherein J is a 5- or         6-membered ring, a 8- to 11-membered bicyclic ring system or a         7- to 11-membered spirocyclic ring system, each ring or ring         system containing ring members selected from carbon and         optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S         and up to 3 N, and optionally including 1 to 3 ring members         selected from the group consisting of C(═O), C(═S), S(O) and         S(O)₂, each ring or ring system optionally substituted with 1 to         5 substituents independently selected from R⁵.

    -   Embodiment 88. A compound of Formula 1 wherein J is a phenyl or         5- or 6-membered heteroaromatic ring, or a naphthalenyl or 8- to         11-membered heteroaromatic bicyclic ring system, each ring or         ring system optionally substituted with 1 to 5 substituents         independently selected from R⁵; or J is a 5-, 6- or 7-membered         nonaromatic ring, an 8- to 11-membered nonaromatic bicyclic or a         7- to 11-membered spirocyclic ring system, each ring or ring         system optionally including 1 to 3 ring members selected from         the group consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸,         and optionally substituted with 1 to 5 substituents         independently selected from R⁵.

    -   Embodiment 89. A compound of Formula 1 wherein each R⁵ is         independently H, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₂-C₆ alkynyl,         C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀         alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,         C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,         halogen, hydroxy, amino, cyano, nitro, C₁-C₆ alkoxy, C₁-C₆         haloalkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆         alkylsulfonyl, C₁-C₆ haloalkylthio, C₁-C₆ haloalkylsulfinyl,         C₁-C₆ haloalkylsulfonyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino,         C₃-C₆ cycloalkylamino, C₂-C₆ alkoxyalkyl, C₂-C₆ haloalkoxyalkyl,         C₁-C₆ hydroxyalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ alkoxycarbonyl,         C₂-C₆ alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆         alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₃-C₆         trialkylsilyl, or —Z²Q; each R⁷ is independently C₁-C₆ alkyl,         C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀         cycloalkylalkyl, C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀         alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆         haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy, amino,         cyano, nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio,         C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,         C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄         alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄         alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆         alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio,         C₂-C₆ alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆         trialkylsilyl; or R⁵ and R⁷ are taken together with the atoms         linking R⁵ and R⁷ to form an optionally substituted 5- to         7-membered ring containing as ring members 2 to 7 carbon atoms         and optionally 1 to 3 heteroatoms selected from up to 1 O, up to         1 S and up to 1 N.

    -   Embodiment 90. A compound of Formula 1 wherein each Q is         independently an optionally substituted phenyl, benzyl,         naphthalenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkenyl or 5- or         6-membered heteroaromatic ring, each optionally substituted with         1 to 3 substituents selected from R⁷ on carbon ring members and         R¹² on nitrogen ring members.

    -   Embodiment 90a. A compound of Formula 1 wherein each Q is         independently a 3- to 7-membered nonaromatic carbocyclic ring, a         5-, 6- or 7-membered nonaromatic heterocyclic ring or an 8- to         11-membered nonaromatic bicyclic ring system, each optionally         including ring members selected from the group consisting of         C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸, and optionally         substituted with 1 to 5 substituents independently selected from         R⁷ on carbon atom ring members and R¹² on nitrogen atom ring         members;

    -   Embodiment 91. A compound of Formula 1 wherein each Z¹ and Z² is         independently a direct bond. O, C(═O). S(O)_(m), CHR²⁰ or NR²¹;

    -   Embodiment 92. A compound of Formula 1 wherein R²¹ is H, C₁-C₃         alkyl, C₁-C₃ alkylcarbonyl or C₂-C₃ alkoxycarbonyl.

    -   Embodiment 93. A compound of Formula 1 wherein when G is an         optionally substituted thiazole ring connected at its 2-position         to X and at its 4-position to Z¹ in Formula 1, A is CHR¹⁵, and J         is an optionally substituted isoxazole ring connected at its         4-position to Z¹, then Z¹ is O, C(═O), S(O)_(m), CHR²⁰ or NR²¹.

    -   Embodiment 94. A compound of Formula 1 wherein when G is an         optionally substituted thiazole ring connected at its 2-position         to X and at its 4-position to Z¹ in Formula 1, and J is an         optionally substituted isoxazole ring connected at its         4-position to Z¹, then Z¹ is O, C(═O), S(O)_(m), CHR²⁰ or NR²¹.

    -   Embodiment 95. A compound of Formula 1 wherein when G is an         optionally substituted thiazole ring connected at its 2-position         to X and at its 4-position to Z¹ in Formula 1. A is CHR¹⁵, Z¹ is         a direct bond, and J is an optionally substituted isoxazole         ring, then J is connected to the remainder of the Formula 1 at         the 3- or 5-position of the isoxazole ring.

    -   Embodiment 96. A compound of Formula 1 wherein when G is an         optionally substituted thiazole ring connected at its 2-position         to X and at its 4-position to Z¹ in Formula 1, A is CHR¹⁵, Z¹ is         a direct bond, and J is an optionally substituted isoxazole         ring, then J is connected to the remainder of the Formula 1 at         the 3-position of the isoxazole ring.

    -   Embodiment 97. A compound of Formula 1 wherein when G is an         optionally substituted thiazole ring connected at its 2-position         to X and at its 4-position to Z¹ in Formula 1, Z¹ is a direct         bond, and J is an optionally substituted isoxazole ring, then J         is connected to the remainder of the Formula 1 at the 3-position         of the isoxazole ring.

    -   Embodiment 98. A compound of Formula 1 wherein when X is X² and         the ring containing X is saturated, A is CHR¹⁵, G is an         optionally substituted 5-membered heteroaromatic ring, Z¹ is a         direct bond, and J is a phenyl or 5- or 6-membered         heteroaromatic ring or a naphthalenyl or 8- to 11-membered         heteroaromatic bicyclic ring system, then the J ring or ring         system is substituted with at least one R⁵ that is other than H.

    -   Embodiment 99. A compound of Formula 1 wherein when X is X² and         the ring containing X is saturated, A is CHR¹⁵, G is an         optionally substituted 5-membered heteroaromatic ring, Z¹ is a         direct bond, and J is a phenyl or 5- or 6-membered         heteroaromatic ring or a naphthalenyl or 8- to 11-membered         heteroaromatic bicyclic ring system, then the J ring or ring         system is substituted with at least one R⁵ that is Z²Q.

    -   Embodiment 100. A compound of Formula 1 wherein when X is X¹ and         the ring containing X is saturated, A is NH, G is an optionally         substituted thiazole ring connected at its 2-position to X and         at its 4-position to Z¹ in Formula 1, and J is an optionally         substituted imidazole ring connected at its 2-position to the         remainder of Formula 1, then Z¹ is O, C(═O), S(O)_(m), CHR²⁰ or         NR²¹.

    -   Embodiment 101. A compound of Formula 1 wherein when X is X¹ and         the ring containing X is saturated, A is NR¹⁶, G is an         optionally substituted thiazole ring connected at its 2-position         to X and at its 4-position to Z¹ in Formula 1, and J is an         optionally substituted imidazole ring connected at its         2-position to the remainder of Formula 1, then Z¹ is O, C(═O),         S(O)_(m), CHR²⁰ or NR²¹.

    -   Embodiment 102. A compound of Formula 1 wherein when G is an         optionally substituted thiazole ring connected at its 2-position         to X and at its 4-position to Z¹ in Formula 1, then J is other         than optionally substituted imidazolyl.

    -   Embodiment 103. A compound of Formula 1 wherein each Z⁴ is         independently C(═O) or S(O)₂.

    -   Embodiment 104. A compound of Embodiment 103 wherein each Z⁴ is         C(═O).

    -   Embodiment 105. A compound of Formula 1 wherein         -   each R² is independently C₁-C₄ alkyl, C₁-C₄ alkenyl, C₁-C₄             haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy; or         -   two R² are taken together as C₁-C₃ alkylene or C₂-C₃             alkenylene to form a bridged bicyclic ring system; or         -   two R² attached to adjacent ring carbon atoms joined by a             double bond are

taken together as —CH═CH—CH═CH— optionally substituted with 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, halogen, hydroxy, amino, cyano and nitro.

Combinations of Embodiments 1-105 are illustrated by:

-   -   Embodiment A1. A compound of Formula 1 wherein         -   G is a 5-membered heteroaromatic ring or 5-membered             saturated or partially saturated heterocyclic ring, each             ring optionally substituted with up to 2 substituents             selected from R³ on carbon ring members and selected from             R¹¹ on nitrogen ring members;         -   R¹ is a phenyl or 5- or 6-membered heteroaromatic ring             optionally substituted with 1 to 2 substituents             independently selected from R^(4a) on carbon ring members             and R^(4b) on nitrogen ring members;         -   each R² is independently C₁-C₂ alkyl, C₁-C₂ haloalkyl, C₁-C₂             alkoxy, halogen, cyano or hydroxy;         -   each R³ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or             halogen;         -   each R^(4a) is independently C₁-C₆ alkyl, C₂-C₆ alkenyl,             C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl,             C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₁-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₄             alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄             alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,             C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄             alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆             alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl or C₃-C₆ trialkylsilyl;         -   each R^(4b) is independently C₁-C₆ alkyl, C₃-C₆ alkenyl,             C₃-C₆ alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkyl, C₃-C₆             haloalkenyl, C₃-C₆ haloalkynyl, C₃-C₆ halocycloalkyl or             C₂-C₄ alkoxyalkyl;         -   each R¹¹ is independently C₁-C₃ alkyl;         -   R¹⁵ is H, halogen, cyano, hydroxy, —CHO, C₁-C₄ alkyl, C₁-C₄             haloalkyl or C₂-C₅ alkoxycarbonyl;         -   R¹⁶ is H, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkylcarbonyl,             C₂-C₄ haloalkylcarbonyl or C₁-C₄ alkoxycarbonyl;         -   when R⁵ and R⁷ are taken together with the atoms linking R⁵             and R⁷ to form an optionally substituted 5- to 7-membered             ring, then R⁵ and R⁷ are taken together with the atoms             linking R⁵ and R⁷ to form a 5- to 7-membered ring containing             ring members selected from carbon and optionally 1 to 3             heteroatoms selected from up to 1 O, up to 1 S and up to 1             N, and optionally including 1 to 3 ring members selected             from the group consisting of C(═O), C(═S), S(O), S(O)₂ and             SiR¹⁷R¹⁸, the ring optionally substituted on ring members             other than the atoms linking R⁵ and R⁷ with up to 4             substituents selected from R⁸;         -   each R⁸ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆             alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀             alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₄             alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄             alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,             C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄             alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆             alkylcarbonylthio. C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl or C₃-C₆ trialkylsilyl; and         -   each Z⁴ is independently C(═O) or S(O)₂.     -   Embodiment A2. A compound of Embodiment A1 wherein         -   G is one of G-1 through G-59 (as depicted in Exhibit 2)             wherein the bond projecting to the left is bonded to X, and             bond projecting to the right is bonded to Z¹;         -   J is one of J-1 through J-82 (as depicted in Exhibit 3)             wherein the bond shown projecting to the left is bonded to             Z¹;         -   Q is one of Q-1 through Q-102 (as depicted in Exhibit 4);         -   R¹ is one of U-1 through U-50 (as depicted in Exhibit 1);         -   each R² is independently methyl, methoxy, cyano or hydroxy;         -   each R^(3a) is independently selected from H and R³;         -   each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₂-C₆             alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl,             C₁-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl,             C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₂-C₆             alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl, C₃-C₈             alkoxyalkoxyalkyl, C₂-C₆ alkylthioalkyl, C₂-C₆             alkoxycarbonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈             cycloalkoxy, C₃-C₈ halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy,             C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy,             C₂-C₆ haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆             alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₄-C₈             cycloalkylcarbonyloxy, C₃-C₆ alkylcarbonylalkoxy, C₁-C₆             alkylthio, C₁-C₆ haloalkylthio, C₃-C₈ cycloalkylthio, C₃-C₁₀             trialkylsilyl, —NR²⁵R²⁶ or Z²Q;         -   R^(11a) is selected from H and R¹¹;         -   R¹⁵ is H, cyano, hydroxy, methyl or methoxycarbonyl;         -   R¹⁶ is H, methyl, methylcarbonyl or methoxycarbonyl;         -   each Z⁴ is C(═O);         -   k is 0, 1 or 2;         -   p is 0, 1, 2 or 3; and         -   x is an integer from 0 to 5;     -   provided that:         -   (a) when R⁴ is attached to a carbon ring member, said R⁴ is             selected from R^(4a);         -   (b) when R⁴ is attached to a nitrogen ring member (e.g., in             U-4, U-11 through U-15, U-24 through U-26, U-31 or U-35),             said R⁴ is selected from R^(4b);         -   (c) when G is G-6, G-16 or G-42, and each R^(3a) is other             than H, then R^(11a) is H;         -   (d) when G is G-25 or G-31, then at least one R^(3a) is H;             and         -   (e) when G is one of G-31 through G-35, then Z¹ is a direct             bond or CHR²⁰.     -   Embodiment A3. A compound of Embodiment A2 wherein         -   G is selected from G-1, G-2, G-7, G-8, G-14, G-15, G-23,             G-24, G-26, G-27, G-36, G-37, G-38, G-49, G-50 and G-55;         -   J is selected from J-1, J-2, J-3, J-4, J-5, J-7, J-8, J-9,             J-10. J-11, J-12, J-14, J-15, J-16, J-20, J-24, J-25, J-26,             J-29, J-30, J-37, J-38, J-45 and J-69;         -   each Q is independently Q-1, Q-20, Q-32 through Q-34, Q-45             through Q-47, Q-60 through Q-73, Q-76 through Q-79, Q-84             through Q-94 and Q-98 through Q-102;         -   A is CH₂ or NH;         -   W is O;         -   X is X¹, X² or X³;         -   each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₁-C₆             haloalkyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₂-C₆             alkoxyalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈             cycloalkoxy, C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆             alkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy,             C₂-C₆ haloalkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆             haloalkylthio, C₃-C₁₀ trialkylsilyl, —NR²⁵R²⁶ or Z²Q;         -   Z¹ is a direct bond;         -   Z² is a direct bond or NR²¹;         -   R¹ is selected from U-1 through U-3, U-11, U-13, U-20, U-22,             U-23, U-36 through U-39 and U-50;         -   each R³ is independently methyl or halogen;         -   each R^(4a) is independently C₁—C alkyl, C₁-C₂ haloalkyl,             halogen, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy;         -   each R^(4b) is independently C₁-C₂ alkyl or C₁-C₂ haloalkyl;         -   each R⁷ is independently halogen, cyano, C₁-C₃ alkyl, C₁-C₃             haloalkyl, hydroxy, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy;         -   k is 1 or 2; and         -   n is 0.

Of note are Embodiment A3 compounds wherein one R⁵ is Z²Q and any other R⁵ substituents are independently selected from H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₂-C₆ alkoxyalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₁₀ trialkylsilyl and —NR²⁵R²⁶. Also of note are Embodiment A3 compounds wherein all R⁵ substituents are other than Z²Q (e.g., each R⁵ is independently selected from H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₂-C₆ alkoxyalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₁₀ trialkylsilyl and —NR²⁵R²⁶).

-   -   Embodiment A4. A compound of Embodiment A3 wherein         -   A is CH₂;         -   G is selected from G-1, G-2, G-15, G-26, G-27, G-36, G-37             and G-38; and G is unsubstituted;         -   J is selected from J-4, J-5, J-8, J-11, J-15, J-16, J-20,             J-29, J-30, J-37, J-38, and J-69;         -   Q is selected from Q-1, Q-45, Q-63, Q-64, Q-65, Q-68, Q-69,             Q-70, Q-71, Q-72, Q-73, Q-76, Q-78, Q-79, Q-84, Q-85, Q-98,             Q-99, Q-100, Q-101 and Q-102;         -   X is X¹ or X²; and the ring comprising X is saturated;         -   R¹ is U-1 or U-50;         -   each R^(4a) is independently C₁—C alkyl, trifluoromethyl,             Cl, Br, I or methoxy;         -   each R^(4b) is independently C₁-C₂ alkyl or trifluoromethyl;             and         -   each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₁-C₆             haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —NR²⁵R²⁶ or Z²Q.     -   Embodiment A5. A compound of Embodiment A4 wherein         -   G is selected from G-1, G-2, G-15, G-26 and G-36;         -   J is selected from J-4, J-5, J-11, J-20, J-29, J-37, J-38,             and J-69;         -   Q is selected from Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70,             Q-71, Q-72 and Q-85; and         -   X is X¹.     -   Embodiment A6. A compound of Formula 1 wherein         -   R¹ is an optionally substituted phenyl or 5- or 6-membered             heteroaromatic ring;         -   A is CH₂ or NH;         -   X is X¹, X², X³, X⁴, X⁵, X⁶, X⁷ or X⁸;         -   each R² is independently C₁-C₄ alkyl, C₁-C₄ alkenyl, C₁-C₄             haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy; or         -   two R² are taken together as C₁-C₃ alkylene or C₂-C₃             alkenylene to form a bridged bicyclic ring system; or         -   two R² attached to adjacent ring carbon atoms joined by a             double bond are taken together as —CH═CH—CH═CH— optionally             substituted with 1 to 3 substituents selected from C₁-C₄             alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy,             halogen, hydroxy, amino, cyano and nitro;         -   G is an optionally substituted 5-membered heteroaromatic             ring or 5-membered saturated or partially saturated             heterocyclic ring;         -   J is a 5- or 6-membered ring or a 8- to 11-membered bicyclic             ring system, each ring or ring system containing ring             members selected from carbon and optionally 1 to 3             heteroatoms selected from up to 1 O, up to 1 S and up to 3             N, and optionally including 1 to 3 ring members selected             from the group consisting of C(═O), C(═S), S(O), or S(O)₂,             each ring or ring system optionally substituted with 1 to 5             substituents independently selected from R⁵;         -   each R⁵ is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl,             C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl,             C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₆             alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ alkylthio, C₁-C₆             alkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylthio,             C₁-C₆ haloalkylsulfinyl, C₁-C₆ haloalkylsulfonyl, C₁-C₆             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₆             alkoxyalkyl, C₂-C₆ haloalkoxyalkyl, C₁-C₆ hydroxyalkyl,             C₂-C₆ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆             alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆             alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₃-C₆             trialkylsilyl, or —Z²Q;         -   each Q is independently an optionally substituted phenyl,             benzyl, naphthalenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkenyl             or 5- or 6-membered heteroaromatic ring, each optionally             substituted with 1 to 3 substituents selected from R⁷ on             carbon ring members and R¹² on nitrogen ring members;         -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆             alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀             alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₂-C₆ haloalkenyl, C₁-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₄             alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄             alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,             C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄             alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆             alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl or C₃-C₆ trialkylsilyl; or         -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and             R⁷ to form an optionally substituted 5- to 7-membered ring             containing as ring members 2 to 7 carbon atoms and             optionally 1 to 3 heteroatoms selected from up to 1 O, up to             1 S and up to 1 N;         -   R¹² is C₁-C₃ alkyl:         -   each Z¹ and Z² are independently a direct bond, O, S(O)_(m),             CHR²⁰ or NR²¹; and         -   R²¹ is H or C₁-C₃ alkyl.     -   Embodiment A7. A compound of Embodiment A6 wherein         -   G is a 5-membered heteroaromatic ring or 5-membered             saturated or partially saturated heterocyclic ring, each             ring optionally substituted with up to 2 substituents             selected from R³ on carbon ring members and selected from             R¹¹ on nitrogen ring members;         -   R¹ is a phenyl or 5- or 6-membered heteroaromatic ring             optionally substituted with 1 to 2 substituents             independently selected from R^(4a) on carbon ring members             and R^(4b) on nitrogen ring members;         -   each R³ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or             halogen;         -   each R^(4a) is independently C₁-C₆ alkyl, C₂-C₆ alkenyl,             C₁-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl,             C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₄             alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄             alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,             C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄             alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆             alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl or C₃-C₆ trialkylsilyl;         -   each R^(4b) is independently C₁-C₆ alkyl, C₃-C₆ alkenyl,             C₃-C₆ alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkyl, C₃-C₆             haloalkenyl, C₃-C₆ haloalkynyl, C₃-C₆ halocycloalkyl or             C₂-C₄ alkoxyalkyl;         -   each R¹¹ is independently C₁-C₃ alkyl; and         -   when R⁵ and R⁷ are taken together with the atoms linking R⁵             and R⁷ to form an optionally substituted 5- to 7-membered             ring, then R⁵ and R⁷ are taken together with the atoms             linking R⁵ and R⁷ to form a 5- to 7-membered ring containing             as ring members 2 to 7 carbon atoms and optionally 1 to 3             heteroatoms selected from up to 1 O, up to 1 S and up to 1             N, optionally substituted with up to 2 substituents selected             from R⁸; and each R⁸ is independently C₁-C₃ alkyl.     -   Embodiment A8. A compound of Embodiment A7 wherein         -   G is one of G-1 through G-55 (as depicted in Exhibit 2)             wherein the bond projecting to the left is bonded to X, and             bond projecting to the right is bonded to Z¹;         -   J is one of J-1 through J-82 (as depicted in Exhibit 3)             wherein the bond shown projecting to the left is bonded to             Z¹;         -   Q is one of Q-1 through Q-55 (as depicted in Exhibit 4);         -   R¹ is one of U-1 through U-50 (as depicted in Exhibit 1);         -   each R^(3a) is independently selected from H and R³;         -   R^(11a) is selected from H and R¹¹;         -   k is 0, 1 or 2;         -   p is 0, 1 or 2; and         -   x is an integer from 0 to 5;     -   provided that:         -   (a) when R⁴ is attached to a carbon ring member, said R⁴ is             selected from R^(4a);         -   (b) when R⁴ is attached to a nitrogen ring member (e.g., in             U-4, U-11 through U-15, U-24 through U-26, U-31 or U-35),             said R⁴ is selected from R^(4b);         -   (c) when G is G-6, G-16 or G-42, and each R^(3a) is other             than H, then R^(11a) is H;         -   (d) when G is G-25 or G-31, then at least one R^(3a) is H;             and         -   (e) when G is one of G-31 through G-35, then Z¹ is a direct             bond or CHR²⁰.     -   Embodiment A9. A compound of Embodiment A8 wherein         -   G is selected from G-1, G-2, G-15, G-26, G-27, G-36, G-37             and G-38;         -   J is selected from J-1, J-2, J-3, J-4, J-5, J-7, J-8, J-9,             J-10, J-11, J-12, J-14, J-15, J-16, J-20, J-24, J-25, J-26,             J-29, J-30, J-45 and J-69;         -   each Q is independently Q-1, Q-20, Q-32 to 34, Q-45 Q-46 or             Q-47;         -   W is O;         -   X is X¹, X² or X³;         -   each Z¹ and Z² is a direct bond;         -   R¹ is selected from U-1 through U-3, U-11, U-13, U-20, U-22,             U-23, U-36 through U-39 and U-50;         -   each R³ is independently methyl or halogen;         -   each R^(4a) is independently C₁-C₂ alkyl, C₁-C₂ haloalkyl,             halogen or C₁-C₂ alkoxy;         -   each R^(4b) is independently C₁-C₂ alkyl or C₁-C₂ haloalkyl;         -   one instance of R⁵ is Z²Q and other instances of R⁵ are             independently selected from H, C₁-C₄ alkyl, C₁-C₄ haloalkyl             and halogen;         -   each R⁷ is independently halogen, C₁-C₃ alkyl, C₁-C₃             haloalkyl, hydroxy, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy;         -   k is 1 or 2; and         -   n is 0.     -   Embodiment A10. A compound of Embodiment A9 wherein         -   A is CH₂;         -   G is selected from G-1, G-2, G-15, G-26, and G-36; and G is             unsubstituted;         -   J is selected from J-11, J-25, J-26, J-29 and J-30;         -   Q is selected from Q-1 and Q-45;         -   X is X¹ or X²; and the ring comprising X is saturated;         -   R¹ is U-1 or U-50;         -   each R^(4a) is independently C₁-C₂ alkyl, trifluoromethyl,             Cl, Br, I or methoxy; and         -   each R^(4b) is independently C₁-C₂ alkyl or trifluoromethyl.     -   Embodiment A11. A compound of Embodiment A10 wherein         -   J is selected from J-11 and J-29;         -   X is X¹; and         -   each R^(4a) is independently C₁-C₂ alkyl, trifluoromethyl or             Cl.     -   Embodiment A12. A compound of Formula 1 wherein         -   R¹ is U-1 or U-50 (as depicted in Exhibit 1) wherein when R⁴             is attached to a carbon ring member, said R⁴ is selected             from R^(4a), and when R⁴ is attached to a nitrogen ring             member, said R⁴ is selected from R^(4b);         -   each R^(4a) is independently C₁-C₂ alkyl, trifluoromethyl,             Cl, Br, I or methoxy;         -   each R^(4b) is independently C₁-C₂ alkyl or trifluoromethyl;         -   A is CH₂;         -   W is O;         -   X is X¹ or X² and ring comprising X is saturated;         -   each R² is independently ethyl, methoxy, cyano or hydroxy;         -   G is selected from G-1, G-2, G-15, G-26 and G-36 (as             depicted in Exhibit 2) wherein the bond projecting to the             left is bonded to X, and bond projecting to the right is             bonded to Z¹; and G is unsubstituted;         -   each R^(3a) is independently selected from H and R³;         -   each R³ is independently methyl or halogen;         -   J is selected from J-11, J-25, J-26, J-29 and J-30 (as             depicted in Exhibit 3); wherein the bond shown projecting to             the left is bonded to Z¹;         -   each R⁵ is independently H, halogen, cyano, hydroxy, amino,             nitro, —CHO, —C(═O)OH, —C(═O)NH₂, —NR²⁵R²⁶, C₁-C₆ alkyl,             C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆             haloalkenyl. C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈             halocycloalkyl, C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀             cycloalkylalkyl, C₆-C₁₄ cycloalkylcycloalkyl, C₄-C₁₀             halocycloalkylalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₃-C₈             cycloalkenyl, C₃-C₈ halocycloalkenyl, C₂-C₆ alkoxyalkyl,             C₄-C₁₀ cycloalkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆             alkylthioalkyl, C₂-C₆ alkylsulfinylalkyl, C₁-C₆             alkylsulfonylalkyl, C₂-C₆ alkylaminoalkyl, C₃-C₈             dialkylaminoalkyl, C₂-C₆ haloalkylaminoalkyl, C₄-C₁₀             cycloalkylaminoalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆             haloalkylcarbonyl, C₄-C₈ cycloalkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₄-C₈ cycloalkoxycarbonyl, C₅-C₁₀             cycloalkylalkoxycarbonyl, C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl, C₄-C₈ cycloalkylaminocarbonyl, C₁-C₆             alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₃-C₈             halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy, C₂-C₆ alkenyloxy,             C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆             haloalkynyloxy, C₁-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy,             C₂-C₆ haloalkylcarbonyloxy, C₄-C₈ cycloalkylcarbonyloxy.             C₃-C₆ alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆             haloalkylthio, C₃-C₈ cycloalkylthio, C₁-C₆ alkylsulfinyl,             C₁-C₆ haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆             haloalkylsulfonyl, C₃-C₈ cycloalkylsulfonyl, C₃-C₁₀             trialkylsilyl, C₁-C₆ alkylsulfonylamino, C₁-C₆             haloalkylsulfonylamino or —Z²Q;         -   R²⁵ is H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl,             C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆             alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl;         -   R²⁶ is C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₂-C₆             alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ haloalkoxycarbonyl or —Z⁴Q;         -   each Q is selected from Q-1, Q-45 and Q-63 (as depicted in             Exhibit 4);         -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆             alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀             alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₄             alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄             alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,             C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄             alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆             alkylcarbonylthio. C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl or C₃-C₆ trialkylsilyl; or         -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and             R⁷ to form a 5- to 7-membered ring containing as ring             members 2 to 7 carbon atoms and optionally 1 to 3             heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si             and up to 1 N, the ring optionally substituted on ring             members other than the atoms linking R⁵ and R⁷ with up to 4             substituents selected from R⁸;         -   each R⁸ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆             alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀             alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆             haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆             halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C₁-C₄             alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄             alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio,             C₁-C₄ haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄             alkylamino, C₂-C₈ dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄             alkoxyalkyl, C₁-C₄ hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆             alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆             alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl, C₃-C₈             dialkylaminocarbonyl or C₃-C₆ trialkylsilyl;         -   R¹² is C₁-C₃ alkyl;         -   each Z¹ and Z² is a direct bond;         -   each Z⁴ is independently C(═O) or S(O)₂;         -   n is 0, 1 or 2;         -   k is 0, 1 or 2;         -   p is 0, 1 or 2; and         -   x is an integer from 0 to 5;             provided that when R¹ is unsubstituted thienyl, X is X¹, G             is an unsubstituted thiazole ring connected at its             2-position to X and at its 4-position to Z¹ in Formula 1,             and J is an isoxazole ring connected at its 4-position to Z¹             and substituted at its 5-position with methyl, then J is not             substituted and at its 3-position with meta-substituted             phenyl.

Embodiments of the present invention also include:

-   -   Embodiment B1. A compound of Formula 1A wherein each R^(4a1) and         R^(4a2) is independently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃         alkynyl, cyclopropyl, C₁-C₃ haloalkyl, halocyclopropyl, halogen,         cyano, nitro, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.     -   Embodiment B2. A compound of Embodiment B1 wherein each R^(4a1)         and R^(4a2) is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl,         halogen, cyano, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.     -   Embodiment B3. A compound of Embodiment B2 wherein each R^(4a1)         and R^(4a2) is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or         halogen.     -   Embodiment B4. A compound of Formula 1A wherein A^(a) is H.     -   Embodiment B5. A compound of Formula 1A wherein A^(a) is         CH₂CO₂H.     -   Embodiment B6. A compound of Formula 1A wherein A^(a) is         CH₂CO₂R³⁰.     -   Embodiment B7. A compound of Formula 1A wherein A^(a) is         CH₂C(═O)Cl.     -   Embodiment B8. A compound of Formula 1B wherein each R^(4a1) and         R^(4a2) is independently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃         alkynyl, cyclopropyl, C₁-C₃ haloalkyl, halocyclopropyl, halogen,         cyano, nitro, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.     -   Embodiment B9. A compound of Embodiment B8 wherein each R^(4a1)         and R^(4a2) is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl,         halogen, cyano, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.     -   Embodiment B10. A compound of Embodiment B9 wherein each R^(4a1)         and R^(4a2) is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or         halogen.     -   Embodiment B11. A compound of Formula 1B wherein Z³ is CN.     -   Embodiment B12. A compound of Formula 1B wherein Z³ is C(═S)NH₂.

With regards to the compounds of Formula 1C of this invention, it is noted that various embodiments of J-29 can be present in two or more enantiomeric forms. The enantiomeric forms of J-29 embodiments for compounds of Formula 1C of this invention are those depicted about in the Exhibit A above. All J-29 enantiomers are included in the Formula 1C compounds in this invention for embodiments where no specific J-29 enantiomeric form is depicted (e.g., J-29-33 enantiomers and J-29-22 enantiomers based on the methyl group position).

-   -   Embodiment B13. A compound of Formula 1C wherein M is C₁-C₂         alkyl, C₁-C₂ haloalkyl, hydroxy, C₁-C₄ alkoxy, C₁-C₂ haloalkoxy,         C₁-C₃ alkylamino, C₂-C₆ dialkylamino, 1-piperidinyl,         1-pyrrolidinyl or 4-morpholinyl.

Specific embodiments include compounds of Formula 1 selected from the group consisting of:

-   4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine     and its enantiomer (Compound 1), -   1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine     (Compound 2), -   1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 15), -   2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(3aS,9bR),3a,4,5,9b-tetrahydronaphth[2,1-d]isoxazol-3-yl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 16), -   1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-ethyl-3-(trifluoromethyl)-1-pyrazol-1-yl]ethanone     and its enantiomer (Compound 19), -   2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 22), -   1-[4-[4-[(5R)-3′,4′-dihydrospiro[isoxazole-5(4H),1′,(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 37), -   1-[4-[4-[(5R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 44), -   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoly]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 107), -   2-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl-5-isoxazolyl]-1H-isoindole-1,3(2H)-dione     and its enantiomer (Compound 129), -   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 232), -   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4H),1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 230), -   2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(3R)-spiro[benzofuran-3(2H),5′(4′H)-isoxazol]-3′-yl-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 185), -   1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)ethanone     and its enantiomer (Compound 165), -   2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4H),1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 229), -   2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 231), -   1-[4-[4-[(5R)-5-(2,6-dichlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 135), -   1-[4-[4-[(5R)-4,5-dihydro-5-[2-(trifluoromethyl)phenyl]-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 79), -   1-[4-[4-[(5R)-4,5-dihydro-5-(2-methylphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 161), -   1-[4-[4-[(5R)-5-(2,6-dimethylphenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 178), -   1-[4-[4-[(5R)-4,5-dihydro-5-(2,4,6-trimethylphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 179), -   1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4H),1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)ethanone     and its enantiomer (Compound 164), -   1-[4-[4-[(5R)-4,5-dihydro-5-(2,4,6-trimethoxyphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 155), -   3-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]-2(3H)-benzoxazolone     and its enantiomer (Compound 225), -   1-[4-[4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 214), -   2-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]benzonitrile     and its enantiomer (Compound 220), -   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 261), -   2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanone     and its enantiomer (Compound 260), -   1-[4-[4-[(5R)-5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 8), -   1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 128), -   1-[4-[4-[(4S)-2,3-dihydrospiro[4H-1-benzopyran-4,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone     and its enantiomer (Compound 137), and -   (5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-phenyl-5-isoxazolecarbonitrile     and its enantiomer (Compound 265).

Specific embodiments also include compounds of Formula 1B selected from the group consisting of:

-   1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide, -   1-[2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide, -   1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile,     and -   1-[2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile.

Of note are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and agriculturally suitable salts thereof, agricultural compositions containing them and their use as fungicides wherein R¹ is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring;

-   -   A is CH₂ or NH;     -   X is X¹, X², X³, X⁴, X⁵, X⁶, X⁷ or X⁸;     -   each R² is independently C₁-C₄ alkyl, C₁-C₄ alkenyl, C₁-C₄         haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy; or     -   two R² are taken together as C₁-C₃ alkylene or C₂-C₃ alkenylene         to form a bridged bicyclic ring system; or     -   two R² attached to adjacent ring carbon atoms joined by a double         bond are taken together as —CH═CH—CH═CH— optionally substituted         with 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, halogen, hydroxy,         amino, cyano and nitro;     -   J is a 5- or 6-membered ring or a 8- to 11-membered bicyclic         ring system, each ring or ring system containing ring members         selected from carbon and optionally 1 to 3 heteroatoms selected         from up to 1 O, up to 1 S and up to 3 N, and optionally         including 1 to 3 ring members selected from the group consisting         of C(═O), C(═S). S(O), or S(O)₂, each ring or ring system         optionally substituted with 1 to 5 substituents independently         selected from R⁵;     -   each R⁵ is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀         alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,         C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,         halogen, hydroxy, amino, cyano, nitro, C₁-C₆ alkoxy, C₁-C₆         haloalkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆         alkylsulfonyl, C₁-C₆ haloalkylthio, C₁-C₆ haloalkylsulfinyl,         C₁-C₆ haloalkylsulfonyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino,         C₃-C₆ cycloalkylamino, C₂-C₆ alkoxyalkyl, C₂-C₆ haloalkoxyalkyl,         C₁-C₆ hydroxyalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ alkoxycarbonyl,         C₂-C₆ alkylcarbonyloxy, C₁-C₆ alkylcarbonylthio, C₂-C₆         alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₃-C₆         trialkylsilyl, or —Z²Q;     -   each Q is independently an optionally substituted phenyl,         benzyl, naphthalenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkenyl or 5-         or 6-membered heteroaromatic ring, each optionally substituted         with 1 to 3 substituents selected from R⁷ on carbon ring members         and R¹² on nitrogen ring members;     -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀         alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,         C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,         halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄         haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄         alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,         C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,         C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,         C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆         alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆         alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆         trialkylsilyl; or     -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to         form an optionally substituted 5- to 7-membered ring containing         as ring members 2 to 7 carbon atoms and optionally 1 to 3         heteroatoms selected from up to 1 O, up to 1 S and up to 1 N;     -   R¹² is C₁-C₃ alkyl;     -   each Z¹ and Z² is independently a direct bond, 0. S(O)_(m),         CHR²⁰ or NR²¹;     -   m is 0, 1 or 2 (which is understood to mean that each m is         independently 0, 1 or 2); and     -   R²¹ is H or C₁-C₃ alkyl (subject to proviso (b) and/or         proviso (c) as applicable).

Also of note are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides wherein

-   -   each R⁵ is independently H, halogen, cyano, hydroxy, amino,         nitro, —CHO, —C(═O)OH, —C(═O)NH₂, —NR²⁵R²⁶, C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl,         C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl,         C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₆-C₁₄         cycloalkylcycloalkyl, C₄-C₁₀ halocycloalkylalkyl, C₅-C₁₀         alkylcycloalkylalkyl, C₃-C₈ cycloalkenyl, C₃-C₈         halocycloalkenyl, C₂-C₆ alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl,         C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆ alkylthioalkyl, C₂-C₆         alkylsulfinylalkyl, C₂-C₆ alkylsulfonylalkyl, C₂-C₆         alkylaminoalkyl, C₃-C₈ dialkylaminoalkyl, C₂-C₆         haloalkylaminoalkyl, C₄-C₁₀ cycloalkylaminoalkyl, C₂-C₆         alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₄-C₈         cycloalkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₄-C₈         cycloalkoxycarbonyl, C₅-C₁₀ cycloalkylalkoxycarbonyl, C₂-C₆         alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₄-C₈         cycloalkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈         cycloalkoxy, C₃-C₈ halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy,         C₂-C₆ alkenyloxy, C₁-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆         haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy,         C₂-C₆ haloalkylcarbonyloxy, C₄-C₈ cycloalkylcarbonyloxy, C₃-C₆         alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈         cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl,         C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈         cycloalkylsulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆         alkylsulfonylamino, C₁-C₆ haloalkylsulfonylamino or —Z²Q;     -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀         alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,         C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,         halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄         haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄         alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,         C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,         C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,         C₂-C₄ alkylcarbonyl. C₂-C₆ alkoxycarbonyl, C₂-C₆         alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆         alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆         trialkylsilyl; or     -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to         form an optionally substituted 5- to 7-membered ring containing         as ring members 2 to 7 carbon atoms and optionally 1 to 3         heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and         up to 1 N; and     -   R¹² is C₁-C₃ alkyl (subject to proviso (b) and/or proviso (c) as         applicable).

This invention provides a fungicidal composition comprising a compound of Formula 1 (including all geometric and stereoisomers. N-oxides, and salts thereof), and at least one other fungicide. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.

This invention provides a fungicidal composition comprising a fungicidally effective amount of a compound of Formula 1 (including all geometric and stereoisomers, N-oxides, and agriculturally suitable salts thereof), and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.

This invention provides a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1 (including all geometric and stereoisomers, N-oxides, and agriculturally suitable salts thereof). Of note as embodiment of such methods are methods comprising applying a fungicidally effective amount of a compound corresponding to any of the compound embodiments describe above. Of particular notes are embodiments where the compounds are applied as compositions of this invention.

The compounds of Formulae 1, 1A, 1B and 1C can be prepared by one or more of the following methods and variations as described in Schemes 1-20. The definitions of A, G, J, W, X, Q, Z¹, R¹, R², R¹⁵, R¹⁶ and n in the compounds of Formulae 1-38 below are as defined above in the Summary of the Invention unless otherwise noted. Formulae 1a-1e and Formulae 1Ba and 1Bb are various subsets of Formula 1 and 1B respectively.

As shown in Scheme 1, compounds of Formula 1a (Formula 1 wherein A is CHR¹⁵) wherein W is O can be prepared by coupling of an acid chloride of Formula 2 with an amine of Formula 3 in the presence of an acid scavenger. Typical acid scavengers include amine bases such as triethylamine, N,N-diisopropylethylamine and pyridine. Other scavengers include hydroxides such as sodium and potassium hydroxide and carbonates such as sodium carbonate and potassium carbonate. In certain instances it is useful to use polymer-supported acid scavengers such as polymer-bound N,N-diisopropylethylamine and polymer-bound 4-(dimethylamino)pyridine. Acid salts of the Formula 3 amines can also be used in this reaction, provided that at least 2 equivalents of the acid scavenger is present. Typical acids used to form salts with amines include hydrochloric acid, oxalic acid and trifluoroacetic acid. In a subsequent step, amides of Formula 1a wherein W is O can be converted to thioamides of Formula 1a wherein W is S using a variety of standard thiating reagents such as phosphorus pentasulfide or 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent).

An alternate procedure for the preparation of compounds of Formula 1a wherein W is O is depicted in Scheme 2 and involves coupling of an acid of Formula 4 with an amine of Formula 3 (or its acid salt) in the presence of a dehydrative coupling reagent such as dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or O-benzotriazol-1-yl-N,N,N′N′-tetramethyluronium hexafluoro-phosphate (HBTU). Polymer-supported reagents are again useful here, such as polymer-bound cyclohexylcarbodiimide. These reactions are typically run at 0-40° C. in a solvent such as dichloromethane or acetonitrile in the presence of a base such as triethylamine or N,N-diisopropylethylamine. The acids of Formula 4 are known or can be prepared by methods known to one skilled in the art. For example, R¹CH₂COOH where R¹ is a heteroaromatic ring linked through nitrogen can be prepared by reacting the corresponding R¹H compound with a haloacetic acid or ester in the presence of base; see, for example, U.S. Pat. No. 4,084,955. R¹CH₂COOH wherein R¹ is a phenyl or a heteroaromatic ring linked through carbon can be prepared from the corresponding R¹CH₂-halogen compounds by displacement of the halogen with cyanide followed by hydrolysis; see, for example, K. Adachi, Yuki Gosei Kagaku Kvokaishi 1969, 27, 875-876; from R¹C(═O)CH₃ by the Willgerodt-Kindler reaction; see, for example, H. R. Darabi et al., Tetrahedron Letters 1999, 40, 7549-7552 and M. M. Alam and S. R. Adapa, Synthetic Communications 2003, 33, 59-63 and references cited therein; or from R¹Br or R1I by palladium-catalyzed coupling with tert-butyl acetate or diethyl malonate followed by ester hydrolysis; see, for example, W. A. Moradi and S. L. Buchwald, J. Am. Chem. Soc. 2001, 123, 7996-8002 and J. F. Hartwig et al., J. Am. Chem. Soc. 2002, 124, 12557-12565.

As the synthetic literature includes many amide-forming methods, the synthetic procedures of Schemes 1 and 2 are simply representative examples of an wide variety of methods useful for the preparation of Formula 1 compounds. One skilled in the art also realizes that acid chlorides of Formula 2 can be prepared from acids of Formula 4 by numerous well-known methods.

Certain compounds of Formula 1b (Formula 1 wherein A is CHR¹⁵ and W is O) wherein R¹ is a 5-membered nitrogen-containing heteroaromatic ring linked through the nitrogen atom can be prepared by reaction of the parent heterocycle of Formula 5 and a haloacetamide of Formula 6 as shown in Scheme 3. The reaction is carried out in the presence of a base such as sodium hydride or potassium carbonate in a solvent such as tetrahydrofuran, N,N-dimethylformamide or acetonitrile at 0 to 80° C. The haloacetamide of Formula 6 can be prepared by the reaction of an amine of Formula 3 with an α-halo carboxylic acid halide or an α-halo carboxylic acid or its anhydride, analogous to the amide-forming reactions described in Schemes 1 and 2, respectively.

wherein R¹ is a 5-membered nitrogen-containing heteroaromatic ring unsubstituted on N; and Y¹ is Cl, Br or I.

Compounds of Formulae 1c (Formula 1 wherein A is NH), wherein R¹ is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, and W is O or S, can be prepared by reaction of an amine of Formula 3 with an isocyanate or isothiocyanate, respectively, of Formula 7 as depicted in Scheme 4. This reaction is typically carried out at an ambient temperature in an aprotic solvent such as dichloromethane or acetonitrile.

Compounds of Formulae 1c can also be prepared by the reaction of an amine of Formula 8 with a carbamoyl or thiocarbamoyl chloride or imidazole of Formula 9 as shown in Scheme 5. When Y is chlorine, the reaction is typically carried out in the presence of an acid scavenger. Typical acid scavengers include amine bases such as triethylamine, N,N-diisopropylethylamine and pyridine. Other scavengers include hydroxides such as sodium and potassium hydroxide and carbonates such as sodium carbonate and potassium carbonate. The carbamoyl or thiocarbamoyl chlorides of Formula 9 (wherein Y is Cl) can be prepared from amines of Formula 3 by treatment with phosgene or thiophosgene, respectively, or their equivalents, while carbamoyl or thiocarbamoyl imidazoles of Formula 9 (wherein Y is imidazol-1-yl) can be prepared from amines of Formula 3 by treatment with 1,1′-carbonyldiimidazole or 1,1′-thiocarbonyldiimidazole, respectively, according to general methods known to one skilled in the art.

wherein W is O or S; and Y is Cl or imidazol-1-yl.

Certain compounds of Formula 1d (i.e. Formula 1 in which the ring containing X is saturated) can be prepared from compounds of Formula 1e where the ring containing X is unsaturated by catalytic hydrogenation as shown in Scheme 6. Typical conditions involve exposing a compound of Formula 1e to hydrogen gas at a pressure of 70 to 700 kPa, preferably 270 to 350 kPa, in the presence of a metal catalyst such as palladium supported on an inert carrier such as activated carbon, in a weight ratio of 5 to 20% of metal to carrier, suspended in a solvent such as ethanol at an ambient temperature. This type of reduction is very well known; see, for example, Catalytic Hydrogenation, L. Cerveny, Ed., Elsevier Science, Amsterdam, 1986. One skilled in the art will recognize that other certain functionalities that may be present in compounds of Formula 1e can also be reduced under catalytic hydrogenation conditions, thus requiring a suitable choice of catalyst and conditions.

wherein X is X¹, X², X⁵, X⁸ or X⁹.

Certain compounds of Formula 1 wherein X is X¹, X⁵, X⁷ or X⁹, and G is linked to the ring containing X via a nitrogen atom, can be prepared by displacement of an appropriate leaving group Y² on the ring containing the X of Formula 10 with a nitrogen-containing heterocycle of Formula 11 in the presence of a base as depicted in Scheme 7. Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as N,N-dimethylformamide or acetonitrile at 0 to 80° C. Suitable leaving groups in the compounds of Formula 10 include bromide, iodide, mesylate (OS(O)₂CH₃), triflate (OS(O)₂CF₃) and the like, and compounds of Formula 10 can be prepared from the corresponding compounds wherein Y² is OH, using general methods known in the art.

wherein W is O or S; X is X¹, X⁵, X⁷ or X⁹; and Y² is a leaving group such as Br, I, OS(O)₂Me or OS(O)₂CF₃.

Compounds of Formula 1 wherein X is X² or X⁸ can be prepared by reaction of a compound of Formula 12 with a heterocyclic halide or triflate (OS(O)₂CF₃) of Formula 13 as shown in Scheme 8. The reaction is carried out in the presence of a base such as potassium carbonate in a solvent such as dimethylsulfoxide, N,N-dimethylformamide or acetonitrile at 0 to 80° C. Compounds of Formula 13 wherein Y² is triflate can be prepared from corresponding compounds wherein Y² is OH by methods known to one skilled in the art.

wherein W is O or S; X is X² or X⁸; and Y² is a leaving group such as Br, IOS(O)₂Me or OS(O)₂CF₃.

The amine compounds of Formula 3 can be prepared from the protected amine compounds of Formula 14 where Y³ is an amine-protecting group as shown in Scheme 9. A wide array of amine-protecting groups are available (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis. 2nd ed.; Wiley: New York, 1991), and the use and choice of the appropriate protecting groups will be apparent to one skilled in chemical synthesis. The protecting group can be removed and the amine isolated as its acid salt or the free amine by general methods known in the art. One skilled in the art will also recognize that the protected amines of Formula 14 can be prepared by methods analogous to those described in Schemes 6, 7, and 8 above where the group R¹AC(═W) is replaced by Y³ to give useful intermediates of Formula 14 for the preparation of compounds of Formula 1.

The compounds of Formula 14 can also be prepared by reaction of a suitably functionalized compound of Formula 15 with a suitably functionalized compound of Formula 16 as shown in Scheme 10. The functional groups Y⁴ and Y⁵ are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines, amideoximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates, and the like, which under the appropriate reaction conditions, will allow the construction of the various heterocyclic rings G. As an example, reaction of a compound of Formula 15 where Y⁴ is a thioamide group with a compound of Formula 16 where Y⁵ is a bromoacetyl group will give a compound of Formula 14 where G is a thiazole ring. The synthetic literature describes many general methods for forming 5-membered heteroaromatic rings and 5-membered partially saturated heterocyclic rings (e.g., G-1 through G-59); see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984; Comprehensive Heterocyclic Chemistry II, Vol. 2-4, A. R. Katritzky, C. W. Rees, and E. F. Scriven editors, Pergamon Press, New York, 1996; and the series, The Chemistry of Heterocyclic Compounds, E. C. Taylor, editor, Wiley, New York. The use of intermediates of Formula 15 where X is X¹ and Y⁴ is Br, I, methanesulfonate or trifluoromethanesulfonate to prepare organozinc reagents for use in cross-coupling reactions with aromatic rings has been described; see, for example, S. Bellotte. Synlett 1998, 379-380, and M. Nakamura et al., Synlett 2005, 1794-1798. One skilled in the art knows how to select the appropriate functional groups to construct the desired heterocyclic rings such as G. Compounds of Formula 15 and 16 are known or can be prepared by one skilled in the art.

wherein Y⁴ and Y⁵ are functional groups suitable for construction of the desired heterocycle G.

Certain compounds of Formula 14 where Z¹ is O, S, or NR²¹ can be prepared by displacement of an appropriate leaving group Y² on G of Formula 17 with a compound of Formula 18 in the presence of a base as depicted in Scheme 11. Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as N,N-dimethylformamide or acetonitrile at 0 to 80° C. Suitable leaving groups in the compounds of Formula 17 include bromide, iodide, mesylate (OS(O)₂CH₃), triflate (OS(O)₂CF₃) and the like. Compounds of Formula 17 can be prepared from corresponding compounds wherein Y² is OH by general methods known in the art. Many of the compounds of Formula 18 are known or can be prepared by general methods known in the art.

wherein Y² is a leaving group such as Br, I, OS(O)₂Me or OS(O)₂CF₃; and Z¹ is O, S or NR²¹.

Certain compounds of Formula 14 where Z¹ is O, S, or NR²¹ can also be prepared by displacement of an appropriate leaving group Y² on J of Formula 20 with a compound of Formula 19 in the presence of a base as depicted in Scheme 12. Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as N,N-dimethylformamide or acetonitrile at 0 to 80° C. Suitable leaving groups in the compounds of Formula 20 include bromide, iodide, mesylate (OS(O)₂CH₃), triflate (OS(O)₂CF₃) and the like. Compounds of Formula 20 can be prepared from corresponding compounds wherein Y² is OH using general methods known in the art.

wherein Y² is a leaving group such as Br, I, OS(O)₂Me or OS(O)₂CF₃; and Z¹ is O, S or NR²¹.

Compounds of Formula 14 can also be prepared by reaction of a suitably functionalized compound of Formula 21 with a suitably functionalized compound of Formula 22 as shown in Scheme 13. The functional groups Y⁶ and Y⁷ are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines, amide oximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates, and the like, which, under the appropriate reaction conditions will allow the construction of the various heterocyclic rings J. As an example, reaction of a compound of Formula 21 where Y⁶ is a chloro oxime moiety with a compound of Formula 22 where Y⁷ is a vinyl or acetylene group in the presence of base will give a compound of Formula 14 where J is an isoxazoline or isoxazole, respectively. The synthetic literature includes many general methods for the formation of carbocyclic and heterocyclic rings and ring systems (for example, J-1 through J-82); see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984; Comprehensive Heterocyclic Chemistry II, Vol. 2-4, A. R. Katritzky, C. W. Rees, and E. F. Scriven editors, Pergamon Press, New York, 1996; the series, The Chemistry of Heterocyclic Compounds, E. C. Taylor, editor, Wiley, New York, and Rodd's Chemistry of Carbon Compounds, Vol. 2-4, Elsevier, New York. General procedures for cycloaddition of nitrile oxides with olefins are well documented in the chemical literature. For relevant references see Lee, Synthesis 1982, 6, 508-509 and Kanemasa et al., Tetrahedron 2000, 56, 1057-1064 as well as references cited within. One skilled in the art knows how to select the appropriate functional groups to construct the desired heterocyclic ring J. Compounds of Formula 22 are known or can be prepared by general methods known in the art.

wherein Y⁶ and Y⁷ are functional groups suitable for construction of the desired heterocycle J.

An alternate preparation for the compounds of Formula 14 where Z¹ is a bond includes the well known Suzuki reaction involving Pd-catalyzed cross-coupling of an iodide or bromide of Formula 23 or 26 with a boronic acid of Formula 24 or 25, respectively, as shown in Scheme 14. Many catalysts are useful for this type of transformation; a typical catalyst is tetrakis(triphenylphosphine)palladium. Solvents such as tetrahydrofuran, acetonitrile, diethyl ether and dioxane are suitable. The Suzuki reaction and related coupling procedures offer many alternatives for creation of the G-J bond. For leading references see for example C. A. Zificsak and D. J. Hlasta, Tetrahedron 2004, 60, 8991-9016. For a thorough review of palladium chemistry applicable to the synthesis of G-J bonds see J. J. Li and G. W. Gribble, editors, Palladium in Heterocyclic Chemistry: A Guide for the Synthetic Chemist, Elsevier: Oxford, UK, 2000. Many variations of catalyst type, base and reaction conditions are known in the art for this general method.

One skilled in the art will recognize that many compounds of Formula 1 can be prepared directly by methods analogous to those described in Schemes 10 through 14 above where the group Y³ is replaced by R¹AC(═W). Thus, compounds corresponding to Formulae 15, 17, 19, 21, 23 and 25 in which Y³ is replaced by R¹AC(═W) are useful intermediates for the preparation of compounds of Formula 1.

Thioamides of Formula 1Bb are particularly useful intermediates for preparing compounds of Formula 1 wherein X is X¹. A thioamide of Formula 1Bb can be prepared by the addition of hydrogen sulfide to the corresponding nitrile of Formula 1Ba as shown in Scheme 15.

wherein R¹ as defined for Formula 1.

The method of Scheme 15 can be carried out by contacting a compound of Formula 1Ba with hydrogen sulfide in the presence of an amine such as pyridine, diethylamine or diethanolamine. Alternatively, hydrogen sulfide can be used in the form of its bisulfide salt with an alkali metal or ammonia. This type of reaction is well documented in the literature (e.g., A. Jackson et al., EP 696,581 (1996)).

Certain compounds of Formula 1Ba wherein R¹ is a 5-membered nitrogen-containing heteroaromatic ring linked through a nitrogen atom can be prepared by reaction of the parent heterocycle of Formula 5 and a haloacetamide of Formula 27 as shown in Scheme 16. The reaction is carried out in the presence of a base such as sodium hydride or potassium carbonate in a solvent such as tetrahydrofuran, N,N-dimethylformamide or acetonitrile at 0 to 80° C.

wherein R¹ is a 5-membered nitrogen-containing heteroaromatic ring unsubstituted on N (i.e. a 5-membered heteroaromatic ring comprising a ring member of the formula —(NH)—); and Y¹ is Cl, Br or I.

The haloacetamides of Formula 27 can be prepared by the two methods shown in Scheme 17.

wherein Y¹ is Cl, Br, or I; and R³¹ is a tertiary alkyl group such as —C(Me)₃.

In one method, 4-cyanopiperidine of Formula 29 is haloacetylated by contact with the appropriate haloacetyl chloride typically in the presence of a base according to standard methods. Preferred conditions involve use of an aqueous solution of an inorganic base such as an alkali metal or alkaline-earth carbonate, bicarbonate, or phosphate, and a non-water-miscible organic solvent such as toluene, ethyl acetate or 1,2-dichloroethane. In the second method depicted in Scheme 17, a 1-(haloacetyl)-N-substituted isonipecotamide derivative of Formula 28, wherein R³¹ is tertiary alkyl such as C(Me)₃, is dehydrated using a standard amide dehydrating agent such as thionyl chloride or phosphorus oxychloride in a suitable solvent. A particularly preferred solvent for this transformation is an N,N-dialkylamide such as N,N-dimethylformamide. The reaction is typically carried out by adding 0.9 to 2 equivalents, preferably 1.1 equivalents, of phosphorus oxychloride or thionyl chloride, to a mixture of a compound of Formula 28 and 0.5 to 10 parts by weight of solvent, at a temperature at which the reaction rapidly proceeds during the addition. The addition time for this reaction is typically around 20 to 90 minutes at typical temperatures of around 35 to 55° C.

As shown in Scheme 18, the compounds of Formula 28 can be prepared from the compound of Formula 30 by analogy with the haloacetylation reaction described for Scheme 17.

The compounds of Formula 30 are known or can be prepared from 4-cyanopyridine or isonicotinic acid using methods well-known in the art; see, for example, G. Marzolph, et al., DE 3,537,762 (1986) for preparation of N-t-butyl pyridinecarboxamides from cyanopyridines and t-butanol and S. F. Nelsen, et al., J. Org. Chem., 1990, 55, 3825 for hydrogenation of N-methylisonicotinamide with a platinum catalyst.

Halomethyl isoxazole ketones of Formula 35 are particularly useful intermediates for preparing certain chiral compounds of Formula 1 wherein J is, for example, selected from J-29-1 through J-29-12 as depicted in Exhibit A. Halomethyl isoxazole ketones of Formula 35 can be prepared by the multi-step reaction sequences shown in Scheme 19.

wherein R³² is C₂-C₈ dialkylamino, C₂-C₆ haloalkylamino, 1-piperidinyl, 1-pyrrolidinyl or 4-morpholinyl; and R⁵ are as defined above in the Summary of the Invention.

The preparation of the racemic carboxylic acids of Formula 32 can be accomplished according to the well-known methods of basic or acidic hydrolysis of the corresponding compounds of Formula 31, preferably using a slight excess of sodium hydroxide in a water-miscible co-solvent such as methanol or tetrahydrofuran at about 25 to 45° C. The product can be isolated by adjusting pH to about 1 to 3 and then filtration or extraction, optionally after removal of the organic solvent by evaporation. The racemic carboxylic acids of Formula 32 can be resolved by classical fractional crystallization of diastereomeric salts of suitable chiral amine bases such as cinchonine, dihydrocinchonine or a mixture thereof. A cinchonine-dihydrocinchonine mixture in about a 85:15 ratio is particularly useful, as it provides, for example, the (R)-configured carboxylic acids of Formula 33, wherein R⁵ is a substituted phenyl group, as the less soluble salt. Furthermore, these chiral amine bases are readily available on a commercial scale. The (R)-configured halomethyl ketone intermediates of Formula 35 afford the more fungicidally active final products of Formula 1 after coupling with thioamides of Formula 1Bb. The halomethyl ketones of Formula 35 can be prepared by first reacting the corresponding amides of Formula 31, either as pure enantiomers (i.e. Formula 31a) or in enantiomerically enriched or racemic mixtures, with one molar equivalent of a methylmagnesium halide (Grignard reagent) in a suitable solvent or solvent mixture such as tetrahydrofuran and toluene at about 0 to 20° C., and the crude ketone products of Formula 34 can be isolated by quenching with aqueous acid, extraction, and concentration. Then the crude ketones of Formula 34 are halogenated with a reagent such as sulfuryl chloride to afford the chloromethyl ketones of Formula 35 wherein Y¹ is Cl or molecular bromine to afford the corresponding bromomethyl ketones of Formula 35 wherein Y¹ is Br. The halomethyl ketones of Formula 35 can be purified by crystallization from a solvent such as hexanes or methanol, or can be used without further purification in the condensation reaction with thioamides.

The isoxazole carboxamides of Formula 31 can be prepared by cycloaddition of the corresponding hydroxamoyl chlorides of Formula 36 with olefin derivatives of Formula 37, as shown in Scheme 20.

In this method, all three reacting components (the compounds of Formulae 36 and 37, and the base) are contacted so as to minimize hydrolysis or dimerization of the hydroxamoyl chloride of Formula 36. In one typical procedure, the base, which can either be a tertiary amine base such as triethylamine or an inorganic base such as an alkali metal or alkaline-earth carbonate, bicarbonate or phosphate, is mixed with the olefin derivative of Formula 37, and the hydroxamoyl chloride of Formula 36 is added gradually at a temperature at which the cycloaddition proceeds at a relatively rapid rate, typically between 5 and 25° C. Alternatively, the base can be added gradually to the other two components (the compounds of Formulae 36 and 37). This alternative procedure is preferable when the hydroxamoyl chloride of Formula 36 is substantially insoluble in the reaction medium. The solvent in the reaction medium can be water or an inert organic solvent such as toluene, hexane or even the olefin derivative used in excess. The product can be separated from the salt co-product by filtration or washing with water, followed by evaporation of the solvent. The crude product can be purified by crystallization, or the crude product can be used directly in the methods of Scheme 19. Compounds of Formula 31 are useful precursors to the corresponding methyl ketones of Formula 34 and halomethyl ketones of Formula 35, and are also useful for preparing the resolved enantiomers of the compounds of Formulae 34 and 35 by hydrolysis, resolution, methyl ketone synthesis and halogenation, as shown in Scheme 19.

It is recognized that some reagents and reaction conditions described above for preparing compounds of Formulae 1, 1A, 1B and 1C may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed.: Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formulae 1, 1A, 1B and 1C. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formulae 1, 1A, 1B and 1C.

One skilled in the art will also recognize that compounds of Formulae 1, 1A, 1B and 1C and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. ¹H NMR spectra are reported in ppm downfield from tetramethylsilane; “s” means singlet, “d” means doublet, “t” means triplet, “m” means multiplet, “q” means quartet, “dd” means doublet of doublet, “br s” means broad singlet, “br d” means broad doublet. “br t” means broad triplet, “br m” means broad multiplet.

EXAMPLE 1 Preparation of 4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (Compound 1) Step A: Preparation of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinecarboxylate

To a suspension of 1,1-dimethylethyl 4-(4-formyl-2-thiazolyl)-1-piperidinecarboxylate (1.0 g, 3.4 mmol) in ethanol (5 mL) was added an aqueous solution of hydroxylamine (50 wt. %, 0.25 mL, 4.0 mmol). The reaction mixture was heated at 60° C. for 1 h, during which time the reaction mixture became homogeneous. The resulting solution was cooled to room temperature and diluted with tetrahydrofuran (10 mL). To the reaction mixture was added styrene (0.57 mL, 5 mmol), followed by portionwise addition of Clorox® aqueous sodium hypochlorite solution (10.5 mL) over 3 h. The reaction mixture was stirred overnight at room temperature, and the resulting solid was filtered, washed with water and diethyl ether, and air dried to give the title compound as a white powder (610 mg). The filtrate was diluted with saturated aqueous sodium bicarbonate solution and extracted with diethyl ether. The extract was dried (MgSO₄) and concentrated under reduced pressure to give 850 mg of the title compound as a yellow oil. The oil was diluted with diethyl ether (4 mL) and allowed to stand to give additional 233 mg of the product as a white solid.

¹H NMR (CDCl₃) δ 1.47 (s, 9H), 1.7 (m, 2H), 2.1 (m, 2H), 2.85 (m, 2H), 3.2 (m, 1H), 3.45 (m, 1H), 3.84 (m, 1H) 4.2 (br s, 2H), 5.75 (m, 1H), 7.25-7.40 (m, 5H), 7.61 (s, 1H).

Step B: Preparation of 4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinecarboxylate (i.e. the product of Example 1, Step A) (0.815 g, 1.97 mmol) in dichloromethane (50 mL) was added a solution of hydrogen chloride in diethyl ether (2 M, 10 mL, 20 mmol). The reaction mixture was stirred at room temperature for 1 h to give a gummy precipitate. Methanol was added to dissolve the precipitate, and the reaction mixture was stirred for an additional 1 h. The reaction mixture was concentrated under reduced pressure and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution, and the organic layer was dried (MgSO₄) and concentrated to give the free amine as a clear oil (0.31 g), which solidified on standing. A mixture of the resulting free amine (0.31 g, 1.0 mmol), 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (0.208 g, 1.0 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.25 g, 1.3 mmol), triethylamine (150 μL, 1.08 mmol) and a catalytic amount of 1-hydroxybenzotriazole hydrate (˜1 mg) in dichloromethane (5 mL) was swirled to form a vortex and held at room temperature for 16 h. The reaction mixture was diluted with dichloromethane (10 mL), and washed with 1 N aqueous hydrochloric acid and saturated aqueous sodium bicarbonate solution. The organic layer was dried (MgSO₄) and concentrated under reduced pressure to give 0.47 g of the title product, a compound of present invention, as a white foam.

¹H NMR (CDCl₃) δ 1.8 (m, 2H), 2.2 (m, 2H), 2.32 (s, 3H), 2.9 (m, 1H), 3.3 (m, 2H), 3.42 (m, 1H), 3.85 (m, 1H) 4.05 (m, 1H), 4.55 (m, 1H), 4.98 (m, 2H), 5.75 (m, 1H), 6.33 (s, 1H), 7.25-7.42 (m, 5H), 7.63 (s, 1H).

The following compounds were prepared by procedures analogous to Step B of Example 1:

1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 128); ¹H NMR (CDCl₃) δ 1.7-1.9 (m, 2H), 2.16 (m, 1H), 2.24 (m, 1H), 2.29 (s, 3H), 2.84-2.92 (br t, 1H), 3.30 (m, 2H), 3.43 (m, 1H), 3.86 (m, 2H), 4.59 (br d, 1H), 5.04 (s, 2H), 5.75 (m, 1H), 6.47 (s, 1H), 7.29-7.39 (m, 5H), 7.64 (s, 1H).

1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 19); m.p. 128-133° C. (crystallized from methyl acetate/petroleum ether); ¹H NMR (CDCl₃) δ 1.28 (t, 3H), 1.8 (m, 2H), 2.2 (m, 2H), 2.62 (q, 2H), 2.9 (m, 1H), 3.3 (m, 2H). 3.42 (m, 1H), 3.85 (m, 1H) 4.05 (m, 1H), 4.55 (m, 1H), 4.98 (m, 2H), 5.75 (m, 1H), 6.33 (s, 1H), 7.25-7.42 (m, 5H), 7.63 (s, 1H).

2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]ethanone (Compound 22) m.p. 130-133° C. (crystallized from methyl acetate/petroleum ether); ¹H NMR (CDCl₃) δ 1.8 (m, 2H), 2.2 (m, 2H), 2.9 (m, 1H), 3.3 (m, 2H), 3.42 (m, 1H), 3.85 (m, 2H), 4.55 (m, 1H), 5.10 (s, 2H), 5.77 (m, 1H), 6.95 (s, 1H), 7.25-7.42 (m, 5H), 7.64 (s, 1H).

1-[4-[4-(2,3-dihydrospiro[4H-1-benzopyran-4,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 137); ¹H NMR (CDCl₃) δ 1.83 (m, 2H), 2.18 (m, 3H), 2.33 (s, 3H), 2.42 (m, 1H), 2.90 (m, 1H), 3.31 (m, 2H), 3.47 (d, 1H), 3.83 (d, 1H), 4.05 (m, 1H), 4.27 (m, 1H), 4.40 (m, 1H), 4.58 (d, 1H), 4.97 (m, 2H), 6.33 (s, 1H), 6.87 (d, 1H), 6.95 (dd, 1H), 7.21 (dd, 1H), 7.38 (d, 1H), 7.67 (s, 1H).

1-[4-[4-(2,3-dihydrospiro[4H-1-benzothiopyran-4,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 102); ¹H NMR (CDCl₃) δ 1.82 (m, 2H), 2.23 (m, 2H), 2.31 (s, 3H), 2.37 (m, 1H), 2.50 (m, 1H), 2.90 (m, 1H), 3.14 (m, 1H), 3.17 (m, 1H), 3.27 (m, 2H), 3.48 (d, 1H), 3.66 (d, 1H), 4.05 (m, 1H), 4.57 (d, 1H), 4.97 (m, 2H), 6.33 (s, 1H), 7.06 (m, 3H), 7.45 (d, 1H), 7.65 (s, 1H).

EXAMPLE 2 Preparation of 1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine (Compound 2) Step A: Preparation of 2-(4-piperidinyl)-4-thiazolecarboxaldehyde monohydrochloride

To a solution of 1,1-dimethylethyl 4-(4-formyl-2-thiazolyl)-1-piperidinecarboxylate (1.0 g, 3.4 mmol) in dichloromethane (20 mL) was added a solution of hydrogen chloride in diethyl ether (2.0 mL, 15 ml, 30 mmol). The reaction mixture was stirred under nitrogen at room temperature for 2 h and then evaporated under reduced pressure to give 1.2 g of the title compound as a white solid.

¹H NMR (CDCl₃) δ 2.31-2.38 (m, 2H), 2.44-2.50 (m, 2H), 3.11-3.20 (m, 2H), 3.36-3.44 (m, 1H), 3.57-3.65 (m, 2H), 8.14 (s, 1H), 10.01 (s, 1H).

Step B: Preparation of 4-(4-formyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (0.8 g, 3.8 mmol) in dichloromethane (10 mL) was added oxalyl chloride (2.4 g, 19.2 nmmnol) and two drops of N,N-dimethylformamide, resulting in slight exothermicity. The reaction mixture was then heated at reflux for 15 minutes. The reaction mixture was concentrated in vacuo, and the residue was suspended in tetrahydrofuran (10 mL) and treated with a solution of 2-(4-piperidinyl)-4-thiazolecarboxaldehyde monohydrochloride (i.e. the product of Example 2, Step A) (1.1 g, 5.1 mmol) in tetrahydrofuran (10 mL), followed by dropwise addition of triethylamine (1.2 g, 11.9 mmol). The reaction mixture was stirred overnight at room temperature and then partitioned between 1 N aqueous hydrochloric acid and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate (2×30 mL). The combined organic layers were washed with 1 N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate solution, and brine. The organic layer was dried (MgSO₄) and evaporated under reduced pressure to give 0.8 g of the title compound as a yellow oil.

¹H NMR (CDCl₃) δ 1.79-1.90 (m, 2H), 2.18-2.29 (m, 2H), 2.33 (s, 3H), 2.87-2.94 (m, 1H), 3.28-3.40 (m, 2H), 4.05-4.15 (m, 1H), 4.56-4.64 (m, 1H), 4.99-5.02 (m, 2H), 6.35 (s, 1H), 8.12 (s, 1H), 10.01 (s, 1H).

Step C: Preparation of 4-[4-[(hydroxyimino)methyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of 4-(4-formyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (i.e. the product of Example 2, Step B) (0.8 g, 2.07 mmol) in ethyl alcohol (15 mL) was added hydroxylamine (50% aqueous solution, 0.136 g, 4.1 mmol), and the reaction mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated under reduced pressure to give a yellow oil, which was purified by flash column chromatography on silica gel using 50% ethyl acetate in hexanes as eluant to give 0.7 g of the title compound as a white solid.

¹H NMR (CDCl₃) δ 1.72-1.85 (m, 2H), 2.17-2.27 (m, 2H), 2.32 (s, 3H), 2.82-2.91 (m, 1H), 3.25-3.37 (m, 2H), 4.02-4.09 (m, 1H), 4.58-4.63 (m, 1H), 4.95-5.03 (m, 2H), 6.35 (s, 1H), 7.43 (s, 1H), 7.71 (s, 1H), 8.19 (s, 1H).

Step D: Preparation of 1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine

4-[4-[(Hydroxyimino)methyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (i.e. the product of Example 2, Step C) (0.2 g, 0.5 mmol) was suspended in tetrahydrofuran (20 mL), and phenylacetylene (1.1 mL, 1 mmol) was added, followed by a slow dropwise addition of Clorox® bleach solution (6.15 wt. % sodium hypochlorite, 10 mL) over 1 h. The reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3×30 mL). The combined organic layers were washed with brine, dried (MgSO₄) and concentrated under reduced pressure to give an oil, which was purified by flash column chromatography on silica gel using 10% methanol in ethyl acetate as eluant to give to give 70 mg of the title product, a compound of present invention, as a clear yellow oil.

¹H NMR (CDCl₃) δ 1.80-1.92 (m, 2H), 2.22-2.32 (m, 2H), 2.34 (s, 3H), 2.90-2.98 (m, 1H), 3.31-3.41 (m, 2H), 4.05-4.11 (m, 1H), 4.58-4.65 (m, 1H), 4.97-5.07 (m, 2H), 6.36 (s, 1H), 6.98 (s, 1H), 7.47-7.53 (m, 3H), 7.84 (s, 2H), 7.88 (m, 1H).

EXAMPLE 3 Preparation of 4-[4-(4,5-dihydro-1-methyl-5-phenyl-1H-imidazol-2-yl)-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (Compound 7)

To a solution of 4-(4-formyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (i.e. the product of Example 2, Step B) (0.8 g, 2.07 mmol) in tert-butanol (5 mL) was added NI-methyl-1-phenyl-1,2-ethanediamine (43.57 mg, 0.29 mmol). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 30 minutes, and then potassium carbonate (107.8 mg, 0.78 mmol) and iodine (43.57 mg, 0.33 mmol) were added. The reaction mixture was stirred at 70° C. for 3 h and then quenched by addition of saturated aqueous sodium sulfite solution until the iodine color almost disappeared. The reaction mixture was extracted with chloroform, and the organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried (Na₂SO₄), filtered and concentrated. The residue was purified by preparative thin-layer chromatography on silica gel using a mixture of 94% ethyl acetate, 5% methanol and 1% triethylamine as eluant to give 64 mg of the title product, a compound of the present invention, as an oil.

¹H NMR (CDCl₃) δ 1.72-1.87 (m, 2H), 2.15-2.28 (m, 2H), 2.31 (s, 3H), 2.86-2.92 (m, 1H), 2.97 (s, 3H), 3.26-3.37 (m, 2H), 3.62-4.39 (m, 2H), 4.0-4.6 (m, 2H), 4.93-5.05 (m, 2H), 6.31 (s, 1H), 7.30-7.41 (m, 5H), 7.88 (s, 1H).

EXAMPLE 4 Preparation of 4-[4-(4,5-dihydro-3-phenyl-5-isoxazolyl)-2-thiazolyl]-1-[(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl]piperidine (Compound 6) Step A: Preparation of 1,1-dimethylethyl 4-(4-ethenyl-2-thiazolyl)-1-piperidinecarboxylate

To a cold (−50° C.) suspension of methyltriphenylphosphonium bromide (1.2 g, 3.3 mmol) in tetrahydrofuran (5 mL) was added a solution of sodium bis(trimethylsilyl)-amide (3.4 mL, 3.4 mmol), and the resulting mixture was stirred for 1 h at room temperature. The resulting cloudy yellow solution was re-cooled to −30° C., and 1,1-dimethylethyl 4-(4-formyl-2-thiazolyl)-1-piperidinecarboxylate (0.5 g, 1.68 mmol) was added. The resulting slightly yellow solution was stirred at room temperature for 3 h, then diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried (MgSO₄), filtered, and purified by column chromatography on silica gel using 15-30% ethyl acetate in hexanes as eluant to give 471 mg of the title compound as a colorless oil.

¹H NMR (CDCl₃) δ 1.47 (s, 9H), 1.68 (m, 2H), 2.10 (m, 2H), 2.88 (m, 2H), 3.15 (m, 1H), 4.18 (m, 2H), 5.34 (d, 1H), 6.02 (d, 1H), 6.68 (dd, 1H), 6.99 (s, 1H).

Step B: Preparation of 4-(4-ethenyl-2-thiazolyl)piperidine

To a solution of 1,1-dimethylethyl 4-(4-ethenyl-2-thiazolyl)-1-piperidinecarboxylate (i.e. the product of Example 4, Step A) (471 mg, 1.6 mmol) in dichloromethane (5 mL) was added a solution of hydrogen chloride in diethyl ether (2.0 M, 7 mL, 14 mmol). The reaction mixture was stirred under nitrogen at room temperature for 4 h, and then 1 N aqueous sodium hydroxide solution was added until pH of the reaction mixture increased to about 10. The resulting mixture was extracted with dichloromethane (2×). The organic layers were combined, washed with brine, dried (MgSO₄), filtered and concentrated in vacuo to give 302 mg of the title compound as an oil.

¹H NMR (CDCl₃) δ 1.70 (m, 2H), 1.82 (br s, 1H), 2.12 (br d, 2H), 2.76 (br t, 2H), 3.11 (m, 1H), 3.18 (m, 2H), 5.32 (d, 1H), 6.02 (d, 1H), 6.70 (dd, 1H), 6.99 (s, 1H).

Step C: Preparation of 4-(4-ethenyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (0.5 g, 2.4 mmol) in dichloromethane (4 mL) was added oxalyl chloride (0.3 mL, 3.6 mmol) and one drop of N,N-dimethylformamide, resulting in slight exothermicity. The reaction mixture was then heated at reflux for 15 minutes. The reaction mixture was evaporated, and the resulting residue was suspended in dichloromethane (4 mL) and treated with a solution of 4-(4-ethenyl-2-thiazolyl)piperidine (i.e. the product of Example 4. Step B) (302 mg, 1.5 mmol) in dichloromethane (2 mL), followed by addition of triethylamine (0.32 mL, 2.3 mmol). The reaction mixture was stirred overnight at room temperature, then concentrated, and purified by column chromatography on silica gel using 30-40% ethyl acetate in hexanes as eluant to give 414 mg of the title compound as a white solid.

¹H NMR (CDCl₃) δ 1.78 (m, 2H), 2.18 (m, 2H), 2.32 (s, 3H), 2.90 (br t, 1H), 3.30 (m, 2H), 4.03 (d, 1H), 4.55 (d, 1H), 5.00 (m, 2H), 5.35 (d, 1H), 6.02 (d, 1H), 6.33 (s, 1H), 6.68 (dd, 1H), 7.01 (s, 1H).

Step D: Preparation of 4-[4-(4,5-dihydro-3-phenyl-5-isoxazolyl)-2-thiazolyl]-1-[(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl]piperidine

To a solution of benzaldehyde oxime (49 mg, 0.4 mmol) in N,N-dimethylformamide (3 mL) was added N-chlorosuccinimide (54 mg, 0.4 mmol), followed by addition of 4-(4-ethenyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (i.e. the product of Example 4, Step C) (103 mg, 0.27 mmol) and triethylamine (41 mg, 0.4 mmol). The resulting mixture was stirred at room temperature for 5 h, then diluted with water, extracted with dichloromethane (2×). The organic layers were combined and dried (MgSO₄), and filtered. The filtrate was concentrated, and the residue was purified by column chromatography on silica gel using 55-70% ethyl acetate in hexanes as eluant to give 90 mg of the title product, a compound of the present invention as a white solid.

¹H NMR (CDCl₃) δ 1.76 (m, 2H), 2.17 (m, 2H), 2.31 (s, 3H), 2.88 (br t, 1H), 3.25 (m, 2H), 3.65 (m, 1H), 3.78 (m, 1H), 4.02 (br d, 1H), 4.56 (br d, 1H), 4.99 (m, 2H), 5.84 (dd, 1H), 6.32 (s, 1H), 7.28 (s, 1H), 7.40-7.42 (m, 3H), 7.69-7.71 (m, 2H).

EXAMPLE 5 Preparation of 1-[4-[4-[5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 8)

To a solution of 1-chloro-2-ethenylbenzene (0.035 g, 0.25 mmol), triethylamine (2.5 mg, 0.025 mmol) and Clorox® aqueous sodium hypochlorite solution (1 mL, 16.1 mmol) in dichloromethane (5 mL) was added 4-[4-[(hydroxyimino)methyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (i.e. the product of Example 2, Step C) (0.10 g, 0.25 mmol) in dichloromethane (5 mL) dropwise over 1 h at 0° C. The reaction mixture was allowed to stir for 1h, then filtered through Celite® diatomaceous filter aid, and concentrated under reduced pressure to give an oil, which was purified by column chromatography on silica gel using 50% ethyl acetate in hexane as eluant to give 73 mg of the title compound as a white foam, melting at 115-122° C. (crystallized from methyl acetate/petroleum ether).

¹H NMR (CDCl₃) δ 1.74-1.80 (m, 2H), 2.14-2.22 (m, 2H), 2.32 (s, 3H), 2.85-2.91 (m, 1H), 3.26-3.30 (m, 2H), 3.31-3.32 (m, 1H), 4.05-4.07 (m, 1H), 4.55-4.58 (m, 1H), 4.93-5.03 (q, 2H), 6.01-6.06 (m, 1H), 6.331 (s, 1H), 7.25-7.29 (m, 2H), 7.38-7.40 (m, 1H), 7.56-7.58 (m, 1H), 7.62 (s, 1H).

EXAMPLE 6 Preparation of 1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanethione (Compound 130)

A solution of 4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine (i.e. the product of Example 1, Step B) (235 mg, 0.47 mmol) and phosphorus pentasulfide (104.5 mg, 0.235 mmol) in pyridine (5 ml) was heated under reflux for 2 h. The reaction mixture was then concentrated under reduced pressure, and the residue was distributed between dichloromethane (10 mL) and water (10 mL). The organic layer was washed with 1 N hydrochloric acid, water, saturated aqueous sodium bicarbonate solution and brine, dried (MgSO₄), and concentrated under reduced pressure to give 240 mg of the title product, a compound of the present invention, as a white foam.

¹H NMR (CDCl₃) δ 1.80-2.00 (m, 2H), 2.20-2.28 (m, 2H), 2.45 (s, 3H), 3.35-3.46 (3H, m), 3.50-3.61 (m, 1H), 3.80-3.88 (m, 1H), 4.70-4.80 (m, 1H), 5.30-5.33 (m, 2H), 5.35-5.40 (m, 1H), 5.74-5.80 (nm, 1H), 6.32 (s, 1H), 7.30-7.40 (m, 5H), 7.65 (s, 1H).

EXAMPLE 7 Preparation of 1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 154) Step A: Preparation of 1,1-dimethylethyl 4-(aminothioxomethyl)-1-piperazinecarboxylate

To a solution of thiocarbonyldiimidazole (2.1 g, 11.8 mmol) in tetrahydrofuran (30 mL) at room temperature, was added 1,1-dimethylethyl 1-piperazinecarboxylate (2 g, 10.75 mmol). The reaction mixture was stirred at room temperature for 2 h and then heated to 55° C. for additional 2 h. The reaction mixture was cooled to room temperature, and concentrated under reduced pressure until approximately 20 mL of tetrahydrofuran remained. The residue was then treated with a 2 M solution of ammonia in methanol (10 mL) and stirred at room temperature for 24 h. The reaction mixture was concentrated under reduced pressure, and the residue was triturated with diethyl ether (25 mL) to give a white precipitate. The precipitate was filtered and dried to give 1.5 g of the title compound as a white solid.

¹H NMR (CDCl₃) δ 1.39 (s, 9H), 3.32 (m, 4H), 3.73 (m, 4H), 7.49 (br s, 2H).

Step B: Preparation of 3-chloro-N-hydroxy-2-oxo-propanimidoyl chloride

To a solution of 1,3-dichloroacetone (100 g, 0.79 mol) in 2 M solution of hydrogen chloride in diethyl ether (400 mL) at 15° C. was added t-butyl nitrite (55 g, 0.534 mol) over 10 minutes. The reaction progress was monitored by ¹H NMR to obtain ˜85% conversion with no more than 3% of the bis-nitrosation side product. The reaction mixture was concentrated under reduced pressure to leave a semi-solid, which was then thoroughly rinsed with n-BuCl. The resulting solid was collected under filtration to give a 77 g of the title compound as a white solid. The filtrate was further concentrated under reduced pressure to give a semi-solid residue, which was rinsed with additional n-BuCl. The resulting solid was collected under filtration to give additional 15 g of the title compound as a white solid.

¹H NMR (DMSO-d₆) δ 4.96 (s, 2H), 13.76 (s, 1H).

Step C: Preparation of 2-chloro-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone

To a mixture of styrene (6.79 g, 65.3 mmol) and sodium bicarbonate (32.1 g, powder) in acetonitrile (100 mL), 3-chloro-N-hydroxy-2-oxo-propanimidoyl chloride (i.e. the product of Example 7, Step B) (10 g, 64.1 mmol) was added in 10 portions over 20 minutes. The reaction mixture was then stirred for additional 1 h and filtered. The filtered solid was rinsed with acetonitrile, and the combined filtrates were concentrated under reduced pressure to leave an oil, which was triturated first with hexanes and then with 1-chlorobutane to give 13.6 g of the title compound as a white solid.

¹H NMR (CDCl₃) δ 3.13 (m, 1H), 3.66 (m, 1H), 4.96 (s, 2H), 5.83 (m, 1H), 7.34-7.44 (m, 5H).

Step D: Preparation of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazineacetate

To a solution of 2-chloro-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone (i.e. the product of Example 7, Step C) (0.450 g, 2.018 mmol) and 1,1-dimethylethyl 4-(aminothioxomethyl)-1-piperazinecarboxylate (i.e. the product of Example 7, Step A) (0.5 g, 2.04 mmol) in ethanol (10 mL) was added triethylamine (0.204 g, 2.013 mmol), and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between ethyl acetate (30 mL) and water (30 mL). The organic layer was separated and washed with brine (25 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The crude residue was purified by column chromatography using 20% ethyl acetate in petroleum ether as eluant to give 700 mg of the title compound as a white solid.

¹H NMR (CDCl₃) δ 1.48 (s, 9H), 3.30 (m, 1H), 3.54 (m, 8H), 3.74 (m, 1H), 5.71 (m, 1H), 6.91 (s, 1H), 7.40-7.29 (m, 5H).

Step E: Preparation of 1-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-piperazine hydrochloride

To a solution of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazineacetate (i.e. the product of Example 7, Step D) (0.7 g, 1.686 mmol) in diethyl ether (10 mL) was added a 2 M solution of hydrogen chloride in methanol (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 8 h. The resulting white precipitate was filtered, and dried to give 500 mg of the title compound as a white solid.

¹H NMR (CDCl₃) δ 3.21 (m, 4H), 3.27 (m, 1H), 3.68 (m, 4H), 3.79 (m, 1H), 5.68 (m, 1H), 7.41-7.29 (m, 6H), 9.49 (br s, 2H).

Step F: Preparation of 1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

To a solution of 1-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]piperazine hydrochloride (i.e. the product of Example 7, Step E) (200 mg, 0.57 mmol) and 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (0.120 g. 0.57 mmol) in dichloromethane (10 mL) at room temperature was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.110 g, 0.57 mmol), triethylamine (0.086 g, 0.85 mmol) and 1-hydroxybenzotriazole hydrate (0.020 g, 0.14 mmol). The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with dichloromethane (30 mL), and washed with water (20 mL) and brine (20 mL). The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure. The crude residue was purified by column chromatography using 3% methanol in chloroform as eluant to give 180 mg of the title product, a compound of the present invention as a white solid.

¹H NMR (CDCl₃) δ 2.32 (s, 3H), 3.29 (m, 1H), 3.52 (m, 2H), 3.61 (m, 2H), 3.79-3.72 (m, 5H), 4.98 (m, 2H), 5.69 (m, 1H), 6.33 (s, 1H), 6.93 (s, 1H), 7.38-7.28 (m, 5H).

Mass spectrum at 505.5 (M+1).

EXAMPLE 8 Preparation of 1-[4-[4-(3′,4′-dihydrospiro[isoxazole-5(4H),1′,(2′H)-naphthalen]-3-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 37) Step A: Preparation of 1-(2-chloroacetyl)-4-piperidinecarbonitrile

A mixture of 4-piperidinecarbonitrile (200 g, 1.80 mol) and 40% aqueous potassium carbonate solution (342 g, 0.99 mol) in dichloromethane (1 L) was cooled to −10° C., and a solution of chloroacetyl chloride (210 g, 1.86 mol) in dichloromethane (300 mL) was added over about 75 minutes while maintaining the reaction mixture at −10 to 0° C. After the addition was complete, the reaction mixture was separated, the upper aqueous phase was extracted with dichloromethane (2×300 mL), and the combined organic phases were concentrated under reduced pressure to give 312 g of the title compound as a liquid which slowly crystallized on standing. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 1.8-2.1 (m, 4H), 2.95 (m, 1H), 3.5-3.8 (m, 4H), 4.08 (q, 2H).

Step A1: Alternative preparation of 1-(2-chloroacetyl)-4-piperidinecarbonitrile

A solution of N-(1,1-dimethylethyl)-4-piperidinecarboxamide (201 g, 1.0 mol) in dichloromethane (1 L) was cooled under nitrogen to −5° C., and chloroacetyl chloride (124 g, 1.1 mol) in 300 mL of dichloromethane was added dropwise over 30 minutes while maintaining the reaction mixture at 0 to 5° C. Then 20% aqueous potassium carbonate solution (450 g, 0.65 mol) was added dropwise over 30 minutes while keeping reaction temperature between 0 and 5° C. The reaction mixture was stirred for an additional 30 minutes at 0° C., and then allowed to warm to room temperature. The layers were separated, and the aqueous layer was extracted with dichloromethane (200 mL). The combined dichloromethane layers were concentrated under reduced pressure to yield a solid, which was triturated with 400 mL of hexanes. The slurry was filtered, and the filter cake was washed with 100 mL of hexanes and dried in a vacuum oven overnight at 50° C. to give 185.5 g of 1-(2-chloroacetyl)-N-(1,1-dimethylethyl)-4-piperidinecarboxamide as a solid, melting at 140.5-141.5° C.

¹H NMR (CDCl₃) δ 1.35 (s, 9H), 1.6-2.0 (m, 4H), 2.25 (m, 1H), 2.8 (t, 1H), 3.2 (t, 1H), 3.9 (d, 1H), 4.07 (s, 2H), 4.5 (d, 1H), 5.3 (br s, 1H).

To a solution of 1-(2-chloroacetyl)-N-(1,1-dimethylethyl)-4-piperidinecarboxamide (26.1 g. 0.10 mol) in N,N-dimethylformamide (35 mL) was added phosphorus oxychloride (18.8 g, 0.123 mol) dropwise over 30 minutes while allowing the temperature of the reaction mixture to rise to 37° C. The reaction mixture was heated at 55° C. for 1 h and then was slowly added to water (about 150 g) cooled with ice to maintain a temperature of about 10° C. The pH of the reaction mixture was adjusted to 5.5 with 50% NaOH aqueous solution. The mixture was extracted with dichloromethane (4×100 mL), and the combined extract was concentrated under reduced pressure to give 18.1 g of the title compound as a solid. This compound was of sufficient purity to use in subsequent reactions.

Step B: Preparation of 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile

A solution of 3-methyl-5-trifluoromethylpyrazole (9.3 g, 62 mmol) and 45% aqueous potassium hydroxide solution (7.79 g, 62 mmol) in N,N-dimethylformamide (25 mL) was cooled to 5° C., and 1-(2-chloroacetyl)-4-piperidinecarbonitrile (i.e. the product of Example 8, Step A or A1) (11.2 g, 60 mmol) was added. The reaction mixture was stirred for 8 h at 5-10° C., then diluted with water (100 mL), and filtered. The filter cake was washed with water and dried at 50° C. in a vacuum-oven to give 15 g of the title compound as a solid containing 3% of its regioisomer, i.e. 1-[2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile.

¹H NMR (CDCl₃) δ 1.88 (m, 4H), 2.32 (s, 3H), 2.95 (m, 1H), 3.7 (m, 4H), 5.0 (q, 2H), 6.34 (s, 1H).

Step C: Preparation of 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide

Hydrogen sulfide gas was passed into a solution of 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile (i.e. the product of Example 8, Step B) (9.0 g, 30 mmol) and diethanolamine (3.15 g, 30 mmol) in N,N-dimethylformamide (15 mL) at 50° C. in a flask equipped with dry-ice condenser. The hydrogen sulfide feed was stopped when the reaction mixture became saturated with hydrogen sulfide, as indicated by condensation on the cold-finger. The reaction mixture was stirred for an additional 30 minutes at 50° C. Then excess hydrogen sulfide gas was sparged into the scrubber by a subsurface nitrogen flow, and water (70 mL) was gradually added. The reaction mixture was cooled to 5° C., filtered, and washed with water (2×30 mL). The filter cake was dried at 50° C. in a vacuum-oven to give 8.0 g of the title compound as a solid, melting at 185-186° C.

¹H NMR (CDCl₃) δ 1.7 (m, 2H), 2.0 (m, 2H), 2.29 (m, 3H), 2.65 (t, 1H), 3.0 (m, 3H), 3.2 (t, 1H), 4.0 (d, 1H), 4.6 (d, 1H), 4.96 (d, 1H), 5.4 (d, 1H), 6.35 (s, 1H), 7.4 (br s, 1H), 7.5 (br s, 1H).

Step D: Preparation of 1-[4-[4-(3′,4′-dihydrospiro[isoxazole-5(4H),1′,(2′H)-naphthalen]-3-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

A solution of 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide (i.e. the product of Example 8, Step C) (0.5 g, 1.5 mmol), 2-chloro-1-(3′,4′-dihydrospiro[isoxazole-5(4H), 1′,(2′H)-naphthalen]-3-yl)ethanone (prepared by a method analogous to Example 7, Step C) (0.4 g, 1.5 mmol) and tetrabutylammonium bromide (0.030 g, 0.10 mmol) in tetrahydrofuran (15 mL) was stirred overnight at room temperature, and then heated at 55-60° C. for 3 h. The reaction mixture was diluted with water and extracted with dichloromethane. The extract was washed with brine, dried (MgSO₄), and concentrated under reduced pressure. The crude product was further purified by medium-pressure liquid chromatography using 50% ethyl acetate in hexanes as eluant to give 260 mg of the title product, a compound of the present invention, as an off-white solid, melting at 81-84° C.

¹H NMR (CDCl₃) δ 1.76-1.86 (m, 3H), 2.04-2.08 (m, 2H), 2.16-2.26 (m, 2H), 2.32 (s, 3H), 2.83-2.87 (m, 2H), 2.88-2.93 (m, 1H), 3.27-3.35 (m, 2H), 3.48-3.65 (m, 2H), 4.02-4.06 (m, 1H), 4.55-4.59 (m, 1H), 4.94-5.04 (q, 2H), 6.33 (s, 1H), 7.10-7.12 (m, 1H), 7.19-7.21 (m, 2H), 7.40-7.43 (m, 1H), 7.62 (s, 1H).

The following compounds were prepared by procedures analogous to Step D of Example 8:

1-[4-[4-(4,5-dihydro-5-methyl-5-phenylolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 15); m.p. 97-100° C. (crystallized from methyl acetate/petroleum ether); ¹H NMR (CDCl₃) δ 1.74-1.80 (m, 1H), 1.81 (s, 3H), 2.14-2.20 (m, 2H), 2.32 (s, 3H), 2.85-2.91 (m, 1H), 3.26-3.32 (m, 2H), 3.52-3.62 (m, 2H), 4.01-4.05 (m, 1H), 4.54-4.58 (m, 1H), 4.94-5.04 (q, 2H), 6.33 (s, 1H), 7.26-7.29 (m, 1H), 7.35-7.38 (m, 2H), 7.48-7.50 (m, 2H), 7.58 (s, 1H).

2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(3a,4,5,9b-tetrahydro-naphth[2,1-d]isoxazol-3-yl)-2-thiazolyl]-1-piperidinyl]ethanone (Compound 16); m.p. 162-165° C. (crystallized from methyl acetate/petroleum ether); ¹H NMR (CDCl₃) δ 1.79-1.85 (m, 2H), 2.00-2.05 (m, 2H), 2.20-2.26 (m, 2H), 2.33 (s, 3H), 2.68-2.72 (m, 2H), 2.88-2.94 (m, 1H), 3.30-3.35 (m, 2H), 3.92-3.98 (m, 1H), 4.06-4.10 (m, 1H), 4.58-4.60 (m, 1H), 4.94-5.06 (m, 2H), 5.58-5.60 (d, 1H), 6.34 (s, 1H), 7.17-7.20 (m, 1H), 7.28-7.30 (m, 2H), 7.47-7.49 (m, 1H), 7.72 (s, 1H).

1-[4-[4-(2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 44); ¹H NMR (CDCl₃) δ 1.77-1.84 (m, 2H), 2.17-2.25 (m, 2H), 2.33 (s, 3H), 2.61-2.68 (m, 1H), 2.90-2.96 (m, 2H), 3.12-3.20 (m, 1H), 3.31-3.35 (m, 2H), 3.54-3.75 (m, 2H), 4.04-4.10 (m, 1H), 4.56-4.60 (m, 1H), 4.94-5.04 (q, 2H), 6.34 (s, 1H), 7.28-7.30 (m, 3H), 7.37-7.38 (m, 1H), 7.64 (s, 1H).

1-[4-[4-[4,5-dihydro-5-(4-methoxyphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 18); m.p.t 119-124° C. (crystallized from methyl acetate/petroleum ether); ¹H NMR (CDCl₃) 1.76-1.82 (m, 2H), 2.16-2.24 (m, 2H), 2.32 (s, 3H), 2.86-2.92 (m, 1H), 3.28-3.34 (m, 2H), 3.37-3.43 (m, 1H), 3.76-3.83 (m, 1H), 3.81 (s, 3H). 4.03-4.06 (m, 1H), 4.56-459 (m, 1H), 4.94-5.04 (q, 2H), 5.67-5.72 (m, 1H), 6.33 (s, 1H), 6.89-6.91 (d, 2H), 7.31-7.33 (d, 2H), 7.62 (s, 1H).

EXAMPLE 9 Preparation of 1-[4-[4-(4,5-dihydro-5-(2-pyridinyl)-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 98)

To a solution of 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide (i.e. the product of Example 8, Step C) (200 mg, 0.6 mmol) in tetrahydrofuran (8 mL) was added 3-chloro-N-hydroxy-2-oxopropanimidoyl chloride (i.e. the product of Example 7, Step B) (93 mg, 0.6 mmol), followed by tetrabutylammonium bromide (15 mg, 0.05 mmol). The reaction mixture was heated at 50° C. for 4 h. The reaction mixture was cooled and concentrated under reduced pressure. To the resulting residue, acetonitrile (8 mL) and finely powdered sodium bicarbonate (151 mg, 1.0 mmol) were added followed by 2-ethenylpyridine (63 mg, 0.6 mmol), and the resulting mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and purified by flash chromatography on a silica gel (20 g), Varian Bond Elute SI® column using 0 to 75% ethyl acetate in hexanes as eluant to give 80 mg of the title product, a compound of the present invention, as a yellow semi-solid.

¹H NMR (CDCl₃) δ 1.47-1.62 (m, 1H), 1.70-1.85 (m, 1H), 2.01-2.18 (m, 2H), 2.49 (s, 3H), 2.82 (t, 1H), 3.20-3.42 (m, 2H), 3.73 (dd, 1H), 3.82 (dd, 1H), 3.98 (d, 1H), 4.38 (d, 1H), 5.26 (m, 2H), 5.80 (dd, 1H), 6.50 (s, 1H), 7.38 (dd, 1H), 7.50 (d, 1H), 7.82 (t, 1H), 8.05 (s, 1H), 8.60 (d, 1H).

EXAMPLE 10 Preparation of 2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]ethanone (Compound 107) Step A: Preparation of N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide

To a solution of 3-trifluoromethylpyrazole (5.0 g, 36 mmol), triethylamine (7.0 mL, 50 mmol) in dichloromethane (40 mL) was added dimethylsulfamoyl chloride (5.5 mL, 51 mmol), and the reaction mixture was heated at reflux for 2 days. The resulting mixture was cooled to ambient temperature and filtered through a pad of silica gel using dichloromethane as eluent. The filtrate was then concentrated under reduced pressure to give an amber residue. The resulting residue was dissolved in diethyl ether. The ether solution was washed with water, dried (MgSO₄), and concentrated under reduced pressure to give 8.71 g of the title compound.

¹H NMR (CDCl₃) δ 3.01 (s, 6H), 6.65 (s, 1H), 8.03 (s, 1H).

Step B: Preparation of 5-chloro-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide

A stirred solution of N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide (i.e. the product of Example 10, Step A) (4.0 g, 16 mmol) in tetrahydrofuran (25 mL) was cooled to −78° C., and then treated dropwise with 2 M n-butyllithium in cyclohexane (8.6 mL, 17.2 mmol). The reaction mixture was stirred for a further 30 minutes, and then a solution of hexachloroethane (4.2 g, 18 mmol) in tetrahydrofuran (15 mL) was added dropwise. The reaction mixture was stirred for 1 h, warmed to room temperature, and quenched with water (50 mL). The resulting solution was extracted with dichloromethane, dried (MgSO₄), and concentrated under reduced pressure to give 4.38 g of title compound. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 3.15 (s, 6H), 6.58 (s, 1H).

Step C: Preparation 5-chloro-3-(trifluoromethyl)-1H-pyrazole

A solution of 5-chloro-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide (i.e. the product of Example 10, Step B) (4.38 g, 15.8 mmol) and trifluoroacetic acid (2.7 mL, 35 mmol) was stirred at 0° C. for 1.5 h. The reaction mixture was diluted with water (15 mL), and sodium carbonate was added to raise the pH to 12. The solution was extracted with diethyl ether, dried (MgSO₄), and concentrated under reduced pressure to give 2.1 g of the title compound. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 6.57 (m, 1H).

Step D: Preparation of ethyl 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetate

To a suspension of 5-chloro-3-(trifluoromethyl)-1H-pyrazole (i.e. the product of Example 10, Step C) (2.1 g, 12.3 mmol) and potassium carbonate (3.6 g, 26.0 mmol) in 20 mL of N,N-dimethylformamide was added ethyl bromoacetate (2.1 mL, 18.8 mmol), and the resulting mixture was stirred at room temperature for 12 h. The resulting mixture was diluted with ethyl acetate, washed with water, and dried (MgSO₄). The reaction mixture was concentrated in vacuo and further purified by medium-pressure liquid chromatography using 0-50% of ethyl acetate in hexanes as eluant to give 940 mg of the title compound as an oil.

¹H NMR (CDCl₃) δ 1.29 (m, 3H), 4.27 (q, 2H), 4.96 (m, 2H), 6.55 (s, 1H).

Step D1: Alternative preparation of ethyl 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetate

To a solution of aluminum chloride (3.0 g, 22.5 mmol) in dichloromethane (100 mL) was added dropwise a solution of trifluoroacetyl chloride (3 g, 22.6 mmol) in dichloromethane (5 mL) while keeping the temperature of the reaction mixture below −30° C. The reaction mixture was stirred for 15 minutes at −50° C. Then a solution of vinylidene chloride (2.2 g, 22.7 mmol) in dichloromethane (10 mL) was added dropwise over 2 h to the reaction mixture. The reaction mixture was stirred an additional 2 h at −50° C. and then warmed gradually to room temperature. The reaction mixture was diluted with water, and the aqueous layer was extracted with dichloromethane. The organic layers were combined, dried (MgSO₄), and concentrated under reduced pressure to give 4,4-dichloro-1,1,1-trifluoro-3-buten-2-one as an oil which was used for the next step without further purification.

¹H NMR (CDCl₃) δ 5.30 (s, 1H).

¹⁹F NMR (CDCl₃) δ −63.6.

To a mixture of ethyl hydrazinoacetate hydrochloride (2.8 g, 18.1 mmol) and triethylamine (9.2 g, 91 mmol) in a solution of ethanol (20 mL) and N,N-dimethylformamide (1 mL), a solution of crude 4,4-dichloro-1,1,1-trifluoro-3-buten-2-one in dichloromethane (20 mL) was added dropwise while keeping the temperature of the reaction mixture below 10° C. After stirring a further 2 h at below 10° C., the reaction mixture was concentrated under reduced pressure. The residue was diluted with diethyl ether, and the mixture was filtered. The resulting filtrate was concentrated to give 4.34 g of the title compound as a solid. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 1.29 (t, 3H), 4.27 (q, 2H), 4.97 (s, 1H), 6.55 (s, 1H). ¹⁹F NMR (CDCl₃) δ −63.4.

Step E: Preparation of 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid

A solution of ethyl 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetate (i.e. the product of Example 10, Step D or D1) (218 mg, 0.85 mmol) in tetrahydrofuran (1 mL) was treated with a 50 wt. % aqueous solution of sodium hydroxide (0.2 mL) in water (0.6 mL). The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was treated with concentrated aqueous hydrochloric acid to lower the pH to 1, and then extracted with ethyl acetate. The extract was dried (MgSO₄) and concentrated under pressure to give 140 mg of the title compound. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (DMSO-d₆) δ 5.41 (s, 2H), 7.09 (s, 1H).

Step F: Preparation of 2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]ethanone

To a solution of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinecarboxylate (i.e. the product of Example 1, Step A) (1.026 g, 2.48 mmol) in ethanol (10 mL) was added a 2 M solution of hydrogen chloride in diethyl ether (4.2 mL, 12.6 mmol). The reaction mixture was stirred at room temperature overnight. Then the reaction mixture was heated at 60° C. for 2 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to give 0.710 g of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidine, hydrochloride as a white solid.

To 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (i.e. the product of Example 10, Step E) (0.14 g, 0.61 mmol) in dichloromethane (5 mL) was added N,N-dimethylformamide (1 drop) followed by oxalyl chloride (0.07 mL, 0.80 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 h, and then concentrated under reduced pressure. The resulting crude 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetyl chloride was taken up in 5 mL of dichloromethane, and the resulting solution was added dropwise to a mixture of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidine, hydrochloride (0.20 g, 0.57 mmol) prepared above and triethylamine (0.40 mL, 2.85 mmol) in 10 mL of dichloromethane at 0° C. The reaction mixture was stirred overnight at room temperature, and then diluted with 1.0 N aqueous hydrochloric acid solution. The organic layer was separated, washed with water, dried (MgSO₄), and concentrated under reduced pressure and purified by medium-pressure liquid chromatography using ethyl acetate in hexanes as eluant to give 40 mg of the title product, a compound of the present invention, as a solid, melting at 128-131° C.

¹H NMR (CDCl₃) δ 1.81 (nm, 2H), 2.20 (m, 2H), 2.89 (m, 1H), 3.31 (m, 2H), 3.46 (m, 1H), 3.87 (m, 2H), 4.55 (m, 1H), 5.08 (m, 2H), 5.75 (m, 1H), 6.54 (s, 1H), 7.25-7.42 (m, 5H), 7.63 (s, 1H).

EXAMPLE 11 Preparation of 2-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazoly)-2-thiazolyl]-1-piperidinyl]ethanone (Compound 126) Step A: Preparation of 5-bromo-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide

A stirred solution of N,N-dimethyl-3-(trifluoromethyl)-H-pyrazole-1-sulfonamide (i.e. the product of Example 10, Step A) (4.25 g, 17.5 mmol) in tetrahydrofuran (50 mL) was cooled to −78° C., and then 2 M n-butyllithium in cyclohexane (10.0 mL, 20.0 mmol) was added dropwise. The reaction mixture was stirred a further 30 minutes, and then bromine (1.0 mL, 3.1 g, 18.7 mmol) was added dropwise. The reaction mixture was stirred for 10 minutes, warmed to room temperature, and quenched with brine (50 mL). The resulting solution was extracted with diethyl ether, dried (MgSO₄), and concentrated under reduced pressure to give 6.77 g of title compound as a light yellow oil. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 3.15 (s, 6H), 6.69 (s, 1H).

Step B: Preparation 5-bromo-3-(trifluoromethyl)-1H-pyrazole

A solution of 5-bromo-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide (i.e. the product of Example 11, Step A) (4.50 g, 14.0 nmmol) and trifluoroacetic acid (2.0 mL, 26 mmol) was stirred at 25° C. for 4 h. The reaction mixture was diluted with water (20 mL), and sodium hydroxide was added to raise the pH to 12. The solution was extracted with chloroform, dried (MgSO₄), and concentrated under reduced pressure to give 2.73 g of the title compound as a yellow light oil. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 6.63 (m, 1H).

Step C: Preparation of ethyl 5-bromo-3-(trifluoromethyl)-1-pyrazole-1-acetate

A suspension of 5-bromo-3-(trifluoromethyl)-1H-pyrazole (i.e. the product of Example 11, Step B) (2.73 g, 12.7 mmol) and potassium carbonate (2.0 g, 14.5 mmol) in N,N-dimethylformamide (20 mL) was treated with ethyl iodoacetate (3.0 ml, 25.3 mmol), and the resulting mixture was stirred at 95° C. for 3 h. The resulting mixture was diluted with ethyl acetate, washed with water, and dried (MgSO₄). The reaction mixture was concentrated in vacuo and further purified by medium-pressure liquid chromatography using 0-50% of ethyl acetate in hexanes as eluant to give 2.84 g of the title compound as a brown oil.

¹H NMR (CDCl₃) δ 1.29 (m, 3H), 4.26 (q, 2H), 5.00 (m, 2H), 6.64 (s, 1H).

Step D: Preparation of 5-bromo-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid

A solution of ethyl 5-bromo-3-(trifluoromethyl)-1H-pyrazole-1-acetate (i.e. the product of Example 11, Step C) (2.84 g, 9.4 mmol) in tetrahydrofuran (10 mL) was treated with a 50 wt. % aqueous solution of sodium hydroxide solution (1.0 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was treated with concentrated aqueous hydrochloric acid to lower the pH to 1, and then extracted with ethyl acetate. The extract was dried (MgSO₄) and concentrated under pressure to give 2.26 g of the title compound as a light brown solid. Recrystallization from 1-chlorobutane (20 mL) gave 0.68 g of the title compound as lustrous light pink plates.

¹H NMR (CDCl₃) δ 5.08 (s, 2H), 6.65 (s, 1H).

Step E: Preparation of 2-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazoly)-2-thiazolyl]-1-piperidinyl]ethanone

To a solution of 5-bromo-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (i.e. the product of Example 11. Step D) (0.12 g, 0.61 mmol) in dichloromethane (5 mL) was added N,N-dimethylformamide (1 drop) followed by oxalyl chloride (0.25 mL, 2.86 mmol). The reaction mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue containing crude acid chloride was taken up in dichloromethane (5 mL), and the solution was added dropwise to a mixture of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidine hydrochloride (i.e. the product of Example 10, Step F) (0.15 g, 0.43 mmol) and triethylamine (0.25 mL, 1.8 mmol) in dichloromethane (5 mL) at 0° C. The reaction mixture was allowed to warm to room temperature, and then stirred overnight at room temperature. The mixture was then partitioned between 1.0 N aqueous hydrochloric acid solution and dichloromethane. The organic layer was washed with water, dried (MgSO₄), concentrated under reduced pressure, and purified by medium-pressure liquid chromatography using ethyl acetate in hexanes as eluant to give 90 mg of the title product, a compound of the present invention, as an amorphous solid.

¹H NMR (CDCl₃) δ 1.84 (m, 2H), 2.20 (m, 2H), 2.89 (m, 1H), 3.31 (m, 2H), 3.46 (m, 1H), 3.89 (m, 2H), 4.58 (m, 1H), 5.11 (m, 2H), 5.75 (m, 1H), 6.63 (s, 1H), 7.25-7.42 (m, 5H), 7.66 (s, 1H).

EXAMPLE 12 Preparation of 1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (Compound 3) Step A: Preparation of 4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide

To a solution of 2-(dimethylamino)-N-hydroxy-2-oxoethanimidoyl chloride (prepared according to the procedure of E. Raleigh. U.S. Pat. No. 3,557,089) (6.0 g, 40 mmol), styrene (6.0 g, 60 mmol) in toluene (15 mL) was added a solution of potassium hydrogen carbonate (5.0 g, 50 mmol) in water (25 mL) over 1 h, while keeping the reaction temperature between 7 and 10° C. The reaction mixture was diluted with 10 mL of toluene, and stirred for an additional 10 minutes. The organic layer was separated and washed with water. The organic layer was concentrated under reduced pressure until no styrene remained to give 8.7 g of the title compound as a light yellow oil. This compound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 3.08 (s, 3H), 3.32 (s, 3H), 3.35 (dd, 1H), 3.71 (dd, 1H), 5.65 (dd, 1H), 7.35 (m, 5H).

Step B: Preparation of 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid

To a solution of 4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide (i.e. the product of Example 12, Step A) (60.0 g, 275 mmol) in methanol (300 mL) was added an aqueous sodium hydroxide solution (44 g of 50 wt. % aqueous NaOH in 50 mL of water) dropwise over 30 minutes while maintaining the temperature of the reaction mixture at 45° C. The reaction mixture was allowed to cool to room temperature and stirred overnight. The resulting mixture was concentrated under reduced pressure, and treated with 200 mL of water. The pH of the reaction mixture was adjusted using concentrated hydrochloric acid to about 1.0. The crude product was extracted into ethyl acetate (200 mL). The ethyl acetate solution was concentrated under reduced pressure, and the residue was triturated with hexanes. The resulting precipitate was filtered, washed with hexanes (2×20 mL), and dried under vacuum to give 46.5 g of the title compound as a solid.

¹H NMR (CDCl₃) δ 3.25 (dd, 1H), 3.75 (dd, 1H), 5.85 (dd, 1H), 7.35 (m, 5H), 8.1 (br s, 1H).

Step C: Preparation of the cinchonine salt of (5R)-4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid

A mixture of racemic 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid (i.e. the product of Example 12, Step B) (9.5 g. 50 mmol) in methanol (70 mL) was heated to 55° C., and cinchonine (containing about 15% dihydrocinchonine, 14.5 g, 50 mmol) was added over 20 minutes while keeping the temperature of the reaction mixture between 53 and 57° C. The reaction mixture was allowed to cool to room temperature over 60 minutes, and then water (35 mL) was added dropwise over 30 minutes. The resulting slurry was cooled to 10° C. and filtered. The filter cake was washed twice with 10 mL of 25% methanol in water, and air dried to give 8.52 g of the title compound as a solid. The diastereomeric ratio of the product was determined using chiral high performance liquid chromatography (HPLC) analysis on a Daicel Chiralcel®, OD HPLC column to be about 99:1.

¹H NMR (CDCl₃) δ 3.25 (dd, 1H), 3.75 (dd, 1H), 5.85 (dd, 1H), 7.35 (m, 5H), 8.1 (br s, 1H).

Step D: Preparation of (5R)-4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide

The cinchonine salt of (5R)-4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid (i.e. the product of Example 12, Step C) (98% diastereomeric excess, 16.5 g, 34.3 mmol) was slurried in a mixture of 1 N hydrochloric acid (90 mL), cyclohexane (100 mL) and ethyl acetate (40 mL). After all the solids dissolved, the phases were separated, and the organic layer was washed with brine (20 mL) and concentrated under reduced pressure to give 5.6 g of white solid. To a solution of the resulting free acid (5.0 g, 26.2 mmol) in ethyl acetate (100 mL) at room temperature was added N,N-dimethylformamide (1 drop) followed by thionyl chloride (4.25 g, 35.7 mmol). The reaction mixture was then heated under reflux for 3 h. The resulting mixture was cooled and concentrated under reduced pressure. The residue containing crude acid chloride was dissolved in ethyl acetate (25 mL), and this solution was added in portions to a pre-cooled (5° C.) mixture of dimethylamine in tetrahydrofuran (29 mL of a 2.0 M solution), while maintaining the temperature of the mixture at 5-10° C. When the addition was complete, the reaction mixture was concentrated under reduced pressure, and diluted with water (50 mL). The resulting precipitate was filtered, washed with water and suction-dried overnight to give 4.1 g of the title compound as a light tan solid, melting at 59-61° C. This compound was of sufficient purity to use in subsequent reactions.

Step E: Preparation of 2-bromo-1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone

A solution of (5R)-4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazole-carboxamide (i.e. the product of Example 12, Step D) (3.5 g, 16.0 mmol) in a mixture of tetrahydrofuran (5 mL) and toluene (10 mL) was cooled to −15° C., and methyl magnesium bromide (3.0 M solution in tetrahydrofuran, 8.8 mL, 26.4 mmol) was added over 1 h at −15° C. Then the reaction mixture was poured over a mixture of 20 g of concentrated hydrochloric acid and 80 g of ice, and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (100 mL), and the combined extract was washed with brine (40 mL) and concentrated under reduced pressure to give 3.2 g of 1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoyl]ethanone.

¹H NMR (CDCl₃) δ 2.55 (s, 3H), 3.17 (dd, 1H), 3.54 (dd, 1H), 5.75 (dd, 1H), 7.35 (m, 5H).

1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoyl]ethanone (3.2 g, 16.7 mmol) was dissolved in 1,2-dichloroethane (15 mL), and a solution of bromine (2.13 g, 13.3 mmol) in dichloroethane (5 mL) was added over 30 minutes while maintaining the temperature of the reaction mixture at about 30° C. The reaction mixture was diluted with water (10 mL), and the organic layer was concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 35% of dichloromethane in hexanes as eluant to give 2.6 g of the title compound as a white solid, melting at 31-33° C.

¹H NMR (CDCl₃) δ 3.20 (dd, 1H), 3.60 (dd, 1H), 4.49 (s, 2H), 5.80 (dd, 1H), 7.35 (m, 5H).

Step E1: Alternative preparation of 2-bromo-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)-ethanone

To a solution of 4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide (i.e. the product of Example 12, Step A) (17 g, 78.0 mmol) in a mixture of tetrahydrofuran (20 mL) and toluene (80 mL) was added methyl magnesium bromide (3.0 M solution in tetrahydrofuran, 28 mL, 84 mmol) over 1 h, while keeping the reaction temperature between −10 and −15° C. The reaction mixture was poured over a mixture of concentrated hydrochloric acid (20 g) and ice (80 g), and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (100 mL), and the combined organic extracts were washed with brine (40 mL) and concentrated under reduced pressure to give 14.4 g of 1-(4,5-dihydro-5-phenyl-3-isoxazoyl)ethanone as a light yellow oil.

¹H NMR (CDCl₃) δ 2.55 (s, 3H), 3.17 (dd, 1H), 3.54 (dd, 1H), 5.75 (dd, 1H), 7.35 (m, 5H).

1-(4,5-Dihydro-5-phenyl-3-isoxazoyl)ethanone (11.5 g, 60 mmol) was dissolved in ethyl acetate (45 mL), and a solution of bromine (9.6 g, 60.0 mmol) in ethyl acetate (30 mL) was added over 30 minutes while maintaining the temperature of the reaction mixture at about 30° C. After 1 h, the reaction mixture was diluted with water (10 mL), and the organic layer was concentrated under reduced pressure to give 16.7 g of reddish oil which contained about 10% starting methyl ketone and −10% dibrominated ketone.

¹H NMR (CDCl₃) 3.20 (dd, 1H), 3.60 (dd, 1H), 4.49 (s, 2H), 5.80 (dd, 1H), 7.35 (m, 5H).

Step F: Preparation of 1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

A mixture of 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide (i.e. the product of Example 8, Step C) (1.7 g, 5.0 mmol) and 2-bromo-1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone (i.e. the product of Example 12, Step E or E1) (1.35 g, 5 mmol) in ethanol (15 mL) was heated at 50° C. for 30 minutes. The reaction mixture was diluted with water and extracted with dichloromethane. The extract was washed with brine, dried (MgSO₄), and concentrated under reduced pressure to give the title product, a compound of the present invention, as a pale-yellow gum. High performance liquid chromatography (HPLC) analysis showed that the title product was about 95% pure and contained the (R)-enantiomer in about 98% enantiomeric excess.

¹H NMR (CDCl₃) δ 1.8 (m, 2H), 2.2 (m, 2H), 2.32 (s, 3H), 2.9 (m, 1H), 3.3 (m, 2H), 3.42 (dd, 1H), 3.82 (dd, 1H), 4.05 (m, 1H), 4.6 (m, 1H), 5.0 (q, 2H), 5.78 (dd, 1H), 6.35 (s, 1H), 7.4 (m, 5H), 7.62 (s, 1H).

EXAMPLE 13 Preparation of 1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-3,6-dihydro-1(2H)-pyridinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1yl]ethanone (Compound 217) Step A: Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]pyridine

To a solution of thioisonicotinamide (0.5 g, 3.6 mmol) in 1-methyl-2-pyrrolidinone (25 mL) was added 2-chloro-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone (0.807 g, 3.6 mmol), at room temperature. The reaction mixture was then heated to 100° C. for 3 h. Then the reaction mixture was cooled to room temperature, quenched with water (100 mL), extracted with ethyl acetate (50 mL×2). The reaction mixture was diluted with water (50 mL) and brine (50 mL), and the organic layer was concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 2% of methanol in chloroform as eluant to give 0.7 g of the title compound as a brown solid.

¹H NMR (CDCl₃) δ 3.5 (m, 1H), 3.9 (m, 1H), 5.8 (m, 1H), 7.35 (m, 5H), 8.16 (s, 1H), 8.3 (d, 2H), 8.8 (d, 2H).

Step B: Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine

To a solution of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]pyridine (i.e. the product of Example 13, Step A) (0.60 g, 1.95 mmol) in toluene (10 mL) was added benzyl bromide (0.670 g, 3.90 mmol), and the reaction mixture was heated to 100° C. for 12 h. Then the reaction mixture was cooled to room temperature. The solid that precipitated out was filtered and dried. The solid was dissolved in methanol (10 mL), and sodium borohydride (0.072 g, 1.95 mmol) was added in portions. The reaction mixture was stirred at room temperature for 2 h, diluted with water (50 mL), neutralized with 1.5 N aqueous hydrochloric acid solution, and extracted with ethyl acetate (50 mL). The organic layer was separated, washed with brine (25 mL), and concentrated under reduced pressure. The residue was purified by medium-pressure liquid chromatography using 3% of methanol in chloroform as eluant to give 0.4 g of the title compound as a white solid.

¹H NMR (CDCl₃) δ 3.03-3.1 (m, 2H), 3.4-3.6 (m, 4H), 3.8-4.0 (m, 2H), 4.25-4.32 (m, 2H), 5.76-5.79 (m, 1H), 6.47 (s, 1H), 7.34-7.48 (m, 10H), 7.72 (s, 1H).

Step C: Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydropyridine hydrochloride

To a solution of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine (i.e. the product of Example 13, Step B) (0.400 g, 0.99 mmol) in dichloroethane (10 mL) was added 1-chloroethyl chloroformate (0.286 g, 1.99 mmol), and the reaction mixture was heated to 80° C. for 5 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Methanol (10 mL) was added to the residue, and the resulting mixture was heated to 60° C. for 1 h, cooled to room temperature, and concentrated under reduced pressure. The residue was triturated with 50% of petroleum ether in ethyl acetate, and the solid formed was filtered and dried to give 0.25 g of the title compound as a white solid.

¹H NMR (DMSO-d₆) δ 2.50-2.55 (m, 2H), 3.31-3.39 (m, 3H), 3.86-3.91 (m, 3H), 5.73-5.78 (m, 1H), 6.67 (s, 1H), 7.34-7.39 (m, 5H), 7.68 (s, 1H), 9.47 (s, 2H).

Step D: Preparation of 1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-3,6-dihydro-1(2H)-pyridinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1yl]ethanone

To a solution of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydropyridine hydrochloride (i.e. the product of Example 13, Step C) (0.250 g, 0.720 mmol) and 5-methyl-3-(trifluoromethyl)-H-pyrazole-1-acetic acid (0.150 g, 0.720 mmol) in dichloromethane (10 mL) was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (0.138 g, 0.720 mmol), 1-hydroxybenzotriazole (0.024 g, 0.177 mmol), and triethylamine (0.145 g, 1.44 mmol) at room temperature. The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with dichloromethane (30 mL) and washed with water (20 mL) and brine (20 mL). The organic layer was separated, washed with water, dried (Na₂SO₄), and concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 3% methanol in chloroform as eluant to give 200 mg of the title product, a compound of the present invention, as a white solid.

¹H NMR (CDCl₃) δ 2.3 (s, 3H), 2.71-2.75 (m, 2H), 3.42-3.46 (m, 1H), 3.74-3.88 (m, 3H), 4.24-4.27 (m, 2H), 5.02 (s, 2H), 5.71-5.76 (m, 1H), 6.32 (s, 1H), 6.57 (s, 1H), 7.3-7.38 (m, 5H), 7.64 (s, 1H).

By the procedures described herein, together with methods known in the art, the following compounds of Tables 1A to 8 can be prepared. The following abbreviations are used in the Tables which follow: t means tertiary, s means secondary, n means normal, i means iso, c means cyclo, Ac means acetyl, Me means methyl, Et means ethyl, Pr means propyl (i.e. n-propyl), i-Pr means isopropyl, c-Pr means cyclopropyl, Bu means butyl, Pen means pentyl, Hex means hexyl, Am means amyl, CN means cyano. A dash (-) indicates no substituents.

The invention includes but is not limited to the following exemplary species.

TABLE 1A

R¹ phenyl 2-methylphenyl 2-methoxyphenyl 2-chlorophenyl 2-bromophenyl 2-ethylphenyl 2-ethoxyphenyl 2-(methylthio)phenyl 2-(ethylthio)phenyl 2-(trifluoromethoxy)phenyl 3-chlorophenyl 3-bromophenyl 3-iodophenyl 3-methylphenyl 2-chloro-5-(trifluoromethyl)phenyl 2 -chloro-5-(2,2,2-trifluoroethyl)phenyl 2-chloro-5-(pentafluoroethyl)phenyl 2-chloro-5-cyanophenyl 2-chloro-5-nitrophenyl 2-bromo-5-chlorophenyl 2,5-dibromophenyl 2-bromo-5-iodophenyl 2 -bromo-5-methylphenyl 2-bromo-5-ethylphenyl 2-bromo-5-propylphenyl 2-bromo-5-isopropylphenyl 2-bromo-5-(trifluoromethyl)phenyl 2-bromo-5-(2,2,2-trifluoroethyl)phenyl 2-bromo-5-(pentafluoroethyl)phenyl 2-bromo-5-cyanophenyl 2-bromo-5-nitrophenyl 5-chloro-2-methylphenyl 5-bromo-2-methylphenyl 5-iodo-2-methylphenyl 2,5-dimethylphenyl 5-ethyl-2-methylphenyl 2-methyl-5-propylphenyl 5-isopropyl-2-methylphenyl 2-methyl-5-(trifluoromethyl)phenyl 2-methyl-5-(2,2,2-trifluoroethyl)phenyl 2-methyl-5-(pentafluoroethyl)phenyl 5-cyano-2-methylphenyl 2-methyl-5-nitrophenyl 5-chloro-2-methoxyphenyl 5-bromo-2-methoxyphenyl 5-iodo-2-methoxyphenyl 2-methoxy-5-methylphenyl 3-iodo-5-methylpyrazol-1-yl 3-ethyl-5-methylpyrazol-1-yl 5-methyl-3-propylpyrazol-1-yl 3-isopropyl-5-methylpyrazol-1-yl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl 5-methyl-3-(2,2,2-trifluoroethyl)pyrazol-1-yl 5-methyl-3-(pentafluoroethyl)pyrazol-1-yl 3-cyano-5-methylpyrazol-1-yl 5-methyl-3-nitropyrazol-1-yl 5-chloro-3-methylpyrazol-1-yl 3,5-dichloropyrazol-1-yl 5-chloro-3-bromopyrazol-1-yl 5-chloro-3-iodopyrazol-1-yl 5-chloro-3-ethylpyrazol-1-yl 5-chloro-3-propylpyrazol-1-yl 5-chloro-3-isopropylpyrazol-1-yl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl 5-chloro-3-(2,2,2-trifluoroethyl)pyrazol-1-yl 5-chloro-3-(pentafluoroethyl)pyrazol-1-yl 5-chloro-3-cyanopyrazol-1-yl 5-chloro-3-nitropyrazol-1-yl 5-bromo-3-methylpyrazol-1-yl 5-bromo-3-chloropyrazol-1-yl 3,5-dibromopyrazol-1-yl 5-bromo-3-iodopyrazol-1-yl 5-bromo-3-ethylpyrazol-1-yl 5-bromo-3-propylpyrazol-1-yl 5-bromo-3-isopropylpyrazol-1-yl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl 5-bromo-3-(2,2,2-trifluoroethyl)pyrazol-1-yl 5-bromo-3-(pentafluoroethyl)pyrazol-1-yl 5-bromo-3-cyanopyrazol-1-yl 5-bromo-3-nitropyrazol-1-yl 2-chloro-5-(dimethylamino)phenyl 2-chloro-5-(diethylamino)phenyl 2-chloro-5-(cyclopropylamino)phenyl 3-(methoxymethyl)phenyl 2-chloro-5-(ethoxymethyl)phenyl 2-chloro-5-(hyroxymethyl)phenyl 2-chloro-5-(methoxycarbonyl)phenyl 2-chloro-5-(ethylcarbonyl)phenyl 2-chloro-5-(methylcarbonyloxy)phenyl 2-chloro-5-(dimethylaminocarbonyl)phenyl 2-chloro-5-(dimethylaminocarbonyl)phenyl 2-methyl-5-(trimethylsilyl)phenyl 3,5-dimethyl-2-thienyl 3,5-dichloro-2-thienyl 3,5-dimethyl-2-furyl 1-methyl-2-pyrrolyl 4-methyl-2-(trifluoromethyl)-5-thiazolyl 4-(trifluoromethyl)-2-thiazolyl 4-(trifluoromethyl)-2-oxazolyl 4-methyl-2-(trifluoromethyl)-5-oxazolyl 4-bromo-5-isothiazolyl 4-bromo-5-isoxazolyl 1-methyl-5-pyrazolyl 1-methyl-5-imidazolyl 1-methyl-4-(trifluoromethyl)-2-imidazolyl 4-methyl-3-(1,3,4-triazolyl) 2-methyl-3-(1,2,4-triazolyl) 5-(trifluoromethyl)-2-(1,3,4-thiadiazolyl) 5-(trifluoromethyl)-2-(1,3,4-oxadiazolyl) 3-(trifluoromethyl)-5-(1,2,4-thiadiazolyl) 3-(trifluoromethyl)-5-(1,2,4-oxadiazolyl) 3-(trifluoromethyl)-1-(1,2,4-triazolyl) 2,5-dimethyl-1-pyrrolyl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl 3-bromo-5-(trifluoromethyl)pyrazol-1-yl 3-iodo-5-(trifluoromethyl)pyrazol-1-yl 3-ethyl-5-(trifluoromethyl)-pyrazol-1-yl 3-propyl-5-(trifluoromethyl)pyrazol-1-yl 3-isopropyl-5-(trifluoromethyl)pyrazol-1-yl 3-methyl-5-(trifluoromethyl)-pyrazol-1-yl 3-methoxy-5-(trifluoromethyl)-pyrazol-1-yl 5-difluoromethoxy-3-methylpyrazol-1-yl 5-difluoromethoxy-3-chloropyrazol-1-yl 3,5-dibromopyrazol-1-yl 5-difluoromethoxy-3-iodopyrazol-1-yl 5-difluoromethoxy-3-ethylpyrazol-1-yl 5-difluoromethoxy-3-propylpyrazol-1-yl 5-difluoromethoxy-3-isopropylpyrazol-1-yl 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl 5-difluoromethoxy-3-(2,2,2-trifluoroethyl)pyrazol-1-yl 5-difluoromethoxy-3-(pentafluoroethyl)pyrazol-1-yl 5-difluoromethoxy-3-cyanopyrazol-1-yl 5-difluoromethoxy-3-nitropyrazol-1-yl 3-carbomethoxy-5-(triftuoromethyl)pyrazol-1-yl 5-methoxy-3-methylpyrazol-1-yl 5-methoxy-3-bromopyrazol-1-yl 5-methoxy-3-iodopyrazol-1-yl 5-methoxy-3-ethylpyrazol-1-yl 5-methoxy-3-propylpyrazol-1-yl 5-methoxy-3-isopropylpyrazol-1-yl 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl 5-methoxy-3-(2,2,2-trifluoroethyl)pyrazol-1-yl 5-methoxy-3-(pentafluoroethyl)pyrazol-1-yl 5-methoxy-3-cyanopyrazol-1-yl 5-methoxy-3-nitropyrazol-1-yl 3-ethylphenyl 3-propylphenyl 3-isopropylphenyl 3-(triftuoromethyl)phenyl 3-(2,2,2-trifluoroethyl)phenyl 3-(pentafluoroethyl)phenyl 3-cyanophenyl 3-nitrophenyl 2,5-dichlorophenyl 5-bromo-2-chlorophenyl 2-chloro-5-iodophenyl 2-chloro-5-methylphenyl 2-chloro-5-ethylphenyl 2-chloro-5-propylphenyl 2-chloro-5-isopropylphenyl 5-ethyl-2-methoxyphenyl 2-methoxy-5-propylphenyl 5-isopropyl-2-methoxyphenyl 2-methoxy-5-(trifluoromethyl)phenyl 2-methoxy-5-(2,2,2-trifluoroethyl)phenyl 2-methoxy-5-(pentafluoroethyl)phenyl 5-cyano-2-methoxyphenyl 2-methoxy-5-nitrophenyl 5-chloro-2-ethylphenyl 5-bromo-2-ethylphenyl 2-ethyl-5-iodophenyl 2-ethyl-5-methylphenyl 2,5-diethylphenyl 2-ethyl-5-propylphenyl 2-ethyl-5-isopropylphenyl 2-ethyl-5-(trifluoromethyl)phenyl 2-ethyl-5-(2,2,2-trifluomethyl)phenyl 2-ethyl-5-(pentafluoroethyl)phenyl 5-cyano-2-ethylphenyl 2-ethyl-5-nitrophenyl 3-methylpyrazol-1-yl 3-chloropyrazol-1-yl 3-bromopyrazol-1-yl 3-iodopyrazol-1-yl 3-ethylpyrazol-1-yl 3-(trifluoromethyl)pyrazol-1-yl 3-(2,2,2-trifluoroethyl)pyrazol-1-yl 3-(pentafluoroethyl)pyrazol-1-yl 3-cyanopyrazol-1-yl 3-nitropyrazol-1-yl 3,5-dimethylpyrazol-1-yl 3-chloro-5-methylpyrazol-1-yl 3-bromo-5-methylpyrazol-1-yl 5-methoxy-3-methylpyrazol-1-yl 3-chloro-5-methoxypyrazol-1-yl 5-ethyl-3-methylpyrazol-1-yl 3-chloro-5-ethylpyrazol-1-yl 3-bromo-5-ethylpyrazol-1-yl 5-ethyl-3-iodopyrazol-1-yl 3,5-diethylpyrazol-1-yl 5-ethyl-3-propylpyrazol-1-yl 5-ethyl-3-isopropylpyrazol-1-yl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl 5-ethyl-3-(2,2,2-trifluoroethyl)pyrazol-1-yl 5-ethyl-3-(pentafluomethyl)pyrazol-1-yl 3-cyano-5-ethylpyrazol-1-yl 5-ethyl-3-nitropyrazol-1-yl 5-butyl-2-methylphenyl 5-hexyl-2-methylphenyl 5-allyl-2-methylphenyl 2-methyl-5-(4-methyl-3-pentenyl)phenyl 2-methyl-5-propargylphenyl 2-methyl-5-(3-methylpropargyl)phenyl 5-cyclopropyl-2-methylphenyl 5-cyclohexyl-2-methylphenyl 2-methyl-5-(pentafluoroisopropyl)phenyl 5-(3,3-dichloro-2-propen-1-yl)-2-methylphenyl 2-methyl-5-(4,4,4-trifluoro-2-butyn-1-yl)phenyl 5-(2,2-dichlorocyclopropan-1-yl)-2-methylphenyl 2-methyl-5-(trifluoromethoxy)phenyl 2-chloro-5-(isobutylthio)phenyl 2-chloro-5-(ethylsulfonyl)phenyl 2-chloro-5-(trifluoromethylthio)phenyl 2-chloro-5-(trifluoromethylsulfonyl)phenyl 2-chloro-5-(methylamino)phenyl 2-chloro-5-(tert-butylamino)phenyl 2,5-dimethyl-3-furyl 2,5-dimethyl-3-thienyl 2,5-dichloro-3-thienyl 1,4-dimethyl-3-pyrrolyl 1,4-dimethyl-3-pyrazolyl 1,3-dimethyl-4-pyrazolyl 2,5-dimethyl-4-oxazolyl 2,5-dimethyl-4-thiazolyl 3-bromo-4-isothiazolyl 3-bromo-4-isooxazolyl 1-methyl-4-imidazolyl 5-(trifluoromethyl)-3-(1,2,4-oxadiazolyl) 5-(trifluoromethyl)-3-(1,2,4-tiadiazolyl) 2-bromo-1-(1,3,4-triazolyl) 5-(trifluoromethyl)-3-(1,2,4-triazolyl) 2-bromo-1-imidazolyl 3,6-dimethyl-2-pyridyl 2,5-dimethyl-3-pyridyl 2,5-dimethyl-4-pyridyl 3,6-dichloro-2-pyridyl 2,5-dichloro-3-pyridyl 2,5-dichloro-4-pyridyl 4-bromo-3-pyridazinyl 4-(trifluoromethyl)-2-pyrimidinyl 3,6-dimethyl-2-pyrazinyl 2,5-dimethyl-4-pyrimidinyl 4-methoxy-5-pyrimidinyl 3,6-dimethyl-4-pyridazinyl 5-(trifluoromethyl)-3-(1,2,4-triazinyl) 5-methoxy-6-(1,2,4-triazinyl) 4-(trifluoromethyl)-2-(1,3,5-triazinyl) 3,6-dimethyl-5-(1,2,4-triazinyl) 1-methyl-4-(trifluoromethyl)imidazol-2-yl 3,5-bis-(trifluoromethyl)pyrazol-1-yl 3-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-1-yl 3-(pentafluoroethyl)-5-(trifluoromethyl)pyrazol-1-yl 3-cyano-5-(trifluoromethyl)pyrazol-1-yl 3-nitro-5-(trifluoromethyl)pyrazol-1-yl 3-chloro-5-(trifluoromethyl)-pyrazol-1-yl 3,5-bis-(trichloromethyl)pyrazol-1-yl 3-difluoromethoxy-5-methylpyrazol-1-yl 3-difluoromethoxy-5-chloropyrazol-1-yl 3-difluoromethoxy-5-bromopyrazol-1-yl 3-difluoromethoxy-5-iodopyrazol-1-yl 3-difluoromethoxy-5-ethylpyrazol-1-yl 3-difluoromethoxy-5-(trifluoromethyl)pyrazol-1-yl 3-difluoromethoxy-5-(2,2,2-trifluoroethyl)pyrazol-1-yl 3-difluoromethoxy-5-(pentafluoroethyl)pyrazol-1-yl 3-difluoromethoxy-5-cyanopyrazol-1-yl 3-difluoromethoxy-5-nitropyrazol-1-yl 3,5-bis-(difluoromethoxy)pyrazol-1-yl 5-carbomethoxy-3-(trifluoromethyl)pyrazol-1-yl 3,5-dimethoxypyrazol-1-yl 5-ethoxy-3-methylpyrazol-1-yl 5-ethoxy-3-bromopyrazol-1-yl 5-ethoxy-3-iodopyrazol-1-yl 5-ethoxy-3-ethylpyrazol-1-yl 5-ethoxy-3-propylpyrazol-1-yl 5-ethoxy-3-isopropylpyrazol-1-yl 5-ethoxy-3-(trifluoromethyl)pyrazol-1-yl 5-ethoxy-3-(2,2,2-trifluoroethyl)pyrazol-1-yl 5-ethoxy-3-(pentafluoroethyl)pyrazol-1-yl 5-ethoxy-3-cyanopyrazol-1-yl 5-ethoxy-3-nitropyrazol-1-yl

TABLE 1B

R¹ A W 2-methoxyphenyl NH O 2,5-dichlorophenyl NH O 5-bromo-2-chlorophenol NH O 2-chloro-5-methylphenyl NH O 2-chloro-5-(trifluoromethyl)phenyl NH O 2,5-dibromophenyl NH O 2-bromo-5-methylphenyl NH O 2-bromo-5-(trifluoromethyl)phenyl NH O 5-chloro-2-methylphenyl NH O 5-bromo-2-methylphenyl NH O 2,5-dimethylphenyl NH O 5-ethyl-2-methylphenyl NH O 2-methyl-5-(trifluoromethyl)phenyl NH O 5-bromo-2-methoxyphenyl NH O 2-methoxy-5-methylphenyl NH O 2-methoxy-5-(trifluoromethyl)phenyl NH O 3-ethyl-5-methylpyrazol-1-yl CH₂ S 5-methyl-3-(trifluoromethyl)pyrazol-1-yl CH₂ S 3,5-dichloropyrazol-1-yl CH₂ S 5-c hloro-3-(trifluoromethyl)pyrazol-1-yl CH₂ S 3,5-bis-(trifluoromethyl)pyrazol-1-yl CH₂ S 3,5-dimethylpyrazol-1-yl CH₂ S 3,5-dibromoryrazol-1-yl CH₂ S 5-bromo-3-(trifluoromethyl)pyrazol-1-yl CH₂ S 3,5-diethylpyrazol-1-yl CH₂ S 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl CH₂ S 2-methoxyphenyl NH S 2,5-dichlorophenyl NH S 5-bromo-2-chlorophenyl NH S 2-chloro-5-methylphenyl NH S 2-chloro-5-(trifluoromethyl)phenyl NH S 2,5-dibromophenyl NH S 2-bromo-5-methylphenyl NH S 2-bromo-5-(trifluoromethyl)phenyl NH S 5-chloro-2-methylphenyl NH S 5-bromo-2-methylphenyl NH S 2,5-dimethylphenyl NH S 5-ethyl-2-methylphenyl NH S 2-methyl-5-(trifluoromethyl)phenyl NH S 5-bromo-2-methoxyphenyl NH S 2-methoxy-5-methylphenyl NH S 2-methoxy-5-(trifluoromethyl)phenyl NH S 5-methyl-3-(trifluoromethyl)pyrazol-1-yl NCH₃ O 5-methyl-3-(trifluoromethyl)pyrazol-1-yl NAc O 3-methyl-5-(trifluoromethyl)pyrazol-1-yl CH₂ S 5-methyl-3-(trifluoromethyl)pyrazol-1-yl CHCH₃ O 5-methyl-3-(trifluoromethyl)pyrazol-1-yl CHCOOCH₃ O 5-methyl-3-(trifluoromethyl)pyrazol-1-yl CHCl O 5-methyl-3-(trifluoromethyl)pyrazol-1-yl NCOOCH₃ O 5-methyl-3-(trifluoromethyl)pyrazol-1-yl NH S 3,5-dimethylpyrazol-1-yl NH O 3,5-dichloropyrazol-1-yl NH O 3,5-dibromopyrazol-1-yl NH O 5-methyl-3-(trifluoromethyl)pyrazol-1-yl NH O 5-chloro-3-(trifluoromethyl)pyrazol-1-yl NH O 5-bromo-3-(trifluoromethyl)pyrazol-1-yl NH O 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl NH O 3,5-bis-(trifluoromethyl)pyrazol-1-yl NH O 3-methyl-5-(triftuoromethyl)pyrazol-1-yl NH O 3-chloro-5-(trifluoromethyl)pyrazol-1-yl NH O 3-bromo-5-(trifluoromethyl)pyrazol-1-yl NH O 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl NH O 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl NH O

TABLE 2*

Z¹ J (R⁵)_(x) Z² Q (R⁷)_(p) R¹² J-orientation** bond J-1 — bond Q-45 — — 2/4 bond J-1 — bond Q-45 — — 2/5 bond J-1 — bond Q-45 — — 4/2 bond J-1 — bond Q-45 — — 5/2 bond J-2 — bond Q-45 — — 2/4 bond J-2 — bond Q-45 — — 2/5 bond J-2 — bond Q-45 — — 4/2 bond J-2 — bond Q-45 — — 5/2 bond J-3 1-Me bond Q-45 — — 2/4 bond J-3 1-Me bond Q-45 — — 2/5 bond J-3 1-Me bond Q-45 — — 4/2 bond J-3 1-Me bond Q-45 — — 5/2 CH₂ J-3 — bond Q-45 — — 1/4 bond J-3 — bond Q-45 — — 4/1 bond J-4 — bond Q-45 — — 2/4 bond J-4 — bond Q-45 — — 2/5 bond J-4 — bond Q-45 — — 4/2 bond J-4 — bond Q-45 — — 5/2 bond J-4 — bond Q-45 — — 3/5 bond J-4 — bond Q-45 — — 5/3 bond J-5 — bond Q-45 — — 2/4 bond J-5 — bond Q-45 — — 2/5 bond J-5 — bond Q-45 — — 4/2 bond J-5 — bond Q-45 — — 5/2 bond J-5 — bond Q-45 — — 3/5 bond J-5 — bond Q-45 — — 5/3 bond J-6 — bond Q-45 — — 2/4 bond J-6 — bond Q-45 — — 2/5 bond J-6 — bond Q-45 — — 4/2 bond J-6 — bond Q-45 — — 5/2 bond J-6 — bond Q-45 — — 3/5 bond J-6 — bond Q-45 — — 5/3 CH₂ J-6 — bond Q-45 — — 1/3 bond J-6 — bond Q-45 — — 3/1 bond J-7 — bond Q-45 — — 5/3 bond J-7 — bond Q-45 — — 3/5 bond J-8 — bond Q-45 — — 5/3 bond J-8 — bond Q-45 — — 3/5 bond J-9 1-Me bond Q-45 — — 5/3 bond J-9 1-Me bond Q-45 — — 3/5 CH₂ J-9 — bond Q-45 — — 1/4 bond J-9 — bond Q-45 — — 4/1 bond J-10 — bond Q-45 — — 3/5 bond J-10 — bond Q-45 — — 5/3 bond J-11 — bond Q-45 — — 3/5 bond J-11 — bond Q-45 — — 5/3 bond J-12 1-Me bond Q-45 — — 3/5 bond J-12 1-Me bond Q-45 — — 5/3 CH₂ J-12 — bond Q-45 — — 1/3 bond J-12 — bond Q-45 — — 3/1 bond J-13 — bond Q-45 — — 1/4 bond J-13 — bond Q-45 — — 4/1 bond J-14 1-Me bond Q-45 — — 3/5 bond J-14 — bond Q-45 — — 5/3 bond J-15 — bond Q-45 — — 2/5 bond J-16 — bond Q-45 — — 2/5 CH₂ J-17 — bond Q-45 — — 2/4 bond J-17 — bond Q-45 — — 4/2 CH₂ J-18 — bond Q-45 — — 2/5 bond J-18 — bond Q-45 — — 5/2 bond J-19 — bond Q-45 — — 2/4 bond J-19 — bond Q-45 — — 4/2 bond J-20 — bond Q-45 — — 2/4 bond J-20 — bond Q-45 — — 2/5 bond J-20 — bond Q-45 — — 2/6 bond J-20 — bond Q-45 — — 3/5 bond J-20 — bond Q-45 — — 4/2 bond J-20 — bond Q-45 — — 5/2 bond J-21 — bond Q-45 — — 3/5 bond J-21 — bond Q-45 — — 3/6 bond J-21 — bond Q-45 — — 5/3 bond J-22 — bond Q-45 — — 2/4 bond J-22 — bond Q-45 — — 2/5 bond J-22 — bond Q-45 — — 4/6 bond J-22 — bond Q-45 — — 4/2 bond J-22 — bond Q-45 — — 5/2 bond J-23 — bond Q-45 — — 2/5 bond J-23 — bond Q-45 — — 2/6 bond J-24 — bond Q-45 — — 2/4 bond J-24 — bond Q-45 — — 2/5 bond J-24 — bond Q-45 — — 4/2 bond J-24 — bond Q-45 — — 5/2 bond J-25 — bond Q-45 — — 2/4 bond J-25 — bond Q-45 — — 2/5 bond J-25 — bond Q-45 — — 4/2 bond J-25 — bond Q-45 — — 5/2 bond J-26 — bond Q-45 — — 2/4 bond J-26 — bond Q-45 — — 2/5 bond J-26 — bond Q-45 — — 4/2 bond J-26 — bond Q-45 — — 5/2 CH₂ J-26 — bond Q-45 — — 1/4 bond J-26 — bond Q-45 — — 4/1 bond J-27 — bond Q-45 — — 2/4 bond J-27 — bond Q-45 — — 2/5 bond J-27 — bond Q-45 — — 3/5 bond J-27 — bond Q-45 — — 4/2 bond J-27 — bond Q-45 — — 5/2 bond J-27 — bond Q-45 — — 5/3 bond J-28 — bond Q-45 — — 3/5 bond J-28 — bond Q-45 — — 5/3 bond J-29 — bond Q-45 — — 3/5 bond J-29 — bond Q-45 — — 5/3 bond J-30 — bond Q-45 — — 3/5 bond J-30 — bond Q-45 — — 5/3 CH₂ J-30 — bond Q-45 — — 1/3 bond J-30 — bond Q-45 — — 3/1 CH₂ J-30 — bond Q-45 — — 1/4 bond J-30 — bond Q-45 — — 4/1 CH₂ J-31 — bond Q-45 — — 1/3 CH₂ J-31 — bond Q-45 — — 1/4 bond J-31 — bond Q-45 — — 2/4 bond J-31 — bond Q-45 — — 2/5 bond J-31 — bond Q-45 — — 3/5 bond J-31 — bond Q-45 — — 3/1 bond J-31 — bond Q-45 — — 4/1 bond J-31 — bond Q-45 — — 4/2 bond J-31 — bond Q-45 — — 5/2 bond J-32 — bond Q-45 — — 2/4 bond J-32 — bond Q-45 — — 2/5 bond J-32 — bond Q-45 — — 3/5 bond J-32 — bond Q-45 — — 5/3 bond J-32 — bond Q-45 — — 5/2 bond J-32 — bond Q-45 — — 4/2 bond J-33 — bond Q-45 — — 2/4 bond J-33 — bond Q-45 — — 2/5 bond J-33 — bond Q-45 — — 3/5 bond J-33 — bond Q-45 — — 5/3 bond J-33 — bond Q-45 — — 5/2 bond J-33 — bond Q-45 — — 4/2 bond J-34 — bond Q-45 — — 1/3 bond J-34 — bond Q-45 — — 1/4 bond J-34 — bond Q-45 — — 3/5 bond J-34 — bond Q-45 — — 3/1 bond J-34 — bond Q-45 — — 4/1 CH₂ J-35 — bond Q-45 — — 1/4 bond J-35 — bond Q-45 — — 4/1 CH₂ J-36 — bond Q-45 — — 1/3 bond J-36 — bond Q-45 — — 3/1 bond J-36 — bond Q-45 — — 3/5 bond J-36 — bond Q-45 — — 5/3 bond J-37 — bond Q-45 — — 2/5 bond J-37 — bond Q-45 — — 5/2 bond J-37 — bond Q-45 — — 2/4 bond J-37 — bond Q-45 — — 4/2 bond J-38 — bond Q-45 — — 2/5 bond J-38 — bond Q-45 — — 5/2 bond J-38 — bond Q-45 — — 2/4 bond J-38 — bond Q-45 — — 4/2 bond J-39 4-Me bond Q-45 — — 3/5 bond J-39 4-Me bond Q-45 — — 5/3 bond J-40 — bond Q-45 — — 3/5 bond J-40 — bond Q-45 — — 5/3 bond J-41 — bond Q-45 — — 1/3 bond J-41 — bond Q-45 — — 1/4 CH₂ J-42 — bond Q-45 — — 1/3 CH₂ J-42 — bond Q-45 — — 1/4 CH₂ J-43 — bond Q-45 — — 1/4 bond J-44 — bond Q-45 — — 1/3 bond J-44 — bond Q-45 — — 2/4 bond J-44 — bond Q-45 — — 2/5 bond J-44 — bond Q-45 — — 2/6 bond J-45 — bond Q-45 — — 2/4 bond J-45 — bond Q-45 — — 2/5 bond J-45 — bond Q-45 — — 2/6 bond J-46 — bond Q-45 — — 2/4 bond J-46 — bond Q-45 — — 2/5 bond J-46 — bond Q-45 — — 4/2 bond J-46 — bond Q-45 — — 5/2 bond J-47 — bond Q-45 — — 2/4 bond J-47 — bond Q-45 — — 2/5 bond J-47 — bond Q-45 — — 4/2 bond J-47 — bond Q-45 — — 5/2 bond J-48 — bond Q-45 — — 3/5 bond J-49 — bond Q-45 — — 2/4 bond J-49 — bond Q-45 — — 2/5 bond J-49 — bond Q-45 — — 4/2 bond J-49 — bond Q-45 — — 5/2 bond J-50 — bond Q-45 — — 2/6 bond J-51 — bond Q-45 — — 2/6 bond J-52 — bond Q-45 — — 2/6 bond J-53 — — — — — 2/3 bond J-54 — — — — — 2/3 bond J-55 — — — — — 2/3 bond J-56 — — — — — 2/3 bond J-57 1-Me — — — — 2/4 bond J-58 1-Me — — — — 3/4 bond J-59 — — — — — 2/4 bond J-60 — — — — — 2/4 bond J-61 — — — — — 2/4 bond J-62 — — — — — 2/4 bond J-63 — — — — — 3/4 bond J-64 — — — — — 2/3 bond J-65 — — — — — 3/4 bond J-66 — — — — — 6/7 bond J-67 — — — — — 2/3 bond J-68 — — — — — 2/3 bond J-69 — bond Q-45 — — 1/3 bond J-69 — bond Q-45 — — 1/4 bond J-70 — bond Q-45 — — 1/3 bond J-71 — bond Q-45 — — 2/4 bond J-71 — bond Q-45 — — 4/2 bond J-72 — bond Q-45 — — 2/4 bond J-72 — bond Q-45 — — 4/2 bond J-73 — bond Q-45 — — 2/4 bond J-73 — bond Q-45 — — 4/2 bond J-73 — bond Q-45 — — 1/3 bond J-73 — bond Q-45 — — 1/4 bond J-73 — bond Q-45 — — 4/1 bond J-74 3-Me bond Q-45 — — 2/4 bond J-74 3-Me bond Q-45 — — 2/5 bond J-74 3-Me bond Q-45 — — 4/2 bond J-74 3-Me bond Q-45 — — 5/2 bond J-74 — bond Q-45 — — 3/5 bond J-74 — bond Q-45 — — 5/3 bond J-75 — bond Q-45 — — 3/5 bond J-75 — bond Q-45 — — 5/3 bond J-75 — bond Q-45 — — 2/4 bond J-75 — bond Q-45 — — 2/5 bond J-75 2-Me bond Q-45 — — 3/5 bond J-75 2-Me bond Q-45 — — 5/3 bond J-76 — bond Q-45 — — 3/6 bond J-76 — bond Q-45 — — 6/3 bond J-77 — bond Q-45 — — 3/5 bond J-77 — bond Q-45 — — 5/3 bond J-78 — bond Q-45 — — 1/3 bond J-79 — bond Q-45 — — 1/3 bond J-79 — bond Q-45 — — 3/1 bond J-80 — bond Q-45 — — 1/3 bond J-80 — bond Q-45 — — 3/1 bond J-81 — bond Q-45 — — 3/5 bond J-81 — bond Q-45 — — 5/3 bond J-82 — bond Q-45 — — 3/5 bond J-82 — bond Q-45 — — 3/6 bond J-82 — bond Q-45 — — 5/3 bond J-82 — bond Q-45 — — 6/3 CH₂ J-83 — — — — — 2/6 O J-29 — bond Q-45 — — 3/5 S J-29 — bond Q-45 — — 3/5 SO J-29 — bond Q-45 — — 3/5 SO₂ J-29 — bond Q-45 — — 3/5 NH J-29 — bond Q-45 — — 3/5 NMe J-29 — bond Q-45 — — 3/5 NPr J-29 — bond Q-45 — — 3/5 CH₂ J-29 — bond Q-45 — — 3/5 CH-i- J-29 — bond Q-45 — — 3/5 Bu bond J-29 4-Me bond Q-45 — — 3/5 bond J-29 5-Me bond Q-45 — — 3/5 bond J-29 4,5-di-Me bond Q-45 — — 3/5 bond J-29 4,4-di-Me bond Q-45 — — 3/5 bond J-29 [Note 1] bond Q-45 6-Me, [Note 1] — 3/5 bond J-29 [Note 2] bond Q-45 6-Me, [Note 2] — 3/5 bond J-29 5-Et bond Q-45 — — 3/5 bond J-29 5-t-Bu — — — — 3/5 bond J-29 5-t-amyl — — — — 3/5 bond J-29 5-(4-Me-3-penten-1-yl) — — — — 3/5 bond J-29 5-(3,3-di-Me-1-butyn-1-yl) — — — — 3/5 bond J-29 5-c-Pr bond Q-45 — — 3/5 bond J-29 5-(4-Me-cyclohexyl) — — — — 3/5 bond J-29 5-CF₃ bond Q-45 — — 3/5 bond J-29 5-perfluoropropyl — — — — 3/5 bond J-29 5-(3,3-di-Cl-2-propen-1-yl) — — — — 3/5 bond J-29 5-OMe bond Q-45 — — 3/5 bond J-29 5-SiMe₃ — — — — 3/5 bond J-69 4-F bond Q-45 — — 1/3 bond J-69 4-Cl bond Q-45 — — 1/3 bond J-69 4-OH bond Q-45 — — 1/3 bond J-69 4-NH₂ bond Q-45 — — 1/3 bond J-69 4-CN O Q-45 — — 1/3 bond J-69 4-NO₂ NH Q-45 — — 1/3 bond J-69 4-CF₃ S Q-45 — — 1/3 bond J-69 — O Q-45 — — 1/3 bond J-69 — S Q-45 — — 1/3 bond J-69 — SO Q-45 — — 1/3 bond J-69 — SO₂ Q-45 — — 1/3 bond J-69 — NH Q-45 — — 1/3 bond J-69 — N—Me Q-45 — — 1/3 bond J-69 — CH₂ Q-45 — — 1/3 bond J-69 4-OEt bond Q-45 — — 1/3 bond J-69 4-OCF₃ bond Q-45 — — 1/3 bond J-69 4-SMe bond Q-45 — — 1/3 bond J-69 4-SOMe bond Q-45 — — 1/3 bond J-69 4-SO₂Me bond Q-45 — — 1/3 bond J-69 4-SO₂—t-Bu — — — — 1/3 bond J-69 4-SCF₃ bond Q-45 — — 1/3 bond J-69 4-SO₂CH₂CF₃ — — — — 1/4 bond J-22 4-NH—i-Bu — — — — 2/4 bond J-22 4-di-EtN — — — — 2/4 bond J-22 4-NH-cyclohexyl — — — — 2/4 bond J-69 4-CH₂O—i-Pr — — — — 1/4 bond J-69 4-CH₂OCHF₂ bond Q-45 — — 1/3 bond J-69 4-CH₂OH bond Q-45 — — 1/3 bond J-74 3-acetyl bond Q-45 — — 2/5 bond J-69 4-CO₂—i-Pr — — — — 1/4 bond J-69 4-O-acetyl bond Q-45 — — 1/3 bond J-69 4-S-acetyl bond Q-45 — — 1/3 bond J-69 4-CONHMe bond Q-45 — — 1/3 bond J-69 4-CONEt₂ — — — — 1/4 bond J-69 — O Q-45 — — 1/4 bond J-29 — bond Q-1 — — 3/5 bond J-29 — bond Q-2 — — 3/5 bond J-29 — bond Q-3 — Me 3/5 bond J-29 — bond Q-4 — — 3/5 bond J-29 — bond Q-5 — — 3/5 bond J-29 — bond Q-6 — — 3/5 bond J-29 — bond Q-7 — — 3/5 bond J-29 — bond Q-8 — — 3/5 bond J-29 — bond Q-9 — — 3/5 bond J-29 — bond Q-10 — Me 3/5 bond J-29 — bond Q-11 — Me 3/5 bond J-29 — bond Q-12 — Me 3/5 bond J-29 — bond Q-13 — Me 3/5 bond J-29 — bond Q-14 — Me 3/5 bond J-29 — bond Q-15 — — 3/5 bond J-29 — bond Q-16 — — 3/5 bond J-29 — bond Q-17 — — 3/5 bond J-29 — bond Q-18 — — 3/5 bond J-29 — bond Q-19 — — 3/5 bond J-29 — bond Q-20 — — 3/5 bond J-29 — bond Q-21 — Me 3/5 bond J-29 — bond Q-22 — Me 3/5 bond J-29 — bond Q-23 — Me 3/5 bond J-29 — bond Q-24 — — 3/5 bond J-29 — bond Q-25 — — 3/5 bond J-29 — bond Q-26 — — 3/5 bond J-29 — bond Q-27 — — 3/5 bond J-29 — bond Q-28 — Me 3/5 bond J-29 — bond Q-29 — — 3/5 bond J-29 — bond Q-30 — — 3/5 bond J-29 — bond Q-31 — Me 3/5 bond J-29 — bond Q-32 — — 3/5 bond J-29 — bond Q-33 — — 3/5 bond J-29 — bond Q-34 — — 3/5 bond J-29 — bond Q-35 — — 3/5 bond J-29 — bond Q-36 — — 3/5 bond J-29 — bond Q-37 — — 3/5 bond J-29 — bond Q-38 — — 3/5 bond J-29 — bond Q-39 — — 3/5 bond J-29 — bond Q-40 — — 3/5 bond J-29 — bond Q-41 — — 3/5 bond J-29 — bond Q-42 — — 3/5 bond J-29 — bond Q-43 — — 3/5 bond J-29 — bond Q-44 — — 3/5 bond J-29 — bond Q-46 — — 3/5 bond J-29 — CH₂ Q-47 — — 3/5 bond J-29 — bond Q-48 — — 3/5 bond J-29 — bond Q-49 — — 3/5 bond J-29 — bond Q-50 — — 3/5 bond J-29 — bond Q-51 — — 3/5 bond J-29 — bond Q-52 — — 3/5 bond J-29 — bond Q-53 — — 3/5 bond J-29 — bond Q-54 — — 3/5 bond J-29 — bond Q-55 — — 3/5 bond J-29 — bond Q-56 — — 3/5 bond J-29 — bond Q-57 — — 3/5 bond J-29 — bond Q-58 — — 3/5 bond J-29 — bond Q-59 — — 3/5 bond J-29 — bond Q-60 — — 3/5 bond J-29 — bond Q-61 — — 3/5 bond J-29 — bond Q-62 — — 3/5 bond J-29 — bond Q-63 — — 3/5 bond J-29 — bond Q-64 — — 3/5 bond J-29 — bond Q-65 — — 3/5 bond J-29 — bond Q-66 — — 3/5 bond J-29 — bond Q-67 — — 3/5 bond J-29 — bond Q-68 — — 3/5 bond J-29 — bond Q-69 — — 3/5 bond J-29 — bond Q-45 2-Me — 3/5 bond J-29 — bond Q-45 3-Me — 3/5 bond J-29 — bond Q-45 4-Me — 3/5 bond J-29 — bond Q-45 2-Cl — 3/5 bond J-29 — bond Q-45 3-Cl — 3/5 bond J-29 — bond Q-45 4-Cl — 3/5 bond J-29 — bond Q-45 2-OMe — 3/5 bond J-29 — bond Q-45 3-OMe — 3/5 bond J-29 — bond Q-45 4-OMe — 3/5 bond J-29 — bond Q-45 2-Et — 3/5 bond J-29 — bond Q-45 3-i-Pr — 3/5 bond J-29 — bond Q-45 2,6-di-Me — 3/5 bond J-29 — bond Q-45 4-vinyl — 3/5 bond J-29 — bond Q-45 4-ethynyl — 3/5 bond J-29 — bond Q-45 4-c-Pr — 3/5 bond J-29 — bond Q-45 3-CF₃ — 3/5 bond J-29 — bond Q-45 3-OCF₃ — 3/5 bond J-29 — bond Q-45 4-Br — 3/5 bond J-29 — bond Q-45 3-OH — 3/5 bond J-29 — bond Q-45 3-NH₂ — 3/5 bond J-29 — bond Q-45 2-CN — 3/5 bond J-29 — bond Q-45 2-NO₂ — 3/5 bond J-29 — bond Q-45 4-O—t-Bu — 3/5 bond J-29 — bond Q-45 4-SMe — 3/5 bond J-29 — bond Q-45 4-SCF₃ — 3/5 bond J-29 — bond Q-45 3-SO₂Me — 3/5 bond J-29 — bond Q-45 3-NHMe — 3/5 bond J-29 — bond Q-45 4-NMe₂ — 3/5 bond J-29 — bond Q-45 2-CH₂OMe — 3/5 bond J-29 — bond Q-45 3-COMe — 3/5 bond J-29 — bond Q-45 3-CO₂Me — 3/5 bond J-29 — bond Q-45 3-CONHMe — 3/5 bond J-29 — bond Q-45 4-OCOMe — 3/5 bond J-29 — bond Q-45 4-SCOMe — 3/5 bond J-29 — bond Q-45 3-CONMe₂ — 3/5 bond J-29 — bond Q-45 4-SiMe₃ — 3/5 bond J-29 — bond Q-45 2,6-di-F — 3/5 bond J-29 — bond Q-45 2,6-di-Cl — 3/5 bond J-29 — bond Q-45 2-OH — 3/5 bond J-29 — bond Q-45 4-OCHF₂ — 3/5 bond J-26 1-Me bond Q-45 — — 2/5 bond J-26 [Note 3] bond Q-45 [Note 3] — 2/5 bond J-26 1-Me, [Note 3] bond Q-45 [Note 3] — 2/5 bond J-26 — bond Q-45 4-OH — 2/5 bond J-26 — bond Q-45 4-OMe — 2/5 bond J-26 — CH₂ Q-45 4-OH — 2/5 bond J-26 — CH₂ Q-45 4-OMe — 2/5 bond J-26 — bond Q-45 4-OH — 2/4 bond J-26 — bond Q-45 4-OMe — 2/4 bond J-26 — CH₂ Q-45 4-OH — 2/4 bond J-26 — CH₂ Q-45 4-OMe — 2/4 bond J-25 — bond Q-45 4-OH — 2/4 bond J-25 — bond Q-45 4-OMe — 2/4 bond J-25 — CH₂ Q-45 4-OH — 2/4 bond J-25 — CH₂ Q-45 4-OMe — 2/4 bond J-1 5-Me bond Q-45 — — 2/4 bond J-3 — bond Q-45 — — 2/4 bond J-3 [Note 4] CH₂ Q-45 [Note 4] — 2/5 bond J-29 5-CO₂Me CH₂ Q-45 — — 3/5 bond J-29 5-CO₂Et bond Q-45 — — 3/5 bond J-29 4,4-di-Me-5-CO₂Me bond Q-45 — — 3/5 bond J-29 5-CONEt₂ bond Q-45 — — 3/5 bond J-29 — NH Q-45 — — 3/5 bond J-29 — NMe Q-45 — — 3/5 bond J-29 — NEt Q-45 — — 3/5 bond J-29 — NPr Q-45 — — 3/5 bond J-29 5-NHAc — — — — 3/5 bond J-29 5-NAc₂ — — — — 3/5 bond J-29 5-N(Me)Ac — — — — 3/5 bond J-29 5-N(Me)C(═O)Ph — — — — 3/5 bond J-29 5-N(Et)Ac — — — — 3/5 bond J-29 5-N(Et)C(═O)Ph — — — — 3/5 bond J-29 5-NHC(═O)OMe — — — — 3/5 bond J-29 5-N(Me)C(═O)OMe — — — — 3/5 bond J-29 5-NHC(═O)OEt — — — — 3/5 bond J-29 5-N(Me)C(═O)OEt — — — — 3/5 bond J-69 3-Cl — — — — 1/3 bond J-69 3-Br — — — — 1/3 bond J-69 3-I — — — — 1/3 bond J-69 3-Me — — — — 1/3 bond J-69 3-Et — — — — 1/3 bond J-69 3-Pr — — — — 1/3 bond J-69 3-i-Pr — — — — 1/3 bond J-69 3-Bu — — — — 1/3 bond J-69 3-i-Bu — — — — 1/3 bond J-69 3-s-Bu — — — — 1/3 bond J-69 3-t-Bu — — — — 1/3 bond J-69 3-Am — — — — 1/3 bond J-69 3-i-Am — — — — 1/3 bond J-69 3-t-Am — — — — 1/3 bond J-69 3-cyclopropyl — — — — 1/3 bond J-69 3-cyclobutyl — — — — 1/3 bond J-69 3-cyclopentyl — — — — 1/3 bond J-69 3-cyclohexyl — — — — 1/3 bond J-69 3-trifluorometoxy — — — — 1/3 bond J-69 3-isopropyoxy — — — — 1/3 bond J-69 3-isobutoxy — — — — 1/3 bond J-69 4-Cl — — — — 1/4 bond J-69 4-Br — — — — 1/4 bond J-69 4-I — — — — 1/4 bond J-69 4-Me — — — — 1/4 bond J-69 4-Et — — — — 1/4 bond J-69 4-Pr — — — — 1/4 bond J-69 4-i-Pr — — — — 1/4 bond J-69 4-Bu — — — — 1/4 bond J-69 4-i-Bu — — — — 1/4 bond J-69 4-s-Bu — — — — 1/4 bond J-69 4-t-Bu — — — — 1/4 bond J-69 4-Am — — — — 1/4 bond J-69 4-i-Am — — — — 1/4 bond J-69 4-t-Am — — — — 1/4 bond J-69 4-cyclopropyl — — — — 1/4 bond J-69 4-cyclobutyl — — — — 1/4 bond J-69 4-cyclopentyl — — — — 1/4 bond J-69 4-cyclohexyl — — — — 1/4 bond J-69 4-trifluorometoxy — — — — 1/4 bond J-69 4-isopropyoxy — — — — 1/4 bond J-69 4-isobutoxy — — — — 1/4 bond J-69 3,4-di-Cl — — — — 1/4 bond J-69 3,4-di-Br — — — — 1/4 bond J-69 3,4-di-Me — — — — 1/4 bond J-69 3,4-di-Et — — — — 1/4 bond J-69 3,4-di-OMe — — — — 1/4 bond J-69 3,4-di-OEt — — — — 1/4 bond J-69 3-OMe-4-O-propargyl — — — — 1/4 bond J-4 5-i-Bu — — — — 2/5 bond J-4 5-i-Am — — — — 2/5 bond J-5 5-i-Bu — — — — 2/5 bond J-5 5-i-Am — — — — 2/5 bond J-11 5-i-Bu — — — — 3/5 bond J-11 5-i-Am — — — — 3/5 bond J-29 — bond Q-70 — — 3/5 bond J-29 — bond Q-71 — — 3/5 bond J-29 — bond Q-72 — Me 3/5 bond J-29 — bond Q-73 — — 3/5 bond J-29 — bond Q-74 — — 3/5 bond J-29 — bond Q-75 — Me 3/5 bond J-29 — bond Q-76 — — 3/5 bond J-29 — bond Q-77 — — 3/5 bond J-29 — bond Q-78 — Me 3/5 bond J-29 — bond Q-79 — Me 3/5 bond J-29 — bond Q-80 — — 3/5 bond J-29 — bond Q-81 — — 3/5 bond J-29 — bond Q-82 — — 3/5 bond J-29 — bond Q-83 — — 3/5 bond J-29 — bond Q-84 — — 3/5 bond J-29 — bond Q-85 — — 3/5 bond J-29 — bond Q-86 — Me 3/5 bond J-29 — bond Q-87 — — 3/5 bond J-29 — bond Q-88 — Me 3/5 bond J-29 — bond Q-89 — — 3/5 bond J-29 — bond Q-90 — — 3/5 bond J-29 — bond Q-91 — — 3/5 bond J-29 — bond Q-92 — Me 3/5 bond J-29 — bond Q-93 — — 3/5 bond J-29 — bond Q-94 — — 3/5 bond J-29 — bond Q-95 — Me 3/5 bond J-29 — bond Q-96 — — 3/5 bond J-29 — bond Q-97 — — 3/5 bond J-29 — bond Q-98 — — 3/5 bond J-29 — bond Q-99 — — 3/5 bond J-29 — bond Q-100 — — 3/5 bond J-29 — bond Q-101 — — 3/5 bond J-29 — bond Q-102 — Me 3/5 bond J-29 — bond Q-87 4-phenyl — 3/5 bond J-29 — bond Q-72 — acetyl 3/5 bond J-29 — bond Q-72 — methoxycarbonyl 3/5 bond J-29 — bond Q-72 — methoxy 3/5 bond J-29 — bond Q-71 4-Cl — 3/5 bond J-29 — bond Q-71 5-Cl — 3/5 bond J-29 — bond Q-71 6-Cl — 3/5 bond J-29 — bond Q-71 7-Cl — 3/5 bond J-29 — bond Q-71 4-Me — 3/5 bond J-29 — bond Q-71 5-Me — 3/5 bond J-29 — bond Q-71 6-Me — 3/5 bond J-29 — bond Q-71 5-CF₃ — 3/5 bond J-29 — bond Q-71 5-NO₂ — 3/5 bond J-29 — bond Q-71 6-Br — 3/5 bond J-29 — bond Q-71 6-NO₂ — 3/5 bond J-29 — bond Q-71 6-NH₂ — 3/5 bond J-29 — bond Q-71 6-OMe — 3/5 bond J-29 — bond Q-71 5,6-di-OMe — 3/5 bond J-29 — bond Q-71 5,6-di-Cl — 3/5 bond J-29 — bond Q-70 5-Cl — 3/5 bond J-29 — bond Q-70 5-Me — 3/5 bond J-29 — bond Q-70 5-NO₂ — 3/5 bond J-29 — bond Q-70 5-NH₂ — 3/5 bond J-29 — bond Q-70 6-Cl — 3/5 bond J-29 — bond Q-70 6-Me — 3/5 bond J-29 — bond Q-70 6-NO₂ — 3/5 bond J-29 — bond Q-70 6-NH₂ — 3/5 bond J-29 — bond Q-70 5,6-di-Cl — 3/5 bond J-29 — bond Q-70 5-Cl-6-OH — 3/5 bond J-29 — bond Q-72 5-Cl Me 3/5 bond J-29 — bond Q-72 5-Me Me 3/5 bond J-29 — bond Q-72 5-NO₂ Me 3/5 bond J-29 — bond Q-72 5-NH₂ Me 3/5 bond J-29 — bond Q-72 6-Cl Me 3/5 bond J-29 — bond Q-72 6-Me Me 3/5 bond J-29 — bond Q-72 6-NO₂ Me 3/5 bond J-29 — bond Q-72 6-NH₂ Me 3/5 bond J-29 — bond Q-72 5,6-di-Cl Me 3/5 bond J-29 — bond Q-63 4-Me — 3/5 bond J-29 — bond Q-63 4-NO₂ — 3/5 bond J-29 — bond Q-63 4-NH₂ — 3/5 bond J-29 — bond Q-63 5-Cl — 3/5 bond J-29 — bond Q-63 5-Me — 3/5 bond J-29 — bond Q-63 5-CN — 3/5 bond J-29 — bond Q-63 5-NO₂ — 3/5 bond J-29 — bond Q-63 5-NH₂ — 3/5 bond J-29 — bond Q-63 5-COOMe — 3/5 bond J-29 — bond Q-63 5-di-Cl — 3/5 bond J-29 5-N(Ac)C(═O)Ph bond — — — 3/5 bond J-29 5-N(Ac)C(═O)(2- bond — — — 3/5 carbomethoxy-Ph) *The definitions of J, R⁵, Q, R⁷ and R¹² in the compounds of this table are as defined in Exhibits 3 and 4 in the above Embodiments. A dash “—” in the (R⁵)_(x) column indicates no substitution on J. A dash in each of the Z² and Q columns indicates that no Z²Q substituent is attached as R⁵ to J. A dash in the (R⁷)_(p) and/or R¹² columns indicates no substitution on Q. **J-orientation refers to the attachment points for Z¹ and Z² (or another R⁵ when Z² is not present) on ring J. The first number refers to the ring position on J where Z¹ is attached, and the second number refers to the ring position on J where Z² is attached or, when Z² is not present, the ring position on J where the substituent listed under (R⁵)_(x) is attached. [Note 1]: R⁵ and R⁷ taken together to form a CH₂CH₂ bridge between position 4 of J-29 and position 2 of Q-45. [Note 2]: R⁵ and R⁷ take together form a CH₂ bridge between position 4 of J-29 and position 2 of Q-45. [Note 3]: R⁵ and R⁷ taken together to form a CH₂CH₂ bridge between position 4 of J-26 and position 2 of Q-45. [Note 4]: R⁵ and R⁷ taken together to form a CH₂CH₂ bridge between position 1 of J-3 and position 2 of Q-45.

TABLE 3*

X (R²)_(n) G R^(3a) R^(11a) X¹ — G-1 H — X¹ — G-2 H — X¹ — G-3 H H X¹ — G-4 H — X¹ — G-5 H — X¹ — G-6 H H X¹ — G-7 H — X¹ — G-8 H — X¹ — G-9 H H X¹ — G-10 H — X¹ — G-11 H — X¹ — G-12 H H X¹ — G-13 H H X¹ — G-14 H — X¹ — G-15 H — X¹ — G-16 H H X¹ — G-17 H — X¹ — G-18 H — X¹ — G-19 H H X¹ — G-20 H — X¹ — G-21 H — X¹ — G-22 H H X¹ — G-23 H — X¹ — G-24 H — X¹ — G-25 H — X¹ — G-26 H — X¹ — G-27 H — X¹ — G-28 H — X¹ — G-29 H — X¹ — G-30 H — X¹ — G-31 H — X¹ — G-32 H — X¹ — G-33 H — X¹ — G-34 H — X¹ — G-35 H — X¹ — G-36 H — X¹ — G-37 H — X¹ — G-38 H — X¹ — G-39 H H X¹ — G-40 H — X¹ — G-41 H — X¹ — G-42 H H X¹ — G-43 H H X¹ — G-44 H — X¹ — G-45 H — X¹ — G-46 H — X¹ — G-47 H — X¹ — G-48 H H X¹ — G-49 H — X¹ — G-50 H — X¹ — G-51 H H X¹ — G-52 H — X¹ — G-53 H — X¹ — G-54 H H X¹ — G-55 H — X¹ — G-56 H — X¹ — G-57 H — X¹ — G-58 H H X¹ — G-59 H H X¹ — G-2 Me — X¹ — G-2 Cl — X¹ — G-2 F — X¹ — G-2 CF₃ — X¹ — G-14 n-Pr — X¹ — G-3 H Me X¹ — G-3 H n-Pr X¹ — G-26 5-Me — X¹ 2-Me G-1 H — X¹ 3-Me G-1 H — X¹ 2,6-di-Me G-1 H — X¹ 3,5-di-Me G-1 H — X¹ 3-n-Bu G-1 H — X¹ 4-MeO G-1 H — X¹ 4-OH G-1 H — X¹ 4-Cl G-1 H — X¹ 4-Br G-1 H — X¹ 4-CN G-1 H — X² — G-1 H — X² — G-2 H — X² — G-3 H H X² — G-4 H — X² — G-5 H — X² — G-6 H H X² — G-7 H — X² — G-8 H — X² — G-9 H H X² — G-10 H — X² — G-11 H — X² — G-12 H H X² — G-13 H H X² — G-14 H — X² — G-15 H — X² — G-16 H H X² — G-17 H — X² — G-18 H — X² — G-19 H H X² — G-20 H — X² — G-21 H — X² — G-22 H H X² — G-23 H — X² — G-24 H — X² — G-31 H — X² — G-32 H — X² — G-33 H — X² — G-34 H — X² — G-35 H — X² — G-37 H — X² — G-38 H — X² — G-39 H H X² — G-40 H — X² — G-41 H — X² — G-42 H H X² — G-43 H H X² — G-44 H — X² — G-45 H — X² — G-46 H — X² — G-47 H — X² — G-48 H H X² — G-49 H — X² — G-50 H — X² — G-51 H H X² — G-52 H — X² — G-53 H — X² — G-54 H H X² — G-2 Me — X² — G-2 Cl — X² — G-2 F — X² — G-2 CF₃ — X² — G-14 n-Pr — X² — G-3 H Me X² — G-3 H n-Pr X² 2-Me G-1 H — X² 3-Me G-1 H — X² 2,6-di-Me G-1 H — X² 3,5-di-Me G-1 H — X² 3-n-Bu G-1 H — X³ — G-1 H — X³ — G-2 H — X³ — G-3 H H X³ — G-4 H — X³ — G-5 H — X³ — G-6 H H X³ — G-7 H — X³ — G-8 H — X³ — G-9 H H X³ — G-10 H — X³ — G-11 H — X³ — G-12 H H X³ — G-13 H H X³ — G-14 H — X³ — G-15 H — X³ — G-16 H H X³ — G-17 H — X³ — G-18 H — X³ — G-19 H H X³ — G-20 H — X³ — G-21 H — X³ — G-22 H H X³ — G-23 H — X³ — G-24 H — X³ — G-31 H — X³ — G-32 H — X³ — G-33 H — X³ — G-34 H — X³ — G-35 H — X³ — G-37 H — X³ — G-38 H — X³ — G-39 H H X³ — G-40 H — X³ — G-41 H — X³ — G-42 H H X³ — G-43 H H X³ — G-44 H — X³ — G-45 H — X³ — G-46 H — X³ — G-47 H — X³ — G-48 H H X³ — G-49 H — X³ — G-50 H — X³ — G-51 H H X³ — G-52 H — X³ — G-53 H — X³ — G-54 H H X³ — G-2 Me — X³ — G-2 Cl — X³ — G-2 F — X³ — G-2 CF₃ — X³ — G-14 n-Pr — X³ — G-3 H Me X³ — G-3 H n-Pr X³ 2-Me G-1 H — X³ 3-Me G-1 H — X³ 2,6-di-Me G-1 H — X³ 3,5-di-Me G-1 H — X³ 3-n-Bu G-1 H — X³ 5-Me G-1 H — X³ 6-Me G-1 H — X⁴ — G-1 H — X⁵ — G-1 H — X⁶ — G-1 H — X⁷ — G-1 H — X⁸ — G-1 H — X⁹ — G-1 H — *The definitions of X, G, R^(3a) and R^(11a) in the compounds of this table are as defined in the Summary of the Invention and Exhibit 2 in the above Embodiments. A dash “—” in the (R²)_(n) column indicates no substituents.

TABLE 4*

R¹ X G ** J *** (R⁵)_(y) R^(7a) 2,5-dichlorophenyl X¹ G-1 J-1 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-1 (2/4) — H 2,5-dimethylphenyl X¹ G-1 J-1 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-1 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-1 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-1 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-1 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-1 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-1 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-1 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-1 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-1 (2/4) — H 2,5-dichlorophenyl X¹ G-1 J-2 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-2 (2/4) — H 2,5-dimethylphenyl X¹ G-1 J-2 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-2 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-2 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-2 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-2 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-2 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-2 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-2 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-2 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-2 (2/4) — H 2,5-dichlorophenyl X¹ G-1 J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-3 (2/4) 1-Me H 2,5-dimethylphenyl X¹ G-1 J-3 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-3 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-3 (7/4) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-3 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-3 (2/4) 1-Me H 2,5-dichlorophenyl X¹ G-1 J-4 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-4 (2/5) — H 2,5-dimethylphenyl X¹ G-1 J-4 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-4 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-4 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-4 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-4 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-4 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-4 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-4 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-4 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-4 (2/5) — H 2,5-dichlorophenyl X¹ G-1 J-8 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-8 (5/3) — H 2,5-dimethylphenyl X¹ G-1 J-8 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-8 (5/3) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-8 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-8 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-8 (5/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-8 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-8 (5/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-8 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-8 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-8 (5/3) — H 2,5-dichlorophenyl X¹ G-1 J-9 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-9 (5/3) — H 2,5-dimethylphenyl X¹ G-1 J-9 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-9 (5/3) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-9 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-9 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-9 (5/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-9 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-9 (5/3) — H 3,5-bis-(trifluoromethyl)pyrazol-4-yl X¹ G-1 J-9 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-9 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-9 (5/3) — H 2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — H 2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-11 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-11 (3/5) — H 2,5-dichlorophenyl X¹ G-1 J-12 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) — H 2,5-dimethylphenyl X¹ G-1 J-12 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-12 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H 3,-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-12 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-12 (3/5) — H 2,5-dichlorophenyl X¹ G-1 J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) 1-Me H 2,5-dimethylphenyl X¹ G-1 J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-12 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-12 (3/5) 1-Me H 2,5-dichlorophenyl X¹ G-1 J-14 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-14 (3/5) — H 2,5-dimethylphenyl X¹ G-1 J-14 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-14 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-14 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-14 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-14 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-14 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-14 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-14 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-14 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-14 (3/5) — H 2,5-dichlorophenyl X¹ G-1 J-15 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-15 (2/5) — H 2,5-dimethylphenyl X¹ G-1 J-15 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-15 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-15 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-15 (2/5) — H 5-chloro-3-(trifluoromethy)pyrazol-1-yl X¹ G-1 J-15 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-15 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-15 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-15 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-15 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-15 (2/5) — H 2,5-dichlorophenyl X¹ G-1 J-16 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-16 (2/5) — H 2,5-dimethylphenyl X¹ G-1 J-16 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-16 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-16 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-16 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-16 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-16 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-16 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-16 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-16 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-16 (2/5) — H 2,5-dichlorophenyl X¹ G-1 J-22 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-22 (2/4) — H 2,5-dimethylphenyl X¹ G-1 J-22 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-22 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-22 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-22 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-22 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-22 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-22 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-22 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-22 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-22 (2/4) — H 2,5-dichlorophenyl X¹ G-1 J-24 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-24 (2/4) — H 2,5-dimethylphenyl X¹ G-1 J-24 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-24 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-24 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-24 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-24 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-24 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-24 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-24 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-24 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-24 (2/4) — H 2,5-dichlorophenyl X¹ G-1 J-25 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-25 (2/4) — H 2,5-dimethylphenyl X¹ G-1 J-25 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-25 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-25 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-25 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-25 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-25 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-25 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-25 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-25 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-25 (2/4) — H 2,5-dichlorophenyl X¹ G-1 J-26 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) — H 2,5-dimethylphenyl X¹ G-1 J-26 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-26 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-26 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-26 (2/4) — H 2,5-dichlorophenyl X¹ G-1 J-26 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) 1-Me H 2,5-dimethylphenyl X¹ G-1 J-26 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-26 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-26 (2/4) 1-Me H 2,5-dichlorophenyl X¹ G-1 J-26 (2/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/5) 1-Me H 2,5-dimethylphenyl X¹ G-1 J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-26 (2/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-26 (2/5) 1-Me H 2,5-dichlorophenyl X¹ G-1 J-28 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-28 (3/5) — H 2,5-dimethylphenyl X¹ G-1 J-28 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-28 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-28 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-28 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-28 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-28 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-28 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-28 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-28 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-28 (3/5) — H 2,5-dichlorophenyl X¹ G-1 J-30 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) — H 2,5-dimethylphenyl X¹ G-1 J-30 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-30 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-30 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-30 (3/5) — H 2,5-dichlorophenyl X¹ G-1 J-30 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) 1-Me H 2,5-dimethylphenyl X¹ G-1 J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-30 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-30 (3/5) 1-Me H 2,5-dichlorophenyl X¹ G-1 J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-36 (3/5) 1-Me H 2,5-dimethylphenyl X¹ G-1 J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-36 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-36 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-36 (3/5) 1-Me H 2,5-dichlorophenyl X¹ G-1 J-37 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-37 (2/5) — H 2,5-dimethylphenyl X¹ G-1 J-37 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-37 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-37 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-37 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-37 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-37 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-37 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-37 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-37 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-37 (2/5) — H 2,5-dichlorophenyl X¹ G-1 J-38 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-38 (2/5) — H 2,5-dimethylphenyl X¹ G-1 J-38 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-38 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-38 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-38 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-38 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-38 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-38 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-38 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-38 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-38 (2/5) — H 2,5-dichlorophenyl X¹ G-1 J-39 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-39 (3/5) — H 2,5-dimethylphenyl X¹ G-1 J-39 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-39 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-39 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-39 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-39 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-39 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-39 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-39 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-39 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-39 (3/5) — H 2,5-dichlorophenyl X¹ G-1 J-40 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-40 (3/5) — H 2,5-dimethylphenyl X¹ G-1 J-40 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-40 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-40 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-40 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-40 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-40 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-40 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-40 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-40 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-40 (3/5) — H 2,5-dichlorophenyl X¹ G-1 J-69 (1/3) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/3) — H 2,5-dimethylphenyl X¹ G-1 J-69 (1/3) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/3) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-69 (1/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-69 (1/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-69 (1/3) — H 2,5-dichlorophenyl X¹ G-1 J-69 (1/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/4) — H 2,5-dimethylphenyl X¹ G-1 J-69 (1/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-69 (1/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-69 (1/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-69 (1/4) — H 2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 2-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2-Me 2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 2-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2-Me 3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-11 (3/5) — 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-11 (3/5) — 2-Me 2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 3-Me 2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-11 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-11 (3/5) — 3-Me 2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4-Me 2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-11 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-11 (3/5) — 4-Me 2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2-Cl 2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2-Cl 3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-11 (3/5) — 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-11 (3/5) — 2-Cl 2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4-Cl 2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-11 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-11 (3/5) — 4-Cl 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 5-Me 2-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2-Me 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 5-Me 2-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2-Me 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) 5-Me 2-Me 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 3-Me 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) — 3-Me 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4-Me 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) — 4-Me 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4-Cl 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) — 4-Cl 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 5-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me H 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 5-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) 5-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) 5-Me H 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 4-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4-Me H 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 4-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) 4-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) 4-Me H 2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 4,4-di-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4,4-di-Me H 2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 4,4-di-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4,4-di-Me H 3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-1 J-29 (3/5) 4,4-di-Me H 2,5-dichlorophenyl X¹ G-2 J-1 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-1 (2/4) — H 2,5-dimethylphenyl X¹ G-2 J-1 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-1 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-1 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-1 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-1 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-1 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-1 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-1 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-1 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-1 (2/4) — H 2,5-dichlorophenyl X¹ G-2 J-2 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-2 (2/4) — H 2,5-dimethylphenyl X¹ G-2 J-2 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-2 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-2 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-2 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-2 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-2 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-2 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-2 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-2 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-2 (2/4) — H 2,5-dichlorophenyl X¹ G-2 J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-3 (2/4) 1-Me H 2,5-dimethylphenyl X¹ G-2 J-3 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-3 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H 5-chloro-1-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-3 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-3 (2/4) 1-Me H 2,5-dichlorophenyl X¹ G-2 J-4 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-4 (2/5) — H 2,5-dimethylphenyl X¹ G-2 J-4 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-4 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-4 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-4 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-4 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-4 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-4 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-4 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-4 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-4 (2/5) — H 2,5-dichlorophenyl X¹ G-2 J-8 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-8 (5/3) — H 2,5-dimethylphenyl X¹ G-2 J-8 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-8 (5/3) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-8 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-8 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-8 (5/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-8 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-8 (5/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-8 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-8 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-8 (5/3) — H 2,5-dichlorophenyl X¹ G-2 J-9 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-9 (5/3) — H 2,5-dimethylphenyl X¹ G-2 J-9 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-9 (5/3) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-9 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-9 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-9 (5/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-9 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-9 (5/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-9 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-9 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-9 (5/3) — H 2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — H 2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-11 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-11 (3/5) — H 2,5-dichlorophenyl X¹ G-2 J-12 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) — H 2,5-dimethylphenyl X¹ G-2 J-12 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-12 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-12 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-12 (3/5) — H 2,5-dichlorophenyl X¹ G-2 J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) 1-Me H 2,5-dimethylphenyl X¹ G-2 J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-12 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-12 (3/5) 1-Me H 2,5-dichlorophenyl X¹ G-2 J-14 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-14 (3/5) — H 2,5-dimethylphenyl X¹ G-2 J-14 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-14 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-14 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-14 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-14 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-14 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-14 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-14 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-14 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-14 (3/5) — H 2,5-dichlorophenyl X¹ G-2 J-15 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-15 (2/5) — H 2,5-dimethylphenyl X¹ G-2 J-15 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-15 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-15 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-15 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-15 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-15 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-15 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-15 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-15 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-15 (2/5) — H 2,5-dichlorophenyl X¹ G-2 J-16 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-16 (2/5) — H 2,5-dimethylphenyl X¹ G-2 J-16 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-16 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-16 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-16 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-16 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-16 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-16 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-16 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-16 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-16 (2/5) — H 2,5-dichlorophenyl X¹ G-2 J-22 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-22 (2/4) — H 2,5-dimethylphenyl X¹ G-2 J-22 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-22 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-22 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-22 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-22 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-22 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-22 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-22 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-22 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-22 (2/4) — H 2,5-dichlorophenyl X¹ G-2 J-24 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-24 (2/4) — H 2,5-dimethylphenyl X¹ G-2 J-24 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-24 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-24 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-24 (2/4) — H 5-chloro-3-(trifluoromethy)pyrazol-1-yl X¹ G-2 J-24 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-24 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-24 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-24 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-24 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-24 (2/4) — H 2,5-dichlorophenyl X¹ G-2 J-25 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-25 (2/4) — H 2,5-dimethylphenyl X¹ G-2 J-25 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-25 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-25 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-25 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-25 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-25 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-25 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-25 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-25 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-25 (2/4) — H 2,5-dichlorophenyl X¹ G-2 J-26 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) — H 2,5-dimethylphenyl X¹ G-2 J-26 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-26 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-26 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-26 (2/4) — H 2,5-dichlorophenyl X¹ G-2 J-26 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) 1-Me H 2,5-dimethylphenyl X¹ G-2 J-26 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H 5-ethyl-3-(trifluoromethy)pyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-26 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-26 (2/4) 1-Me H 2,5-dichlorophenyl X¹ G-2 J-26 (2/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/5) 1-Me H 2,5-dimethylphenyl X¹ G-2 J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-26 (2/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-26 (2/5) 1-Me H 2,5-dichlorophenyl X¹ G-2 J-28 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-28 (3/5) — H 2,5-dimethylphenyl X¹ G-2 J-28 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-28 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-28 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-28 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-28 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-28 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-28 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-28 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-28 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-28 (3/5) — H 2,5-dichlorophenyl X¹ G-2 J-30 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3/5) — H 2,5-dimethylphenyl X¹ G-2 J-30 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-30 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-30 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-30 (3/5) — H 2,5-dichlorophenyl X¹ G-2 J-30 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3/5) 1-Me H 2,5-dimethylphenyl X¹ G-2 J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3,5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-30 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-30 (3/5) 1-Me H 2,5-dichlorophenyl X¹ G-2 J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-36 (3/5) 1-Me H 2,5-dimethylphenyl X¹ G-2 J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-36 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-36 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-36 (3/5) 1-Me H 2,5-dichlorophenyl X¹ G-2 J-37 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-37 (2/5) — H 2,5-dimethylphenyl X¹ G-2 J-37 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-37 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-37 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-37 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-37 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-37 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-37 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-37 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-37 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-37 (2/5) — H 2,5-dichlorophenyl X¹ G-2 J-38 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-38 (2/5) — H 2,5-dimethylphenyl X¹ G-2 J-38 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-38 (2/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-38 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-38 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-38 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-38 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-38 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-38 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-38 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-38 (2/5) — H 2,5-dichlorophenyl X¹ G-2 J-39 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-39 (3/5) — H 2,5-dimethylphenyl X¹ G-2 J-39 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-39 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-39 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-39 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-39 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-39 (3/5) — H 5-ethyl-3-(trifluoromethy)pyrazol-1-yl X¹ G-2 J-39 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-39 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-39 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-39 (3/5) — H 2,5-dichlorophenyl X¹ G-2 J-40 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-40 (3/5) — H 2,5-dimethylphenyl X¹ G-2 J-40 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-40 (3/5) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-40 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-40 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-40 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-40 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-40 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-40 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-40 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-40 (3/5) — H 2,5-dichlorophenyl X¹ G-2 J-69 (1/3) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/3) — H 2,5-dimethylphenyl X¹ G-2 J-69 (1/3) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/3) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-69 (1/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-69 (1/3) — H 1-methyl-4-(tritiuoromethyl)imidazol-2-yl X¹ G-2 J-69 (1/3) — H 2,5-dichlorophenyl X¹ G-2 J-69 (1/4) — H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/4) — H 2,5-dimethylphenyl X¹ G-2 J-69 (1/4) — H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/4) — H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-69 (1/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-69 (1/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-69 (1/4) — H 2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 2-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 2-Me 2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 2-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 2-Me 3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Me 5-methyl-3-4 trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-11 (3/5) — 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-11 (3/5) — 2-Me 2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 3-Me 2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-11 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-11 (3/5) — 3-Me 2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4-Me 2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-11 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-11 (3/5) — 4-Me 2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 2-Cl 2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 2-Cl 2-methyl-5-(trifluoroethyl)phenyl X¹ G-2 J-11 (3/5) — 2-Cl 3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-11 (3/5) — 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-11 (3/5) — 2-Cl 2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4-Cl 2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-11 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-11 (3/5) — 4-Cl 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 2-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2-Me 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 2-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2-Me 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) — 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) — 2-Me 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 3-Me 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) — 3-Me 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4-Me 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) — 4-Me 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2-Cl 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2-Cl 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) — 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) — 2-Cl 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4-Cl 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) — 4-Cl 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) 5-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 5-Me H 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) 5-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 5-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H 5-bromo-3-(trifluormethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) 5-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) 5-Me H 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) 4-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4-Me H 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) 4-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) 4-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) 4-Me H 2,5-dichlorophenyl X¹ G-2 J-29 (3/5) 4,4-di-Me H 2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4,4-di-Me H 2,5-dimethylphenyl X¹ G-2 J-29 (3/5) 4,4-di-Me H 2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4,4-di-Me H 3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X¹ G-2 J-29 (3/5) 4,4-di-Me H 2,5-dichlorophenyl X² G-1 J-1 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-1 (2/4) — H 2,5-dimethylphenyl X² G-1 J-1 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-1 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-1 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-1 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-1 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-1 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-1 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-1 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-1 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-1 (2/4) — H 2,5-dichlorophenyl X² G-1 J-2 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-2 (2/4) — H 2,5-dimethylphenyl X² G-1 J-2 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-2 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-2 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-2 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-2 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-2 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-2 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-2 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-2 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-2 (2/4) — H 2,5-dichlorophenyl X² G-1 J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-3 (2/4) 1-Me H 2,5-dimethylphenyl X² G-1 J-3 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-3 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-3 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-3 (2/4) 1-Me H 2,5-dichlorophenyl X² G-1 J-4 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-4 (2/5) — H 2,5-dimethylphenyl X² G-1 J-4 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-4 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-4 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-4 (2/5) — H 5-chloro-3-(trifluoromethyHpyrazol-1-yl X² G-1 J-4 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-4 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-4 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-4 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-4 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-4 (2/5) — H 2,5-dichlorophenyl X² G-1 J-8 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-8 (5/3) — H 2,5-dimethylphenyl X² G-1 J-8 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-8 (5/3) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-8 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-8 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-8 (5/3) — H 5-bromo-3-(trifluoromethyltpyrazol-1-yl X² G-1 J-8 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-8 (5/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-8 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-8 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-8 (5/3) — H 2,5-dichlorophenyl X² G-1 J-9 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-9 (5/3) — H 2,5-dimethylphenyl X² G-1 J-9 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-9 (5/3) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-9 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-9 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-9 (5/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-9 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-9 (5/3) — H 3,5-bis-(trifluoroethyl)pyrazol-1-yl X² G-1 J-9 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-9 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-9 (5/3) — H 2,5-dichlorophenyl X² G-1 J-11 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — H 2,5-dimethylphenyl X² G-1 J-11 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — H 5-chloro-3-(trinuoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-11 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-11 (3/5) — H 2,5-dichlorophenyl X² G-1 J-12 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-12 (3/5) — H 2,5-dimethylphenyl X² G-1 J-12 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-12 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-12 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-12 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-12 (3/5) — H 2,5-dichlorophenyl X² G-1 J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-12 (3/5) 1-Me H 2,5-dimethylphenyl X² G-1 J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-12 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-12 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-12 (3/5) 1-Me H 2,5-dichlorophenyl X² G-1 J-14 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-14 (3/5) — H 2,5-dimethylphenyl X² G-1 J-14 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-14 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-14 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-14 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-14 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-14 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-14 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-14 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-14 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-14 (3/5) — H 2,5-dichlorophenyl X² G-1 J-15 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-15 (2/5) — H 2,5-dimethylphenyl X² G-1 J-15 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-15 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-15 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-15 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-15 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-15 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-15 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-15 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-15 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-15 (2/5) — H 2,5-dichlorophenyl X² G-1 J-16 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-16 (2/5) — H 2,5-dimethylphenyl X² G-1 J-16 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-16 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-16 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-16 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-16 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-16 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-16 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-16 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-16 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-16 (2/5) — H 2,5-dichlorophenyl X² G-1 J-22 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-22 (2/4) — H 2,5-dimethylphenyl X² G-1 J-22 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-22 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-22 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-22 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-22 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-22 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-22 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-22 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-22 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-22 (2/4) — H 2,5-dichlorophenyl X² G-1 J-24 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-24 (2/4) — H 2,5-dimethylphenyl X² G-1 J-24 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-24 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-24 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-24 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-24 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-24 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-24 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-24 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-24 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-24 (2/4) — H 2,5-dichlorophenyl X² G-1 J-25 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-25 (2/4) — H 2,5-dimethylphenyl X² G-1 J-25 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-25 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-25 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-25 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-25 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-25 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-25 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-25 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-25 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-25 (2/4) — H 2,5-dichlorophenyl X² G-1 J-26 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) — H 2,5-dimethylphenyl X² G-1 J-26 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-26 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) — H 5-chloro-3-(trifluoromethy)pyrazol-1-yl X² G-1 J-26 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-26 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-26 (2/4) — H 2,5-dichlorophenyl X² G-1 J-26 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) 1-Me H 2,5-dimethylphenyl X² G-1 J-26 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H 3,5-bis-(trifluoromethy)pyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-26 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-26 (2/4) 1-Me H 2,5-dichlorophenyl X² G-1 J-26 (2/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/5) 1-Me H 2,5-dimethylphenyl X² G-1 J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H 5-bromo-.-(trifluoromethyl)pyzol-1-yl X² G-1 J-26 (2/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-26 (2/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-26 (2/5) 1-Me H 2,5-dichlorophenyl X² G-1 J-28 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-28 (3/5) — H 2,5-dimethylphenyl X² G-1 J-28 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-28 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-28 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-28 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-28 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-28 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-28 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-28 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-28 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-28 (3/5) — H 2,5-dichlorophenyl X² G-1 J-30 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-30 (3/5) — H 2,5-dimethylphenyl X² G-1 J-30 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-30 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-30 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-30 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-30 (3/5) — H 2,5-dichlorophenyl X² G-1 J-30 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-30 (3/5) 1-Me H 2,5-dimethylphenyl X² G-1 J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-30 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-30 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-30 (3/5) 1-Me H 2,5-dichlorophenyl X² G-1 J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-36 (3/5) 1-Me H 2,5-dimethylphenyl X² G-1 J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-36 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-36 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-36 (3/5) 1-Me H 2,5-dichlorophenyl X² G-1 J-37 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-37 (2/5) — H 2,5-dimethylphenyl X² G-1 J-37 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-37 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-37 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-37 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-37 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-37 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-37 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-37 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-37 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-37 (2/5) — H 2,5-dichlorophenyl X² G-1 J-38 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-38 (2/5) — H 2,5-dimethylphenyl X² G-1 J-38 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-38 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-38 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-38 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-38 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-38 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-38 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-38 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-38 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-38 (2/5) — H 2,5-dichlorophenyl X² G-1 J-39 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-39 (3/5) — H 2,5-dimethylphenyl X² G-1 J-39 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-39 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-39 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-39 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-39 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-39 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-39 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-39 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-39 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-39 (3/5) — H 2,5-dichlorophenyl X² G-1 J-40 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-40 (3/5) — H 2,5-dimethylphenyl X² G-1 J-40 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-40 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-40 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-40 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-40 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-40 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-40 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-40 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-40 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-40 (3/5) — H 2,5-dichlorophenyl X² G-1 J-69 (1/3) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-69 (1/3) — H 2,5-dimethylphenyl X² G-1 J-69 (1/3) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-69 (1/3) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-69 (1/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-69 (1/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-69 (1/3) — H 2,5-dichlorophenyl X² G-1 J-69 (1/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 1-69 (1/4) — H 2,5-dimethylphenyl X² G-1 J-69 (1/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-69 (1/4) — H 3,5-dimethylpyrazol-1-yl X² G-1 J-69 (1/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-69 (1/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-69 (1/4) — H 2,5-dichlorophenyl X² G-1 J-11 (3/5) — 2-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2-Me 2,5-dimethylphenyl X² G-1 J-11 (3/5) — 2-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2-Me 3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 2-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-11 (3/5) — 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-11 (3/5) — 2-Me 2,5-dichlorophenyl X² G-1 J-11 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 3-Me 2,5-dimethylphenyl X² G-1 J-11 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-11 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-11 (3/5) — 3-Me 2,5-dichlorophenyl X² G-1 J-11 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4-Me 2,5-dimethylphenyl X² G-1 J-11 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-11 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-11 (3/5) — 4-Me 2,5-dichlorophenyl X² G-1 J-11 (3/5) — 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2-Cl 2,5-dimethylphenyl X² G-1 J-11 (3/5) — 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2-Cl 3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-11 (3/5) — 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-11 (3/5) — 2-Cl 2,5-dichlorophenyl X² G-1 J-11 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4-Cl 2,5-dimethylphenyl X² G-1 J-11 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-11 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-11 (3/5) — 4-Cl 2,5-dichlorophenyl X² G-1 J-29 (3/5) — 2-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2-Me 2,5-dimethylphenyl X² G-1 J-29 (3/5) — 2-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2-Me 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 2-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) — 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) — 2-Me 2,5-dichlorophenyl X² G-1 J-29 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 3-Me 2,5-dimethylphenyl X² G-1 J-29 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) — 3-Me 2,5-dichlorophenyl X² G-1 J-29 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4-Me 2,5-dimethylphenyl X² G-1 J-29 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) — 4-Me 2,5-dichlorophenyl X² G-1 J-29 (3/5) — 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2-Cl 2,5-dimethylphenyl X² G-1 J-29 (3/5) — 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2-Cl 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) — 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) — 2-Cl 2,5-dichlorophenyl X² G-1 J-29 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4-Cl 2,5-dimethylphenyl X² G-1 J-29 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1- X² G-1 J-29 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) — 4-Cl 2,5-dichlorophenyl X² G-1 J-29 (3/5) 5-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 5-Me H 2,5-dimethylphenyl X² G-1 J-29 (3/5) 5-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 5-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) 5-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) 5-Me H 2,5-dichlorophenyl X² G-1 J-29 (3/5) 4-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4-Me H 2,5-dimethylphenyl X² G-1 J-29 (3/5) 4-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H 5-methyl-3-(trifluoromethy)pyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) 4-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) 4-Me H 2,5-dichlorophenyl X² G-1 J-29 (3/5) 4,4-di-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4,4-di-Me H 2,5-dimethylphenyl X² G-1 J-29 (3/5) 4,4-di-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4,4-di-Me H 3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) 4,4-di-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4,4-di-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4,4-di-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4,4-di-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4,4-di-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4,4-di-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-1 J-29 (3/5) 4,4-di-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-1 J-29 (3/5) 4,4-di-Me H 2,5-dichlorophenyl X² G-2 J-1 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-1 (2/4) — H 2,5-dimethylphenyl X² G-2 J-1 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-1 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-1 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-1 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-1 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-1 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-1 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-1 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-1 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-1 (2/4) — H 2,5-dichlorophenyl X² G-2 J-2 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-2 (2/4) — H 2,5-dimethylphenyl X² G-2 J-2 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-2 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-2 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-2 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-2 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-2 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-2 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-2 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-2 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-2 (2/4) — H 2,5-dichlorophenyl X² G-2 J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-3 (2/4) 1-Me H 2,5-dimethylphenyl X² G-2 J-3 (2/4) 1-Me H 2-ethyl-5-(trifluoromethyl)phenyl X² G-2 J-3 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-3 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-3 (2/4) 1-Me H 2,5-dichlorophenyl X² G-2 J-4 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-4 (2/5) — H 2,5-dimethylphenyl X² G-2 J-4 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-4 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-4 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-4 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-4 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1yl X² G-2 J-4 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-4 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-4 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-4 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-4 (2/5) — H 2,5-dichlorophenyl X² G-2 J-8 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-8 (5/3) — H 2,5-dimethylphenyl X² G-2 J-8 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-8 (5/3) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-8 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-8 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-8 (5/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-8 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-8 (5/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-8 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-8 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-8 (5/3) — H 2,5-dichlorophenyl X² G-2 J-9 (5/3) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-9 (5/3) — H 2,5-dimethylphenyl X² G-2 J-9 (5/3) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-9 (5/3) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-9 (5/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-9 (5/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-9 (5/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-9 (5/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-9 (5/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-9 (5/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-9 (5/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-9 (5/3) — H 2,5-dichlorophenyl X² G-2 J-11 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — H 2,5-dimethylphenyl X² G-2 J-11 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-11 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-11 (3/5) — H 2,5-dichlorophenyl X² G-2 J-12 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) — H 2,5-dimethylphenyl X² G-2 J-12 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-12 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-12 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-12 (3/5) — H 2,5-dichlorophenyl X² G-2 J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) 1-Me H 2,5-dimethylphenyl X² G-2 J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H 3,5-bis-(trifluoromethy)pyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-12 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-12 (3/5) 1-Me H 2,5-dichlorophenyl X² G-2 J-14 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-14 (3/5) — H 2,5-dimethylphenyl X² G-2 J-14 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-14 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-14 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-14 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-14 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-14 (3/5) — H 5-ethly-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-14 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-14 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-14 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-14 (3/5) — H 2,5-dichlorophenyl X² G-2 J-15 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-15 (2/5) — H 2,5-dimethylphenyl X² G-2 J-15 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-15 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-15 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-15 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-15 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-15 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-15 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-15 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-15 (2/5) — H 1-methyl-4-(triftuoromethyl)imidazol-2-yl X² G-2 J-15 (2/5) — H 2,5-dichlorophenyl X² G-2 J-16 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-16 (2/5) — H 2,5-dimethylphenyl X² G-2 J-16 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-16 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-16 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-16 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-16 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-16 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-16 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-16 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-16 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-16 (2/5) — H 2,5-dichlorophenyl X² G-2 J-22 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-22 (2/4) — H 2,5-dimethylphenyl X² G-2 J-22 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-22 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-22 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-22 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-22 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-22 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-22 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-22 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-22 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-22 (2/4) — H 2,5-dichlorophenyl X² G-2 J-24 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-24 (2/4) — H 2,5-dimethylphenyl X² G-2 J-24 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-24 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-24 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-24 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-24 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-24 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-24 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-24 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-24 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-24 (2/4) — H 2,5-dichlorophenyl X² G-2 J-25 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-25 (2/4) — H 2,5-dimethylphenyl X² G-2 J-25 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-25 (2/4) — H 3,5-dimethylpryrazol-1-yl X² G-2 J-25 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-25 (2/4) — H 5-chloro-3-(trifluoromethy)pyrazol-1-yl X² G-2 J-25 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1- X² G-2 J-25 (2/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-25 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-25 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-25 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-25 (2/4) — H 2,5-dichlorophenyl X² G-2 J-26 (2/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) — H 2,5-dimethylphenyl X² G-2 J-26 (2/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-26 (2/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) — H 5-ethyl-3-(trifluoromethy)pyrazol-1-yl X² G-2 J-26 (2/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-26 (2/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-26 (2/4) — H 2,5-dichlorophenyl X² G-2 J-26 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) 1-Me H 2,5-dimethylphenyl X² G-2 J-26 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol 4-yl X² G-2 J-26 (2/4) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-26 (2/4) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-26 (2/4) 1-Me H 2,5-dichlorophenyl X² G-2 J-26 (2/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/5) 1-Me H 2,5-dimethylphenyl X² G-2 J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-26 (2/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-26 (2/5) 1-Me H 2,5-dichlorophenyl X² G-2 J-28 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-28 (3/5) — H 2,5-dimethylphenyl X² G-2 J-28 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-28 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-28 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-28 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-28 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-28 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-28 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-28 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-28 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-28 (3/5) — H 2,5-dichlorophenyl X² G-2 J-30 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) — H 2,5-dimethylphenyl X² G-2 J-30 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-30 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-30 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-30 (3/5) — H 2,5-dichlorophenyl X² G-2 J-30 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) 1-Me H 2,5-dimethylphenyl X² G-2 J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-30 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-30 (3/5) 1-Me H 2,5-dichlorophenyl X² G-2 J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-36 (3/5) 1-Me H 2,5-dimethylphenyl X² G-2 J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-36 (3/5) 1-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-36 (3/5) 1-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-36 (3/5) 1-Me H 2,5-dichlorophenyl X² G-2 J-37 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-37 (2/5) — H 2,5-dimethylphenyl X² G-2 J-37 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-37 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-37 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-37 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-37 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-37 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-37 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-37 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-37 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-37 (2/5) — H 2,5-dichlorophenyl X² G-2 J-38 (2/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-38 (2/5) — H 2,5-dimethylphenyl X² G-2 J-38 (2/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-38 (2/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-38 (2/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-38 (2/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-38 (2/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-38 (2/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-38 (2/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-38 (2/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-38 (2/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-38 (2/5) — H 2,5-dichlorophenyl X² G-2 J-39 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-39 (3/5) — H 2,5-dimethylphenyl X² G-2 J-39 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-39 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-39 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-39 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-39 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-39 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-39 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-39 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-39 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-39 (3/5) — H 2,5-dichlorophenyl X² G-2 J-40 (3/5) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-40 (3/5) — H 2,5-dimethylphenyl X² G-2 J-40 (3/5) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-40 (3/5) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-40 (3/5) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-40 (3/5) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-40 (3/5) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-40 (3/5) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-40 (3/5) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-40 (3/5) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-40 (3/5) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-40 (3/5) — H 2,5-dichlorophenyl X² G-2 J-69 (1/3) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/3) — H 2,5-dimethylphenyl X² G-2 J-69 (1/3) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/3) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-69 (1/3) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/3) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/3) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/3) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/3) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/3) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-69 (1/3) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-69 (1/3) — H 2,5-dichlorophenyl X² G-2 J-69 (1/4) — H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/4) — H 2,5-dimethylphenyl X² G-2 J-69 (1/4) — H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/4) — H 3,5-dimethylpyrazol-1-yl X² G-2 J-69 (1/4) — H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/4) — H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/4) — H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/4) — H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/4) — H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/4) — H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-69 (1/4) — H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-69 (1/4) — H 2,5-dichlorophenyl X² G-2 J-11 (3/5) — 2-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2-Me 2,5-dimethylphenyl X² G-2 J-11 (3/5) — 2-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2-Me 3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 2-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-11 (3/5) — 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-11 (3/5) — 2-Me 2,5-dichlorophenyl X² G-2 J-11 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 3-Me 2,5-dimethylphenyl X² G-2 J-11 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-11 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-11 (3/5) — 3-Me 2,5-dichlorophenyl X² G-2 J-11 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4-Me 2,5-dimethylphenyl X² G-2 J-11 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-11 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-11 (3/5) — 4-Me 2,5-dichlorophenyl X² G-2 J-11 (3/5) — 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2-Cl 2,5-dimethylphenyl X² G-2 J-11 (3/5) — 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2-Cl 3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl 5-bromo-3-(rifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-11 (3/5) — 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-11 (3/5) — 2-Cl 2,5-dichlorophenyl X² G-2 J-11 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4-Cl 2,5-dimethylphenyl X² G-2 J-11 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-11 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-11 (3/5) — 4-Cl 2,5-dichlorophenyl X² G-2 J-29 (3/5) — 2-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2-Me 2,5-dimethylphenyl X² G-2 J-29 (3/5) — 2-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2-Me 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 2-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) — 2-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) — 2-Me 2,5-dichlorophenyl X² G-2 J-29 (3/5) — 3-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 3-Me 2,5-dimethylphenyl X² G-2 J-29 (3/5) — 3-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 3-Me 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 3-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 3-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 3-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 3-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) — 3-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) — 3-Me 2,5-dichlorophenyl X² G-2 J-29 (3/5) — 4-Me 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4-Me 2,5-dimethylphenyl X² G-2 J-29 (3/5) — 4-Me 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4-Me 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 4-Me 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Me 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Me 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Me 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Me 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Me 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) — 4-Me 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) — 4-Me 2,5-dichlorophenyl X² G-2 J-29 (3/5) — 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2-Cl 2,5-dimethylphenyl X² G-2 J-29 (3/5) — 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2-Cl 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) — 2-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) — 2-Cl 2,5-dichlorophenyl X² G-2 J-29 (3/5) — 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4-Cl 2,5-dimethylphenyl X² G-2 J-29 (3/5) — 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4-Cl 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) — 4-Cl 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) — 4-Cl 2,5-dichlorophenyl X² G-2 J-29 (3/5) 5-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 5-Me H 2,5-dimethylphenyl X² G-2 J-29 (3/5) 5-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 5-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) 5-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) 5-Me H 2,5-dichlorophenyl X² G-2 J-29 (3/5) 4-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4-Me H 2,5-dimethylphenyl X² G-2 J-29 (3/5) 4-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) 4-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) 4-Me H 2,5-dichlorophenyl X² G-2 J-29 (3/5) 4,4-di-Me H 2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4,4-di-Me H 2,5-dimethylphenyl X² G-2 J-29 (3/5) 4,4-di-Me H 2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4,4-di-Me H 3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) 4,4-di-Me H 5-methyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4,4-di-Me H 5-chloro-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4,4-di-Me H 5-bromo-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4,4-di-Me H 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4,4-di-Me H 3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4,4-di-Me H 1-methyl-3-(trifluoromethyl)pyrazol-5-yl X² G-2 J-29 (3/5) 4,4-di-Me H 1-methyl-4-(trifluoromethyl)imidazol-2-yl X² G-2 J-29 (3/5) 4,4-di-Me H *The definitions of G and J in the compounds of this table are as defined in Exhibits 2 and 3 in the above Embodiments. The (R⁵)_(y) column refers the substituents (R⁵)_(x) shown on J groups in Exhibit 3 other than the phenyl ring substituted by R^(7a) shown in the structure heading this table. R^(7a) may be selected from H (to indicate no substitution on the phenyl ring) as well as the substituents defined for R⁷. A dash “—” in the (R⁵)_(y) column indicates no substitution on J besides the phenyl ring substituted by R^(7a). ** R^(3a) substituent in G is H. *** Numbers in parentheses refer to the attachment points on ring J. The first number is the attachment point for ring G; the second number is the attachment point for the phenyl ring.

TABLE 5

wherein J is one of J-29-1 through J-29-57 (as depicted in Exhibit A above). J R¹ is 2,5-dichlorophenyl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2,5-dichlorophenyl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2,5-dichlorophenyl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2,5-dichlorophenyl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-chloro-5-(trifluoromethyl)phenyl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-chloro-5-(trifluoromethyl)phenyl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-chloro-5-(trifluoromethyl)phenyl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-chloro-5-(trifluoromethyl)phenyl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-methyl-5-(trifluoromethyl)phenyl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-methyl-5-(trifluoromethyl)phenyl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-methyl-5-(trifluoromethyl)phenyl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 2-methyl-5-(trifluoromethyl)phenyl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dimethylpyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dimethylpyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dimethylpyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dimethylpyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dibromopyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dibromopyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dibromopyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dibromopyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methyl-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methyl-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57

Table 5 above identifies particular compounds comprising a J group selected from J-29-1 through J-29-57 (i.e. particular examples of J-29). As many J-29-1 to J-29-57 include a chiral center, these J groups are illustrated in a particular enantiomeric configuration, which in some instances may provide the greatest fungicidal activity. One skilled in the art immediately recognizes the antipode (i.e. opposite enantiomer) for each of the compounds listed, and furthermore understands that the enantiomers can be present as pure enantiomers or in mixtures enriched in one enantiomer or in racemic mixtures.

** R^(3a) substituent in G is H.

TABLE 6

R^(4a1) R^(4a2) A^(a) R^(4a1) R^(4a2) A^(a) Me Me H Me Me CH₂CO₂Et Me Et H Me Et CH₂CO₂Et Me Cl H Me Cl CH₂CO₂Et Me Br H Me Br CH₂CO₂Et Me I H Me I CH₂CO₂Et Me CF₂H H Me CF₂H CH₂CO₂Et Me CF₃ H Me CF₃ CH₂CO₂Et Me CF₃CH₂ H Me CF₃CH₂ CH₂CO₂Et Me CF₃CF₂ H Me CF₃CF₂ CH₂CO₂Et Me CCl₃ H Me CCl₃ CH₂CO₂Et Me MeO H Me MeO CH₂CO₂Et Et Me H Et Me CH₂CO₂Et Et Et H Et Et CH₂CO₂Et Et Cl H Et Cl CH₂CO₂Et Et Br H Et Br CH₂CO₂Et Et I H Et I CH₂CO₂Et Et CF₂H H Et CF₂H CH₂CO₂Et Et CF₃ H Et CF₃ CH₂CO₂Et Et CF₃CH₂ H Et CF₃CH₂ CH₂CO₂Et Et CF₃CF₂ H Et CF₃CF₂ CH₂CO₂Et Et CCl₃ H Et CCl₃ CH₂CO₂Et Et MeO H Et MeO CH₂CO₂Et Cl Me H Cl Me CH₂CO₂Et Cl Et H Cl Et CH₂CO₂Et Cl Cl H Cl Cl CH₂CO₂Et Cl Br H Cl Br CH₂CO₂Et Cl I H Cl I CH₂CO₂Et Cl CF₂H H Cl CF₂H CH₂CO₂Et Cl CF₃ H Cl CF₃ CH₂CO₂Et Cl CF₃CH₂ H Cl CF₃CH₂ CH₂CO₂Et Cl CF₃CF₂ H Cl CF₃CF₂ CH₂CO₂Et Cl CCl₃ H Cl CCl₃ CH₂CO₂Et Cl MeO H Cl MeO CH₂CO₂Et Br Me H Br Me CH₂CO₂Et Br Et H Br Et CH₂CO₂Et Br Cl H Br Cl CH₂CO₂Et Br Br H Br Br CH₂CO₂Et Br I H Br I CH₂CO₂Et Br CF₂H H Br CF₂H CH₂CO₂Et Br CF₃ H Br CF₃ CH₂CO₂Et Br CF₃CH₂ H Br CF₃CH₂ CH₂CO₂Et Br CF₃CF₂ H Br CF₃CF₂ CH₂CO₂Et Br CCl₃ H Br CCl₃ CH₂CO₂Et Br MeO H Br MeO CH₂CO₂Et I Me H I Me CH₂CO₂Et I Et H I Et CH₂CO₂Et I Cl H I Cl CH₂CO₂Et I Br H I Br CH₂CO₂Et I I H I I CH₂CO₂Et I CF₂H H I CF₂H CH₂CO₂Et I CF₃ H I CF₃ CH₂CO₂Et I CF₃CH₂ H I CF₃CH₂ CH₂CO₂Et I CF₃CF₂ H I CF₃CF₂ CH₂CO₂Et I CCl₃ H I CCl₃ CH₂CO₂Et I MeO H I MeO CH₂CO₂Et CF₂H Me H CF₂H Me CH₂CO₂Et CF₂H Et H CF₂H Et CH₂CO₂Et CF₂H Cl H CF₂H Cl CH₂CO₂Et CF₂H Br H CF₂H Br CH₂CO₂Et CF₂H I H CF₂H I CH₂CO₂Et CF₂H CF₂H H CF₂H CF₂H CH₂CO₂Et CF₂H CF₃ H CF₂H CF₃ CH₂CO₂Et CF₂H CF₃CH₂ H CF₂H CF₃CH₂ CH₂CO₂Et CF₂H CF₃CF₂ H CF₂H CF₃CF₂ CH₂CO₂Et CF₂H CCl₃ H CF₂H CCl₃ CH₂CO₂Et CF₂H MeO H CF₂H MeO CH₂CO₂Et CF₃ Me H CF₃ Me CH₂CO₂Et CF₃ Et H CF₃ Et CH₂CO₂Et CF₃ Cl H CF₃ Cl CH₂CO₂Et CF₃ Br H CF₃ Br CH₂CO₂Et CF₃ I H CF₃ I CH₂CO₂Et CF₃ CF₂H H CF₃ CF₂H CH₂CO₂Et CF₃ CF₃ H CF₃ CF₃ CH₂CO₂Et CF₃ CF₃CH₂ H CF₃ CF₃CH₂ CH₂CO₂Et CF₃ CF₃CF₂ H CF₃ CF₃CF₂ CH₂CO₂Et CF₃ CCl₃ H CF₃ CCl₃ CH₂CO₂Et CF₃ MeO H CF₃ MeO CH₂CO₂Et CF₃CH₂ Me H CF₃CH₂ Me CH₂CO₂Et CF₃CH₂ Et H CF₃CH₂ Et CH₂CO₂Et CF₃CH₂ Cl H CF₃CH₂ Cl CH₂CO₂Et CF₃CH₂ Br H CF₃CH₂ Br CH₂CO₂Et CF₃CH₂ I H CF₃CH₂ I CH₂CO₂Et CF₃CH₂ CF₂H H CF₃CH₂ CF₂H CH₂CO₂Et CF₃CH₂ CF₃ H CF₃CH₂ CF₃ CH₂CO₂Et CF₃CH₂ CF₃CH₂ H CF₃CH₂ CF₃CH₂ CH₂CO₂Et CF₃CH₂ CF₃CF₂ H CF₃CH₂ CF₃CF₂ CH₂CO₂Et CF₃CH₂ CCl₃ H CF₃CH₂ CCl₃ CH₂CO₂Et CF₃CH₂ MeO H CF₃CH₂ MeO CH₂CO₂Et CF₃CF₂ Me H CF₃CF₂ Me CH₂CO₂Et CF₃CF₂ Et H CF₃CF₂ Et CH₂CO₂Et CF₃CF₂ Cl H CF₃CF₂ Cl CH₂CO₂Et CF₃CF₂ Br H CF₃CF₂ Br CH₂CO₂Et CF₃CF₂ I H CF₃CF₂ I CH₂CO₂Et CF₃CF₂ CF₂H H CF₃CF₂ CF₂H CH₂CO₂Et CF₃CF₂ CF₃ H CF₃CF₂ CF₃ CH₂CO₂Et CF₃CF₂ CF₃CH₂ H CF₃CF₂ CF₃CH₂ CH₂CO₂Et CF₃CF₂ CF₃CF₂ H CF₃CF₂ CF₃CF₂ CH₂CO₂Et CF₃CF₂ CCl₃ H CF₃CF₂ CCl₃ CH₂CO₂Et CF₃CF₂ MeO H CF₃CF₂ MeO CH₂CO₂Et CCl₃ Me H CCl₃ Me CH₂CO₂Et CCl₃ Et H CCl₃ Et CH₂CO₂Et CCl₃ Cl H CCl₃ Cl CH₂CO₂Et CCl₃ Br H CCl₃ Br CH₂CO₂Et CCl₃ I H CCl₃ I CH₂CO₂Et CCl₃ CF₂H H CCl₃ CF₂H CH₂CO₂Et CCl₃ CF₃ H CCl₃ CF₃ CH₂CO₂Et CCl₃ CF₃CH₂ H CCl₃ CF₃CH₂ CH₂CO₂Et CCl₃ CF₃CF₂ H CCl₃ CF₃CF₂ CH₂CO₂Et CCl₃ CCl₃ H CCl₃ CCl₃ CH₂CO₂Et CCl₃ MeO H CCl₃ MeO CH₂CO₂Et MeO Me H MeO Me CH₂CO₂Et MeO Et H MeO Et CH₂CO₂Et MeO Cl H MeO Cl CH₂CO₂Et MeO Br H MeO Br CH₂CO₂Et MeO I H MeO I CH₂CO₂Et MeO CF₂H H MeO CF₂H CH₂CO₂Et MeO CF₃ H MeO CF₃ CH₂CO₂Et MeO CF₃CH₂ H MeO CF₃CH₂ CH₂CO₂Et MeO CF₃CF₂ H MeO CF₃CF₂ CH₂CO₂Et MeO CCl₃ H MeO CCl₃ CH₂CO₂Et MeO MeO H MeO MeO CH₂CO₂Et Me Me CH₂CO₂H Me Me CH₂C(═O)Cl Me Et CH₂CO₂H Me Et CH₂C(═O)Cl Me Cl CH₂CO₂H Me Cl CH₂C(═O)Cl Me Br CH₂CO₂H Me Br CH₂C(═O)Cl Me I CH₂CO₂H Me I CH₂C(═O)Cl Me CF₂H CH₂CO₂H Me CF₂H CH₂C(═O)Cl Me CF₃ CH₂CO₂H Me CF₃ CH₂C(═O)Cl Me CF₃CH₂ CH₂CO₂H Me CF₃CH₂ CH₂C(═O)Cl Me CF₃CF₂ CH₂CO₂H Me CF₃CF₂ CH₂C(═O)Cl Me CCl₃ CH₂CO₂H Me CCl₃ CH₂C(═O)Cl Me MeO CH₂CO₂H Me MeO CH₂C(═O)Cl Et Me CH₂CO₂H Et Me CH₂C(═O)Cl Et Et CH₂CO₂H Et Et CH₂C(═O)Cl Et Cl CH₂CO₂H Et Cl CH₂C(═O)Cl Et Br CH₂CO₂H Et Br CH₂C(═O)Cl Et I CH₂CO₂H Et I CH₂C(═O)Cl Et CF₂H CH₂CO₂H Et CF₂H CH₂C(═O)Cl Et CF₃ CH₂CO₂H Et CF₃ CH₂C(═O)Cl Et CF₃CH₂ CH₂CO₂H Et CF₃CH₂ CH₂C(═O)Cl Et CF₃CF₂ CH₂CO₂H Et CF₃CF₂ CH₂C(═O)Cl Et CCl₃ CH₂CO₂H Et CCl₃ CH₂C(═O)Cl Et MeO CH₂CO₂H Et MeO CH₂C(═O)Cl Cl Me CH₂CO₂H Cl Me CH₂C(═O)Cl Cl Et CH₂CO₂H Cl Et CH₂C(═O)Cl Cl Cl CH₂CO₂H Cl Cl CH₂C(═O)Cl Cl Br CH₂CO₂H Cl Br CH₂C(═O)Cl Cl I CH₂CO₂H Cl I CH₂C(═O)Cl Cl CF₂H CH₂CO₂H Cl CF₂H CH₂C(═O)Cl Cl CF₃ CH₂CO₂H Cl CF₃ CH₂C(═O)Cl Cl CF₃CH₂ CH₂CO₂H Cl CF₃CH₂ CH₂C(═O)Cl Cl CF₃CF₂ CH₂CO₂H Cl CF₃CF₂ CH₂C(═O)Cl Cl CCl₃ CH₂CO₂H Cl CCl₃ CH₂C(═O)Cl Cl MeO CH₂CO₂H Cl MeO CH₂C(═O)Cl Br Me CH₂CO₂H Br Me CH₂C(═O)Cl Br Et CH₂CO₂H Br Et CH₂C(═O)Cl Br Cl CH₂CO₂H Br Cl CH₂C(═O)Cl Br Br CH₂CO₂H Br Br CH₂C(═O)Cl Br I CH₂CO₂H Br I CH₂C(═O)Cl Br CF₂H CH₂CO₂H Br CF₂H CH₂C(═O)Cl Br CF₃ CH₂CO₂H Br CF₃ CH₂C(═O)Cl Br CF₃CH₂ CH₂CO₂H Br CF₃CH₂ CH₂C(═O)Cl Br CF₃CF₂ CH₂CO₂H Br CF₃CF₂ CH₂C(═O)Cl Br CCl₃ CH₂CO₂H Br CCl₃ CH₂C(═O)Cl Br MeO CH₂CO₂H Br MeO CH₂C(═O)Cl I Me CH₂CO₂H I Me CH₂C(═O)Cl I Et CH₂CO₂H I Et CH₂C(═O)Cl I Cl CH₂CO₂H I Cl CH₂C(═O)Cl I Br CH₂CO₂H I Br CH₂C(═O)Cl I I CH₂CO₂H I I CH₂C(═O)Cl I CF₂H CH₂CO₂H I CF₂H CH₂C(═O)Cl I CF₃ CH₂CO₂H I CF₃ CH₂C(═O)Cl I CF₃CH₂ CH₂CO₂H I CF₃CH₂ CH₂C(═O)Cl I CF₃CF₂ CH₂CO₂H I CF₃CF₂ CH₂C(═O)Cl I CCl₃ CH₂CO₂H I CCl₃ CH₂C(═O)Cl I MeO CH₂CO₂H I MeO CH₂C(═O)Cl CF₂H Me CH₂CO₂H CF₂H Me CH₂C(═O)Cl CF₂H Et CH₂CO₂H CF₂H Et CH₂C(═O)Cl CF₂H Cl CH₂CO₂H CF₂H Cl CH₂C(═O)Cl CF₂H Br CH₂CO₂H CF₂H Br CH₂C(═O)Cl CF₂H I CH₂CO₂H CF₂H I CH₂C(═O)Cl CF₂H CF₂H CH₂CO₂H CF₂H CF₂H CH₂C(═O)Cl CF₂H CF₃ CH₂CO₂H CF₂H CF₃ CH₂C(═O)Cl CF₂H CF₃CH₂ CH₂CO₂H CF₂H CF₃CH₂ CH₂C(═O)Cl CF₂H CF₃CF₂ CH₂CO₂H CF₂H CF₃CF₂ CH₂C(═O)Cl CF₂H CCl₃ CH₂CO₂H CF₂H CCl₃ CH₂C(═O)Cl CF₂H MeO CH₂CO₂H CF₂H MeO CH₂C(═O)Cl CF₃ Me CH₂CO₂H CF₃ Me CH₂C(═O)Cl CF₃ Et CH₂CO₂H CF₃ Et CH₂C(═O)Cl CF₃ Cl CH₂CO₂H CF₃ Cl CH₂C(═O)Cl CF₃ Br CH₂CO₂H CF₃ Br CH₂C(═O)Cl CF₃ I CH₂CO₂H CF₃ I CH₂C(═O)Cl CF₃ CF₂H CH₂CO₂H CF₃ CF₂H CH₂C(═O)Cl CF₃ CF₃ CH₂CO₂H CF₃ CF₃ CH₂C(═O)Cl CF₃ CF₃CH₂ CH₂CO₂H CF₃ CF₃CH₂ CH₂C(═O)Cl CF₃ CF₃CF₂ CH₂CO₂H CF₃ CF₃CF₂ CH₂C(═O)Cl CF₃ CCl₃ CH₂CO₂H CF₃ CCl₃ CH₂C(═O)Cl CF₃ MeO CH₂CO₂H CF₃ MeO CH₂C(═O)Cl CF₃CH₂ Me CH₂CO₂H CF₃CH₂ Me CH₂C(═O)Cl CF₃CH₂ Et CH₂CO₂H CF₃CH₂ Et CH₂C(═O)Cl CF₃CH₂ Cl CH₂CO₂H CF₃CH₂ Cl CH₂C(═O)Cl CF₃CH₂ Br CH₂CO₂H CF₃CH₂ Br CH₂C(═O)Cl CF₃CH₂ I CH₂CO₂H CF₃CH₂ I CH₂C(═O)Cl CF₃CH₂ CF₂H CH₂CO₂H CF₃CH₂ CF₂H CH₂C(═O)Cl CF₃CH₂ CF₃ CH₂CO₂H CF₃CH₂ CF₃ CH₂C(═O)Cl CF₃CH₂ CF₃CH₂ CH₂CO₂H CF₃CH₂ CF₃CH₂ CH₂C(═O)Cl CF₃CH₂ CF₃CF₂ CH₂CO₂H CF₃CH₂ CF₃CF₂ CH₂C(═O)Cl CF₃CH₂ CCl₃ CH₂CO₂H CF₃CH₂ CCl₃ CH₂C(═O)Cl CF₃CH₂ MeO CH₂CO₂H CF₃CH₂ MeO CH₂C(═O)Cl CF₃CF₂ Me CH₂CO₂H CF₃CF₂ Me CH₂C(═O)Cl CF₃CF₂ Et CH₂CO₂H CF₃CF₂ Et CH₂C(═O)Cl CF₃CF₂ Cl CH₂CO₂H CF₃CF₂ Cl CH₂C(═O)Cl CF₃CF₂ Br CH₂CO₂H CF₃CF₂ Br CH₂C(═O)Cl CF₃CF₂ I CH₂CO₂H CF₃CF₂ I CH₂C(═O)Cl CF₃CF₂ CF₂H CH₂CO₂H CF₃CF₂ CF₂H CH₂C(═O)Cl CF₃CF₂ CF₃ CH₂CO₂H CF₃CF₂ CF₃ CH₂C(═O)Cl CF₃CF₂ CF₃CH₂ CH₂CO₂H CF₃CF₂ CF₃CH₂ CH₂C(═O)Cl CF₃CF₂ CF₃CF₂ CH₂CO₂H CF₃CF₂ CF₃CF₂ CH₂C(═O)Cl CF₃CF₂ CCl₃ CH₂CO₂H CF₃CF₂ CCl₃ CH₂C(═O)Cl CF₃CF₂ MeO CH₂CO₂H CF₃CF₂ MeO CH₂C(═O)Cl CCl₃ Me CH₂CO₂H CCl₃ Me CH₂C(═O)Cl CCl₃ Et CH₂CO₂H CCl₃ Et CH₂C(═O)Cl CCl₃ Cl CH₂CO₂H CCl₃ Cl CH₂C(═O)Cl CCl₃ Br CH₂CO₂H CCl₃ Br CH₂C(═O)Cl CCl₃ I CH₂CO₂H CCl₃ I CH₂C(═O)Cl CCl₃ CF₂H CH₂CO₂H CCl₃ CF₂H CH₂C(═O)Cl CCl₃ CF₃ CH₂CO₂H CCl₃ CF₃ CH₂C(═O)Cl CCl₃ CF₃CH₂ CH₂CO₂H CCl₃ CF₃CH₂ CH₂C(═O)Cl CCl₃ CF₃CF₂ CH₂CO₂H CCl₃ CF₃CF₂ CH₂C(═O)Cl CCl₃ CCl₃ CH₂CO₂H CCl₃ CCl₃ CH₂C(═O)Cl CCl₃ MeO CH₂CO₂H CCl₃ MeO CH₂C(═O)Cl MeO Me CH₂CO₂H MeO Me CH₂C(═O)Cl MeO Et CH₂CO₂H MeO Et CH₂C(═O)Cl MeO Cl CH₂CO₂H MeO Cl CH₂C(═O)Cl MeO Br CH₂CO₂H MeO Br CH₂C(═O)Cl MeO I CH₂CO₂H MeO I CH₂C(═O)Cl MeO CF₂H CH₂CO₂H MeO CF₂H CH₂C(═O)Cl MeO CF₃ CH₂CO₂H MeO CF₃ CH₂C(═O)Cl MeO CF₃CH₂ CH₂CO₂H MeO CF₃CH₂ CH₂C(═O)Cl MeO CF₃CF₂ CH₂CO₂H MeO CF₃CF₂ CH₂C(═O)Cl MeO CCl₃ CH₂CO₂H MeO CCl₃ CH₂C(═O)Cl MeO MeO CH₂CO₂H MeO MeO CH₂C(═O)Cl OCF₂H Me CH₂CO₂H OCF₂H Me CH₂C(═O)Cl OCF₂H Et CH₂CO₂H OCF₂H Et CH₂C(═O)Cl OCF₂H Cl CH₂CO₂H OCF₂H Cl CH₂C(═O)Cl OCF₂H Br CH₂CO₂H OCF₂H Br CH₂C(═O)Cl OCF₂H I CH₂CO₂H OCF₂H I CH₂C(═O)Cl OCF₂H CF₂H CH₂CO₂H OCF₂H CF₂H CH₂C(═O)Cl OCF₂H CF₃ CH₂CO₂H OCF₂H CF₃ CH₂C(═O)Cl OCF₂H CF₃CH₂ CH₂CO₂H OCF₂H CF₃CH₂ CH₂C(═O)Cl OCF₂H CF₃CF₂ CH₂CO₂H OCF₂H CF₃CF₂ CH₂C(═O)Cl OCF₂H CCl₃ CH₂CO₂H OCF₂H CCl₃ CH₂C(═O)Cl OCF₂H MeO CH₂CO₂H OCF₂H MeO CH₂C(═O)Cl

TABLE 7

R^(4a1) R^(4a2) Z³ R^(4a1) R^(4a2) Z³ Me Me CN Me Me C(═S)NH₂ Me Et CN Me Et C(═S)NH₂ Me Cl CN Me Cl C(═S)NH₂ Me Br CN Me Br C(═S)NH₂ Me I CN Me I C(═S)NH₂ Me CF₂H CN Me CF₂H C(═S)NH₂ Me CF₃ CN Me CF₃ C(═S)NH₂ Me CF₃CH₂ CN Me CF₃CH₂ C(═S)NH₂ Me CF₃CF₂ CN Me CF₃CF₂ C(═S)NH₂ Me CCl₃ CN Me CCl₃ C(═S)NH₂ Me MeO CN Me MeO C(═S)NH₂ Et Me CN Et Me C(═S)NH₂ Et Et CN Et Et C(═S)NH₂ Et Cl CN Et Cl C(═S)NH₂ Et Br CN Et Br C(═S)NH₂ Et I CN Et I C(═S)NH₂ Et CF₂H CN Et CF₂H C(═S)NH₂ Et CF₃ CN Et CF₃ C(═S)NH₂ Et CF₃CH₂ CN Et CF₃CH₂ C(═S)NH₂ Et CF₃CF₂ CN Et CF₃CF₂ C(═S)NH₂ Et CCl₃ CN Et CCl₃ C(═S)NH₂ Et MeO CN Et MeO C(═S)NH₂ Cl Me CN Cl Me C(═S)NH₂ Cl Et CN Cl Et C(═S)NH₂ Cl Cl CN Cl Cl C(═S)NH₂ Cl Br CN Cl Br C(═S)NH₂ Cl I CN Cl I C(═S)NH₂ Cl CF₂H CN Cl CF₂H C(═S)NH₂ Cl CF₃ CN Cl CF₃ C(═S)NH₂ Cl CF₃CH₂ CN Cl CF₃CH₂ C(═S)NH₂ Cl CF₃CF₂ CN Cl CF₃CF₂ C(═S)NH₂ Cl CCl₃ CN Cl CCl₃ C(═S)NH₂ Cl MeO CN Cl MeO C(═S)NH₂ Br Me CN Br Me C(═S)NH₂ Br Et CN Br Et C(═S)NH₂ Br Cl CN Br Cl C(═S)NH₂ Br Br CN Br Br C(═S)NH₂ Br I CN Br I C(═S)NH₂ Br CF₂H CN Br CF₂H C(═S)NH₂ Br CF₃ CN Br CF₃ C(═S)NH₂ Br CF₃CH₂ CN Br CF₃CH₂ C(═S)NH₂ Br CF₃CF₂ CN Br CF₃CF₂ C(═S)NH₂ Br CCl₃ CN Br CCl₃ C(═S)NH₂ Br MeO CN Br MeO C(═S)NH₂ I Me CN I Me C(═S)NH₂ I Et CN I Et C(═S)NH₂ I Cl CN I Cl C(═S)NH₂ I Br CN I Br C(═S)NH₂ I I CN I I C(═S)NH₂ I CF₂H CN I CF₂H C(═S)NH₂ I CF₃ CN I CF₃ C(═S)NH₂ I CF₃CH₂ CN I CF₃CH₂ C(═S)NH₂ I CF₃CF₂ CN I CF₃CF₂ C(═S)NH₂ I CCl₃ CN I CCl₃ C(═S)NH₂ I MeO CN I MeO C(═S)NH₂ CF₂H Me CN CF₂H Me C(═S)NH₂ CF₂H Et CN CF₂H Et C(═S)NH₂ CF₂H Cl CN CF₂H Cl C(═S)NH₂ CF₂H Br CN CF₂H Br C(═S)NH₂ CF₂H I CN CF₂H I C(═S)NH₂ CF₂H CF₂H CN CF₂H CF₂H C(═S)NH₂ CF₂H CF₃ CN CF₂H CF₃ C(═S)NH₂ CF₂H CF₃CH₂ CN CF₂H CF₃CH₂ C(═S)NH₂ CF₂H CF₃CF₂ CN CF₂H CF₃CF₂ C(═S)NH₂ CF₂H CCl₃ CN CF₂H CCl₃ C(═S)NH₂ CF₂H MeO CN CF₂H MeO C(═S)NH₂ CF₃ Me CN CF₃ Me C(═S)NH₂ CF₃ Et CN CF₃ Et C(═S)NH₂ CF₃ Cl CN CF₃ Cl C(═S)NH₂ CF₃ Br CN CF₃ Br C(═S)NH₂ CF₃ I CN CF₃ I C(═S)NH₂ CF₃ CF₂H CN CF₃ CF₂H C(═S)NH₂ CF₃ CF₃ CN CF₃ CF₃ C(═S)NH₂ CF₃ CF₃CH₂ CN CF₃ CF₃CH₂ C(═S)NH₂ CF₃ CF₃CF₂ CN CF₃ CF₃CF₂ C(═S)NH₂ CF₃ CCl₃ CN CF₃ CCl₃ C(═S)NH₂ CF₃ MeO CN CF₃ MeO C(═S)NH₂ CF₃CH₂ Me CN CF₃CH₂ Me C(═S)NH₂ CF₃CH₂ Et CN CF₃CH₂ Et C(═S)NH₂ CF₃CH₂ Cl CN CF₃CH₂ Cl C(═S)NH₂ CF₃CH₂ Br CN CF₃CH₂ Br C(═S)NH₂ CF₃CH₂ I CN CF₃CH₂ I C(═S)NH₂ CF₃CH₂ CF₂H CN CF₃CH₂ CF₂H C(═S)NH₂ CF₃CH₂ CF₃ CN CF₃CH₂ CF₃ C(═S)NH₂ CF₃CH₂ CF₃CH₂ CN CF₃CH₂ CF₃CH₂ C(═S)NH₂ CF₃CH₂ CF₃CF₂ CN CF₃CH₂ CF₃CF₂ C(═S)NH₂ CF₃CH₂ CCl₃ CN CF₃CH₂ CCl₃ C(═S)NH₂ CF₃CH₂ MeO CN CF₃CH₂ MeO C(═S)NH₂ CF₃CF₂ Me CN CF₃CF₂ Me C(═S)NH₂ CF₃CF₂ Et CN CF₃CF₂ Et C(═S)NH₂ CF₃CF₂ Cl CN CF₃CF₂ Cl C(═S)NH₂ CF₃CF₂ Br CN CF₃CF₂ Br C(═S)NH₂ CF₃CF₂ I CN CF₃CF₂ I C(═S)NH₂ CF₃CF₂ CF₂H CN CF₃CF₂ CF₂H C(═S)NH₂ CF₃CF₂ CF₃ CN CF₃CF₂ CF₃ C(═S)NH₂ CF₃CF₂ CF₃CH₂ CN CF₃CF₂ CF₃CH₂ C(═S)NH₂ CF₃CF₂ CF₃CF₂ CN CF₃CF₂ CF₃CF₂ C(═S)NH₂ CF₃CF₂ CCl₃ CN CF₃CF₂ CCl₃ C(═S)NH₂ CF₃CF₂ MeO CN CF₃CF₂ MeO C(═S)NH₂ CCl₃ Me CN CCl₃ Me C(═S)NH₂ CCl₃ Et CN CCl₃ Et C(═S)NH₂ CCl₃ Cl CN CCl₃ Cl C(═S)NH₂ CCl₃ Br CN CCl₃ Br C(═S)NH₂ CCl₃ I CN CCl₃ I C(═S)NH₂ CCl₃ CF₂H CN CCl₃ CF₂H C(═S)NH₂ CCl₃ CF₃ CN CCl₃ CF₃ C(═S)NH₂ CCl₃ CF₃CH₂ CN CCl₃ CF₃CH₂ C(═S)NH₂ CCl₃ CF₃CF₂ CN CCl₃ CF₃CF₂ C(═S)NH₂ CCl₃ CCl₃ CN CCl₃ CCl₃ C(═S)NH₂ CCl₃ MeO CN CCl₃ MeO C(═S)NH₂ MeO Me CN MeO Me C(═S)NH₂ MeO Et CN MeO Et C(═S)NH₂ MeO Cl CN MeO Cl C(═S)NH₂ MeO Br CN MeO Br C(═S)NH₂ MeO I CN MeO I C(═S)NH₂ MeO CF₂H CN MeO CF₂H C(═S)NH₂ MeO CF₃ CN MeO CF₃ C(═S)NH₂ MeO CF₃CH₂ CN MeO CF₃CH₂ C(═S)NH₂ MeO CF₃CF₂ CN MeO CF₃CF₂ C(═S)NH₂ MeO CCl₃ CN MeO CCl₃ C(═S)NH₂ MeO MeO CN MeO MeO C(═S)NH₂ OCF₂H Me CN OCF₂H Me C(═S)NH₂ OCF₂H Et CN OCF₂H Et C(═S)NH₂ OCF₂H Cl CN OCF₂H Cl C(═S)NH₂ OCF₂H Br CN OCF₂H Br C(═S)NH₂ OCF₂H I CN OCF₂H I C(═S)NH₂ OCF₂H CF₂H CN OCF₂H CF₂H C(═S)NH₂ OCF₂H CF₃ CN OCF₂H CF₃ C(═S)NH₂ OCF₂H CF₃CH₂ CN OCF₂H CF₃CH₂ C(═S)NH₂ OCF₂H CF₃CF₂ CN OCF₂H CF₃CF₂ C(═S)NH₂ OCF₂H CCl₃ CN OCF₂H CCl₃ C(═S)NH₂ OCF₂H MeO CN OCF₂H MeO C(═S)NH₂

TABLE 8

wherein J¹ is one of J-29-1 through J-29-58 (as depicted in Exhibit A above). M J¹ CH₃ J-29-1  CH₂Cl J-29-1  CH₂Br J-29-1  CH₂I J-29-1  OH J-29-1  OMe J-29-1  OEt J-29-1  OPr J-29-1  O-i-Pr J-29-1  O-n-Bu J-29-1  O-t-Bu J-29-1  NMe₂ J-29-1  NEt₂ J-29-1  N(n-Pr)₂ J-29-1  1-piperdinyl J-29-1  1-pyrrolidinyl J-29-1  4-morpholinyl J-29-1  CH₃ J-29-2  CH₂Cl J-29-2  CH₂Br J-29-2  CH₂I J-29-2  OH J-29-2  OMe J-29-2  OEt J-29-2  OPr J-29-2  O-i-Pr J-29-2  O-n-Bu J-29-2  O-t-Bu J-29-2  NMe₂ J-29-2  NEt₂ J-29-2  N(n-Pr)₂ J-29-2  1-piperdinyl J-29-2  1-pyrrolidinyl J-29-2  4-morpholinyl J-29-2  CH₃ J-29-3  CH₂Cl J-29-3  CH₂Br J-29-3  CH₂I J-29-3  OH J-29-3  OMe J-29-3  OEt J-29-3  OPr J-29-3  O-i-Pr J-29-3  O-n-Bu J-29-3  O-t-Bu J-29-3  NMe₂ J-29-3  NEt₂ J-29-3  N(n-Pr)₂ J-29-3  1-piperdinyl J-29-3  1-pyrrolidinyl J-29-3  4-morpholinyl J-29-3  CH₃ J-29-4  CH₂Cl J-29-4  CH₂Br J-29-4  CH₂I J-29-4  OH J-29-4  OMe J-29-4  OEt J-29-4  OPr J-29-4  O-i-Pr J-29-4  O-n-Bu J-29-4  O-t-Bu J-29-4  NMe₂ J-29-4  NEt₂ J-29-4  N(n-Pr)₂ J-29-4  1-piperdinyl J-29-4  1-pyrrolidinyl J-29-4  4-morpholinyl J-29-4  CH₃ J-29-5  CH₂Cl J-29-5  CH₂Br J-29-5  CH₂I J-29-5  OH J-29-5  OMe J-29-5  OEt J-29-5  OPr J-29-5  O-i-Pr J-29-5  O-n-Bu J-29-5  O-t-Bu J-29-5  NMe₂ J-29-5  NEt₂ J-29-5  N(n-Pr)₂ J-29-5  1-piperdinyl J-29-5  1-pyrrolidinyl J-29-5  4-morpholinyl J-29-5  CH₃ J-29-6  CH₂Cl J-29-6  CH₂Br J-29-6  CH₂I J-29-6  OH J-29-6  OMe J-29-6  OEt J-29-6  OPr J-29-6  O-i-Pr J-29-6  O-n-Bu J-29-6  O-t-Bu J-29-6  NMe₂ J-29-6  NEt₂ J-29-6  N(n-Pr)₂ J-29-6  1-piperdinyl J-29-6  1-pyrrolidinyl J-29-6  4-morpholinyl J-29-6  CH₃ J-29-7  CH₂Cl J-29-7  CH₂Br J-29-7  CH₂I J-29-7  OH J-29-7  OMe J-29-7  OEt J-29-7  OPr J-29-7  O-i-Pr J-29-7  O-n-Bu J-29-7  O-t-Bu J-29-7  NMe₂ J-29-7  NEt₂ J-29-7  N(n-Pr)₂ J-29-7  1-piperdinyl J-29-7  1-pyrrolidinyl J-29-7  4-morpholinyl J-29-7  CH₃ J-29-8  CH₂Cl J-29-8  CH₂Br J-29-8  CH₂I J-29-8  OH J-29-8  OMe J-29-8  OEt J-29-8  OPr J-29-8  O-i-Pr J-29-8  O-n-Bu J-29-8  O-t-Bu J-29-8  NMe₂ J-29-8  NEt₂ J-29-8  N(n-Pr)₂ J-29-8  1-piperdinyl J-29-8  1-pyrrolidinyl J-29-8  4-morpholinyl J-29-8  CH₃ J-29-9  CH₂Cl J-29-9  CH₂Br J-29-9  CH₂I J-29-9  OH J-29-9  OMe J-29-9  OEt J-29-9  OPr J-29-9  O-i-Pr J-29-9  O-n-Bu J-29-9  O-t-Bu J-29-9  NMe₂ J-29-9  NEt₂ J-29-9  N(n-Pr)₂ J-29-9  1-piperdinyl J-29-9  1-pyrrolidinyl J-29-9  4-morpholinyl J-29-9  CH₃ J-29-10 CH₂Cl J-29-10 CH₂Br J-29-10 CH₂I J-29-10 OH J-29-10 OMe J-29-10 OEt J-29-10 OPr J-29-10 O-i-Pr J-29-10 O-n-Bu J-29-10 O-t-Bu J-29-10 NMe₂ J-29-10 NEt₂ J-29-10 N(n-Pr)₂ J-29-10 1-piperdinyl J-29-10 1-pyrrolidinyl J-29-10 4-morpholinyl J-29-10 CH₃ J-29-11 CH₂Cl J-29-11 CH₂Br J-29-11 CH₂I J-29-11 OH J-29-11 OMe J-29-11 OEt J-29-11 OPr J-29-11 O-i-Pr J-29-11 O-n-Bu J-29-11 O-t-Bu J-29-11 NMe₂ J-29-11 NEt₂ J-29-11 N(n-Pr)₂ J-29-11 1-piperdinyl J-29-11 1-pyrrolidinyl J-29-11 4-morpholinyl J-29-11 CH₃ J-29-12 CH₂Cl J-29-12 CH₂Br J-29-12 CH₂I J-29-12 OH J-29-12 OMe J-29-12 OEt J-29-12 OPr J-29-12 O-i-Pr J-29-12 O-n-Bu J-29-12 O-t-Bu J-29-12 NMe₂ J-29-12 NEt₂ J-29-12 N(n-Pr)₂ J-29-12 1-piperdinyl J-29-12 1-pyrrolidinyl J-29-12 4-morpholinyl J-29-12 CH₃ J-29-13 CH₂Cl J-29-13 CH₂Br J-29-13 CH₂I J-29-13 OH J-29-13 OMe J-29-13 OEt J-29-13 OPr J-29-13 O-i-Pr J-29-13 O-n-Bu J-29-13 O-t-Bu J-29-13 NMe₂ J-29-13 NEt₂ J-29-13 N(n-Pr)₂ J-29-13 1-piperdinyl J-29-13 1-pyrrolidinyl J-29-13 4-morpholinyl J-29-13 CH₃ J-29-14 CH₂Cl J-29-14 CH₂Br J-29-14 CH₂I J-29-14 OH J-29-14 OMe J-29-14 OEt J-29-14 OPr J-29-14 O-i-Pr J-29-14 O-n-Bu J-29-14 O-t-Bu J-29-14 NMe₂ J-29-14 NEt₂ J-29-14 N(n-Pr)₂ J-29-14 1-piperdinyl J-29-14 1-pyrrolidinyl J-29-14 4-morpholinyl J-29-14 CH₃ J-29-15 CH₂Cl J-29-15 CH₂Br J-29-15 CH₂I J-29-15 OH J-29-15 OMe J-29-15 OEt J-29-15 OPr J-29-15 O-i-Pr J-29-15 O-n-Bu J-29-15 O-t-Bu J-29-15 NMe₂ J-29-15 NEt₂ J-29-15 N(n-Pr)₂ J-29-15 1-piperdinyl J-29-15 1-pyrrolidinyl J-29-15 4-morpholinyl J-29-15 CH₃ J-29-16 CH₂Cl J-29-16 CH₂Br J-29-16 CH₂I J-29-16 OH J-29-16 OMe J-29-16 OEt J-29-16 OPr J-29-16 O-i-Pr J-29-16 O-n-Bu J-29-16 O-t-Bu J-29-16 NMe₂ J-29-16 NEt₂ J-29-16 N(n-Pr)₂ J-29-16 1-piperdinyl J-29-16 1-pyrrolidinyl J-29-16 4-morpholinyl J-29-16 CH₃ J-29-17 CH₂Cl J-29-17 CH₂Br J-29-17 CH₂I J-29-17 OH J-29-17 OMe J-29-17 OEt J-29-17 OPr J-29-17 O-i-Pr J-29-17 O-n-Bu J-29-17 O-t-Bu J-29-17 NMe₂ J-29-17 NEt₂ J-29-17 N(n-Pr)₂ J-29-17 1-piperdinyl J-29-17 1-pyrrolidinyl J-29-17 4-morpholinyl J-29-17 CH₃ J-29-18 CH₂Cl J-29-18 CH₂Br J-29-18 CH₂I J-29-18 OH J-29-18 OMe J-29-18 OEt J-29-18 OPr J-29-18 O-i-Pr J-29-18 O-n-Bu J-29-18 O-t-Bu J-29-18 NMe₂ J-29-18 NEt₂ J-29-18 N(n-Pr)₂ J-29-18 1-piperdinyl J-29-18 1-pyrrolidinyl J-29-18 4-morpholinyl J-29-18 CH₃ J-29-19 CH₂Cl J-29-19 CH₂Br J-29-19 CH₂I J-29-19 OH J-29-19 OMe J-29-19 OEt J-29-19 OPr J-29-19 O-i-Pr J-29-19 O-n-Bu J-29-19 O-t-Bu J-29-19 NMe₂ J-29-19 NEt₂ J-29-19 N(n-Pr)₂ J-29-19 1-piperdinyl J-29-19 1-pyrrolidinyl J-29-19 4-morpholinyl J-29-19 CH₃ J-29-20 CH₂Cl J-29-20 CH₂Br J-29-20 CH₂I J-29-20 OH J-29-20 OMe J-29-20 OEt J-29-20 OPr J-29-20 O-i-Pr J-29-20 O-n-Bu J-29-20 O-t-Bu J-29-20 NMe₂ J-29-20 NEt₂ J-29-20 N(n-Pr)₂ J-29-20 1-piperdinyl J-29-20 1-pyrrolidinyl J-29-20 4-morpholinyl J-29-20 CH₃ J-29-21 CH₂Cl J-29-21 CH₂Br J-29-21 CH₂I J-29-21 OH J-29-21 OMe J-29-21 OEt J-29-21 OPr J-29-21 O-i-Pr J-29-21 O-n-Bu J-29-21 O-t-Bu J-29-21 NMe₂ J-29-21 NEt₂ J-29-21 N(n-Pr)₂ J-29-21 1-piperdinyl J-29-21 1-pyrrolidinyl J-29-21 4-morpholinyl J-29-21 CH₃ J-29-22 CH₂Cl J-29-22 CH₂Br J-29-22 CH₂I J-29-22 OH J-29-22 OMe J-29-22 OEt J-29-22 OPr J-29-22 O-i-Pr J-29-22 O-n-Bu J-29-22 O-t-Bu J-29-22 NMe₂ J-29-22 NEt₂ J-29-22 N(n-Pr)₂ J-29-22 1-piperdinyl J-29-22 1-pyrrolidinyl J-29-22 4-morpholinyl J-29-22 CH₃ J-29-23 CH₂Cl J-29-23 CH₂Br J-29-23 CH₂I J-29-23 OH J-29-23 OMe J-29-23 OEt J-29-23 OPr J-29-23 O-i-Pr J-29-23 O-n-Bu J-29-23 O-t-Bu J-29-23 NMe₂ J-29-23 NEt₂ J-29-23 N(n-Pr)₂ J-29-23 1-piperdinyl J-29-23 1-pyrrolidinyl J-29-23 4-morpholinyl J-29-23 CH₃ J-29-24 CH₂Cl J-29-24 CH₂Br J-29-24 CH₂I J-29-24 OH J-29-24 OMe J-29-24 OEt J-29-24 OPr J-29-24 O-i-Pr J-29-24 O-n-Bu J-29-24 O-t-Bu J-29-24 NMe₂ J-29-24 NEt₂ J-29-24 N(n-Pr)₂ J-29-24 1-piperdinyl J-29-24 1-pyrrolidinyl J-29-24 4-morpholinyl J-29-24 CH₃ J-29-25 CH₂Cl J-29-25 CH₂Br J-29-25 CH₂I J-29-25 OH J-29-25 OMe J-29-25 OEt J-29-25 OPr J-29-25 O-i-Pr J-29-25 O-n-Bu J-29-25 O-t-Bu J-29-25 NMe₂ J-29-25 NEt₂ J-29-25 N(n-Pr)₂ J-29-25 1-piperdinyl J-29-25 1-pyrrolidinyl J-29-25 4-morpholinyl J-29-25 CH₃ J-29-26 CH₂Cl J-29-26 CH₂Br J-29-26 CH₂I J-29-26 OH J-29-26 OMe J-29-26 OEt J-29-26 OPr J-29-26 O-i-Pr J-29-26 O-n-Bu J-29-26 O-t-Bu J-29-26 NMe₂ J-29-26 NEt₂ J-29-26 N(n-Pr)₂ J-29-26 1-piperdinyl J-29-26 1-pyrrolidinyl J-29-26 4-morpholinyl J-29-26 CH₃ J-29-27 CH₂Cl J-29-27 CH₂Br J-29-27 CH₂I J-29-27 OH J-29-27 OMe J-29-27 OEt J-29-27 OPr J-29-27 O-i-Pr J-29-27 O-n-Bu J-29-27 O-t-Bu J-29-27 NMe₂ J-29-27 NEt₂ J-29-27 N(n-Pr)₂ J-29-27 1-piperdinyl J-29-27 1-pyrrolidinyl J-29-27 4-morpholinyl J-29-27 CH₃ J-29-28 CH₂Cl J-29-28 CH₂Br J-29-28 CH₂I J-29-28 OH J-29-28 OMe J-29-28 OEt J-29-28 OPr J-29-28 O-i-Pr J-29-28 O-n-Bu J-29-28 O-t-Bu J-29-28 NMe₂ J-29-28 NEt₂ J-29-28 N(n-Pr)₂ J-29-28 1-piperdinyl J-29-28 1-pyrrolidinyl J-29-28 4-morpholinyl J-29-28 CH₃ J-29-29 CH₂Cl J-29-29 CH₂Br J-29-29 CH₂I J-29-29 OH J-29-29 OMe J-29-29 OEt J-29-29 OPr J-29-29 O-i-Pr J-29-29 O-n-Bu J-29-29 O-t-Bu J-29-29 NMe₂ J-29-29 NEt₂ J-29-29 N(n-Pr)₂ J-29-29 1-piperdinyl J-29-29 1-pyrrolidinyl J-29-29 4-morpholinyl J-29-29 CH₃ J-29-30 CH₂Cl J-29-30 CH₂Br J-29-30 CH₂I J-29-30 OH J-29-30 OMe J-29-30 OEt J-29-30 OPr J-29-30 O-i-Pr J-29-30 O-n-Bu J-29-30 O-t-Bu J-29-30 NMe₂ J-29-30 NEt₂ J-29-30 N(n-Pr)₂ J-29-30 1-piperdinyl J-29-30 1-pyrrolidinyl J-29-30 4-morpholinyl J-29-30 CH₃ J-29-31 CH₂Cl J-29-31 CH₂Br J-29-31 CH₂I J-29-31 OH J-29-31 OMe J-29-31 OEt J-29-31 OPr J-29-31 O-i-Pr J-29-31 O-n-Bu J-29-31 O-t-Bu J-29-31 NMe₂ J-29-31 NEt₂ J-29-31 N(n-Pr)₂ J-29-31 1-piperdinyl J-29-31 1-pyrrolidinyl J-29-31 4-morpholinyl J-29-31 CH₃ J-29-32 CH₂Cl J-29-32 CH₂Br J-29-32 CH₂I J-29-32 OH J-29-32 OMe J-29-32 OEt J-29-32 OPr J-29-32 O-i-Pr J-29-32 O-n-Bu J-29-32 O-t-Bu J-29-32 NMe₂ J-29-32 NEt₂ J-29-32 N(n-Pr)₂ J-29-32 1-piperdinyl J-29-32 1-pyrrolidinyl J-29-32 4-morpholinyl J-29-32 CH₃ J-29-33 CH₂Cl J-29-33 CH₂Br J-29-33 CH₂I J-29-33 OH J-29-33 OMe J-29-33 OEt J-29-33 OPr J-29-33 O-i-Pr J-29-33 O-n-Bu J-29-33 O-t-Bu J-29-33 NMe₂ J-29-33 NEt₂ J-29-33 N(n-Pr)₂ J-29-33 1-piperdinyl J-29-33 1-pyrrolidinyl J-29-33 4-morpholinyl J-29-33 CH₃ J-29-34 CH₂Cl J-29-34 CH₂Br J-29-34 CH₂I J-29-34 OH J-29-34 OMe J-29-34 OEt J-29-34 OPr J-29-34 O-i-Pr J-29-34 O-n-Bu J-29-34 O-t-Bu J-29-34 NMe₂ J-29-34 NEt₂ J-29-34 N(n-Pr)₂ J-29-34 1-piperdinyl J-29-34 1-pyrrolidinyl J-29-34 4-morpholinyl J-29-34 CH₃ J-29-35 CH₂Cl J-29-35 CH₂Br J-29-35 CH₂I J-29-35 OH J-29-35 OMe J-29-35 OEt J-29-35 OPr J-29-35 O-i-Pr J-29-35 O-n-Bu J-29-35 O-t-Bu J-29-35 NMe₂ J-29-35 NEt₂ J-29-35 N(n-Pr)₂ J-29-35 1-piperdinyl J-29-35 1-pyrrolidinyl J-29-35 4-morpholinyl J-29-35 CH₃ J-29-36 CH₂Cl J-29-36 CH₂Br J-29-36 CH₂I J-29-36 OH J-29-36 OMe J-29-36 OEt J-29-36 OPr J-29-36 O-i-Pr J-29-36 O-n-Bu J-29-36 O-t-Bu J-29-36 NMe₂ J-29-36 NEt₂ J-29-36 N(n-Pr)₂ J-29-36 1-piperdinyl J-29-36 1-pyrrolidinyl J-29-36 4-morpholinyl J-29-36 CH₃ J-29-37 CH₂Cl J-29-37 CH₂Br J-29-37 CH₂I J-29-37 OH J-29-37 OMe J-29-37 OEt J-29-37 OPr J-29-37 O-i-Pr J-29-37 O-n-Bu J-29-37 O-t-Bu J-29-37 NMe₂ J-29-37 NEt₂ J-29-37 N(n-Pr)₂ J-29-37 1-piperdinyl J-29-37 1-pyrrolidinyl J-29-37 4-morpholinyl J-29-37 CH₃ J-29-38 CH₂Cl J-29-38 CH₂Br J-29-38 CH₂I J-29-38 OH J-29-38 OMe J-29-38 OEt J-29-38 OPr J-29-38 O-i-Pr J-29-38 O-n-Bu J-29-38 O-t-Bu J-29-38 NMe₂ J-29-38 NEt₂ J-29-38 N(n-Pr)₂ J-29-38 1-piperdinyl J-29-38 1-pyrrolidinyl J-29-38 4-morpholinyl J-29-38 CH₃ J-29-39 CH₂Cl J-29-39 CH₂Br J-29-39 CH₂I J-29-39 OH J-29-39 OMe J-29-39 OEt J-29-39 OPr J-29-39 O-i-Pr J-29-39 O-n-Bu J-29-39 O-t-Bu J-29-39 NMe₂ J-29-39 NEt₂ J-29-39 N(n-Pr)₂ J-29-39 1-piperdinyl J-29-39 1-pyrrolidinyl J-29-39 4-morpholinyl J-29-39 CH₃ J-29-40 CH₂Cl J-29-40 CH₂Br J-29-40 CH₂I J-29-40 OH J-29-40 OMe J-29-40 OEt J-29-40 OPr J-29-40 O-i-Pr J-29-40 O-n-Bu J-29-40 O-t-Bu J-29-40 NMe₂ J-29-40 NEt₂ J-29-40 N(n-Pr)₂ J-29-40 1-piperdinyl J-29-40 1-pyrrolidinyl J-29-40 4-morpholinyl J-29-40 CH₃ J-29-41 CH₂Cl J-29-41 CH₂Br J-29-41 CH₂I J-29-41 OH J-29-41 OMe J-29-41 OEt J-29-41 OPr J-29-41 O-i-Pr J-29-41 O-n-Bu J-29-41 O-t-Bu J-29-41 NMe₂ J-29-41 NEt₂ J-29-41 N(n-Pr)₂ J-29-41 1-piperdinyl J-29-41 1-pyrrolidinyl J-29-41 4-morpholinyl J-29-41 CH₃ J-29-42 CH₂Cl J-29-42 CH₂Br J-29-42 CH₂I J-29-42 OH J-29-42 OMe J-29-42 OEt J-29-42 OPr J-29-42 O-i-Pr J-29-42 O-n-Bu J-29-42 O-t-Bu J-29-42 NMe₂ J-29-42 NEt₂ J-29-42 N(n-Pr)₂ J-29-42 1-piperdinyl J-29-42 1-pyrrolidinyl J-29-42 4-morpholinyl J-29-42 CH₃ J-29-43 CH₂Cl J-29-43 CH₂Br J-29-43 CH₂I J-29-43 OH J-29-43 OMe J-29-43 OEt J-29-43 OPr J-29-43 O-i-Pr J-29-43 O-n-Bu J-29-43 O-t-Bu J-29-43 NMe₂ J-29-43 NEt₂ J-29-43 N(n-Pr)₂ J-29-43 1-piperdinyl J-29-43 1-pyrrolidinyl J-29-43 4-morpholinyl J-29-43 CH₃ J-29-44 CH₂Cl J-29-44 CH₂Br J-29-44 CH₂I J-29-44 OH J-29-44 OMe J-29-44 OEt J-29-44 OPr J-29-44 O-i-Pr J-29-44 O-n-Bu J-29-44 O-t-Bu J-29-44 NMe₂ J-29-44 NEt₂ J-29-44 N(n-Pr)₂ J-29-44 1-piperdinyl J-29-44 1-pyrrolidinyl J-29-44 4-morpholinyl J-29-44 CH₃ J-29-45 CH₂Cl J-29-45 CH₂Br J-29-45 CH₂I J-29-45 OH J-29-45 OMe J-29-45 OEt J-29-45 OPr J-29-45 O-i-Pr J-29-45 O-n-Bu J-29-45 O-t-Bu J-29-45 NMe₂ J-29-45 NEt₂ J-29-45 N(n-Pr)₂ J-29-45 1-piperdinyl J-29-45 1-pyrrolidinyl J-29-45 4-morpholinyl J-29-45 CH₃ J-29-46 CH₂Cl J-29-46 CH₂Br J-29-46 CH₂I J-29-46 OH J-29-46 OMe J-29-46 OEt J-29-46 OPr J-29-46 O-i-Pr J-29-46 O-n-Bu J-29-46 O-t-Bu J-29-46 NMe₂ J-29-46 NEt₂ J-29-46 N(n-Pr)₂ J-29-46 1-piperdinyl J-29-46 1-pyrrolidinyl J-29-46 4-morpholinyl J-29-46 CH₃ J-29-47 CH₂Cl J-29-47 CH₂Br J-29-47 CH₂I J-29-47 OH J-29-47 OMe J-29-47 OEt J-29-47 OPr J-29-47 O-i-Pr J-29-47 O-n-Bu J-29-47 O-t-Bu J-29-47 NMe₂ J-29-47 NEt₂ J-29-47 N(n-Pr)₂ J-29-47 1-piperdinyl J-29-47 1-pyrrolidinyl J-29-47 4-morpholinyl J-29-47 CH₃ J-29-48 CH₂Cl J-29-48 CH₂Br J-29-48 CH₂I J-29-48 OH J-29-48 OMe J-29-48 OEt J-29-48 OPr J-29-48 O-i-Pr J-29-48 O-n-Bu J-29-48 O-t-Bu J-29-48 NMe₂ J-29-48 NEt₂ J-29-48 N(n-Pr)₂ J-29-48 1-piperdinyl J-29-48 1-pyrrolidinyl J-29-48 4-morpholinyl J-29-48 CH₃ J-29-49 CH₂Cl J-29-49 CH₂Br J-29-49 CH₂I J-29-49 OH J-29-49 OMe J-29-49 OEt J-29-49 OPr J-29-49 O-i-Pr J-29-49 O-n-Bu J-29-49 O-t-Bu J-29-49 NMe₂ J-29-49 NEt₂ J-29-49 N(n-Pr)₂ J-29-49 1-piperdinyl J-29-49 1-pyrrolidinyl J-29-49 4-morpholinyl J-29-49 CH₃ J-29-50 CH₂Cl J-29-50 CH₂Br J-29-50 CH₂I J-29-50 OH J-29-50 OMe J-29-50 OEt J-29-50 OPr J-29-50 O-i-Pr J-29-50 O-n-Bu J-29-50 O-t-Bu J-29-50 NMe₂ J-29-50 NEt₂ J-29-50 N(n-Pr)₂ J-29-50 1-piperdinyl J-29-50 1-pyrrolidinyl J-29-50 4-morpholinyl J-29-50 CH₃ J-29-51 CH₂Cl J-29-51 CH₂Br J-29-51 CH₂I J-29-51 OH J-29-51 OMe J-29-51 OEt J-29-51 OPr J-29-51 O-i-Pr J-29-51 O-n-Bu J-29-51 O-t-Bu J-29-51 NMe₂ J-29-51 NEt₂ J-29-51 N(n-Pr)₂ J-29-51 1-piperdinyl J-29-51 1-pyrrolidinyl J-29-51 4-morpholinyl J-29-51 CH₃ J-29-52 CH₂Cl J-29-52 CH₂Br J-29-52 CH₂I J-29-52 OH J-29-52 OMe J-29-52 OEt J-29-52 OPr J-29-52 O-i-Pr J-29-52 O-n-Bu J-29-52 O-t-Bu J-29-52 NMe₂ J-29-52 NEt₂ J-29-52 N(n-Pr)₂ J-29-52 1-piperdinyl J-29-52 1-pyrrolidinyl J-29-52 4-morpholinyl J-29-52 CH₃ J-29-53 CH₂Cl J-29-53 CH₂Br J-29-53 CH₂I J-29-53 OH J-29-53 OMe J-29-53 OEt J-29-53 OPr J-29-53 O-i-Pr J-29-53 O-n-Bu J-29-53 O-t-Bu J-29-53 NMe₂ J-29-53 NEt₂ J-29-53 N(n-Pr)₂ J-29-53 1-piperdinyl J-29-53 1-pyrrolidinyl J-29-53 4-morpholinyl J-29-53 CH₃ J-29-54 CH₂Cl J-29-54 CH₂Br J-29-54 CH₂I J-29-54 OH J-29-54 OMe J-29-54 OEt J-29-54 OPr J-29-54 O-i-Pr J-29-54 O-n-Bu J-29-54 O-t-Bu J-29-54 NMe₂ J-29-54 NEt₂ J-29-54 N(n-Pr)₂ J-29-54 1-piperdinyl J-29-54 1-pyrrolidinyl J-29-54 4-morpholinyl J-29-54 CH₃ J-29-55 CH₂Cl J-29-55 CH₂Br J-29-55 CH₂I J-29-55 OH J-29-55 OMe J-29-55 OEt J-29-55 OPr J-29-55 O-i-Pr J-29-55 O-n-Bu J-29-55 O-t-Bu J-29-55 NMe₂ J-29-55 NEt₂ J-29-55 N(n-Pr)₂ J-29-55 1-piperdinyl J-29-55 1-pyrrolidinyl J-29-55 4-morpholinyl J-29-55 CH₃ J-29-56 CH₂Cl J-29-56 CH₂Br J-29-56 CH₂I J-29-56 OH J-29-56 OMe J-29-56 OEt J-29-56 OPr J-29-56 O-i-Pr J-29-56 O-n-Bu J-29-56 O-t-Bu J-29-56 NMe₂ J-29-56 NEt₂ J-29-56 N(n-Pr)₂ J-29-56 1-piperdinyl J-29-56 1-pyrrolidinyl J-29-56 4-morpholinyl J-29-56 CH₃ J-29-57 CH₂Cl J-29-57 CH₂Br J-29-57 CH₂I J-29-57 OH J-29-57 OMe J-29-57 OEt J-29-57 OPr J-29-57 O-i-Pr J-29-57 O-n-Bu J-29-57 O-t-Bu J-29-57 NMe₂ J-29-57 NEt₂ J-29-57 N(n-Pr)₂ J-29-57 1-piperdinyl J-29-57 1-pyrrolidinyl J-29-57 4-morpholinyl J-29-57 CH₃ J-29-58 CH₂Cl J-29-58 CH₂Br J-29-58 CH₂I J-29-58 OH J-29-58 OMe J-29-58 OEt J-29-58 OPr J-29-58 O-i-Pr J-29-58 O-n-Bu J-29-58 O-t-Bu J-29-58 NMe₂ J-29-58 NEt₂ J-29-58 N(n-Pr)₂ J-29-58 1-piperdinyl J-29-58 1-pyrrolidinyl J-29-58 4-morpholinyl J-29-58

Table 8 above identifies particular compounds comprising a J¹ group selected from J-29-1 through J-29-58. As many J-29-1 through J-29-58 include a chiral center, these J¹ groups are illustrated in a particular enantiomeric configuration, which in some instances may provide the greatest fungicidal activity for compounds of Formula 1. One skilled in the art immediately recognizes the antipode (i.e. opposite enantiomer) for each of the compounds listed, and furthermore understands that the enantiomers can be present as pure enantiomers or in mixtures enriched in one enantiomer or in racemic mixtures.

Formulation/Utility

A compound of Formula 1 of this invention will generally be used as a fungicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serve as a carrier. Compounds within the scope of exclusion of proviso (a) of Formula 1 can also be used. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature.

Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion and suspo-emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.

The general types of solid compositions are dusts, powders, granules, pellets, pills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible (“wettable”) or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or “overcoated”). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High-strength compositions are primarily used as intermediates for further formulation.

Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water. Spray volumes can range from about from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto vegetable seeds as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake.

The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.

Weight Percent Active Ingredient Diluent Surfactant Water-Dispersible and 0.001-90    0-99.999 0-15 Water-soluble Granules, Tablets and Powders. Oil Dispersions,    1-50 40-99 0-50 Suspensions, Emulsions, Solutions (including Emulsifiable Concentrates) Dusts    1-25 70-99 0-5  Granules and Pellets 0.001-99    5-99.999 0-15 High Strength Compositions   90-99  0-10 0-2 

Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books. Caldwell, N.J.

Liquid diluents include, for example, water, N,N-dimethylalkanamides (e.g., N,N-dimethylformamide), limonene, dimethyl sulfoxide, N-alkylpyrrolidones (e.g., N-methylpyrrolidinone), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, triacetin, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters and γ-butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C₆-C₂₂), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents arm described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950.

The solid and liquid compositions of the present invention often include one or more surfactants. Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar-derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.

Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as N,N-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts.

Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as N-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.

Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon's Emulsifiers and Detergents, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987.

Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids. Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes (e.g., Rhodorsil®) 416)), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions (e.g., Pro-Ized® Colorant Red)), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.

Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm. Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. Pat. No. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and, usually, grinding as in a hammer mill or fluid-energy mill. Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, “Agglomeration”, Chemical Engineering, Dec. 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. Pat. No. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. Pat. No. 4,144,050, U.S. Pat. No. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. Pat. No. 5,180,587, U.S. Pat. No. 5,232,701 and U.S. Pat. No. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. Pat. No. 3,299,566.

For further information regarding the art of formulation, see T. S. Woods, “The Formulator's Toolbox—Product Forms for Modern Agriculture” in Pesticide Chemistry and Bioscience, The Food-Environment Challenge, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry. The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also U.S. Pat. No. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. Pat. No. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. Pat. No. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81-96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, UK, 2000.

In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Table A.

EXAMPLE A High Strength Concentrate

Compound 1 98.5% silica aerogel 0.5% synthetic amorphous fine silica 1.0%.

EXAMPLE B Wettable Powder

Compound 2 65.0% dodecylphenol polyethylene glycol ether 2.0% sodium ligninsulfonate 4.0% sodium silicoaluminate 6.0% montmorillonite (calcined) 23.0%.

EXAMPLE C Granule

Compound 16 10.0% attapulgite granules (low volatile matter, 90.0%. 0.71/0.30 mm; U.S.S. No. 25-50 sieves)

EXAMPLE D Aqueous Suspension

Compound 37 25.0% hydrated attapulgite 3.0% crude calcium ligninsulfonate 10.0% sodium dihydrogen phosphate 0.5% water 61.5%.

EXAMPLE E Extruded Pellet

Compound 107 25.0% anhydrous sodium sulfate 10.0% crude calcium ligninsulfonate 5.0% sodium alkylnaphthalenesulfonate 1.0% calcium/magnesium bentonite 59.0%.

EXAMPLE F Microemulsion

Compound 44 1.0% triacetine 30.0% C₈-C₁₀ alkylpolyglycoside 30.0% glyceryl monooleate 19.0% water 20.0%.

EXAMPLE G Emulsifiable Concentrate

Compound 1 10.0% C₈-C₁₀ fatty acid methyl ester 70.0% polyoxyethylene sorbitol hexoleate 20.0%.

The compounds of Formula 1 of this invention are useful as plant disease control agents. The present invention therefore further comprises a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof to be protected, or to the plant seed to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. Compounds within the scope of exclusion of proviso (a) of Formula 1 and fungicidal compositions containing them can also be used to control plant diseases in accordance with this invention. The compounds and/or compositions of this invention provide control of diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and Deuteromycete classes. They are effective in controlling a broad spectrum of plant diseases, particularly foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops. These pathogens include: Oomycetes, including Phytophthora diseases such as Phytophthora infestans, Phytophthora megasperma, Phytophthora parasitica, Phytophthora cinnamomi and Phytophthora capsici, Pythium diseases such as Pythium aphanidermatum, and diseases in the Peronosporaceae family such as Plasmopara viticola, Peronospora spp. (including Peronospora tabacina and Peronospora parasitica), Pseudoperonospora spp. (including Pseudoperonospora cubensis) and Bremia lactucae; Ascomycetes, including Alternaria diseases such as Altermaria solani and Alternaria brassicae, Guignardia diseases such as Guignardia bidwell, Venturia diseases such as Venturia inaequalis, Septoria diseases such as Septoria nodorum and Septoria tritici, powdery mildew diseases such as Erysiphe spp. (including Erysiphe graminis and Erysiphe polygoni), Uncinula necatur, Sphaerotheca fuligena and Podosphaera leucotricha, Pseudocercosporella herpotrichoides, Botrvtis diseases such as Botrvtis cinerea, Monilinia fructicola, Sclerotinia diseases such as Sclerotinia sclerotiorum. Magnaporthe grisea, Phomopsis viticola, Helminthosporium diseases such as Helminthosporium tritici repentis, Pyrenophora teres, anthracnose diseases such as Glomerella or Colletotrichum spp. (such as Colletotrichum graminicola and Colletotrichum orbiculare), and Gaeumannomyces graminis; Basidiomycetes, including rust diseases caused by Puccinia spp. (such as Puccinia recondita, Puccinia striiformis, Puccinia hordei, Puccinia graminis and Puccinia arachidis), Hemileia vastatrix and Phakopsora pachvrhizi; other pathogens including Rhizoctonia spp. (such as Rhizoctonia solani); Fusarium diseases such as Fusarium roseum, Fusarium graminearum and Fusarium oxysporum; Verticillium dahliae; Sclerotium rolfsii; Rynchosporium secalis; Cercosporidium personatum, Cercospora arachidicola and Cercospora beticola; and other genera and species closely related to these pathogens. In addition to their fungicidal activity, the compositions or combinations also have activity against bacteria such as Erwinia amylovora, Xanthomonas campestris, Pseudomonas syringae, and other related species. Of note is control provided of disease caused by the Ascomycete and Oomycete classes. Of particular note is control provided of disease caused by the Oomycete class.

Plant disease control is ordinarily accomplished by applying an effective amount of a compound of this invention either pre- or post-infection, to the portion of the plant to be protected such as the roots, stems, foliage, fruit, seeds, tubers or bulbs, or to the media (soil or sand) in which the plants to be protected are growing. The compounds can also be applied to seeds to protect the seeds and seedlings developing from the seeds. The compounds can also be applied through irrigation water to treat plants.

Rates of application for these compounds can be influenced by many factors of the environment and should be determined under actual use conditions. Foliage can normally be protected when treated at a rate of from less than about 1 g/ha to about 5,000 g/ha of active ingredient. Seed and seedlings can normally be protected when seed is treated at a rate of from about 0.1 to about 10 g per kilogram of seed.

Compounds of this invention can also be mixed with one or more other insecticides, fungicides, nematocides, bactericides, acaricides, growth regulators, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants or other biologically active compounds to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Examples of such agricultural protectants with which compounds of this invention can be formulated are: insecticides such as abamectin, acephate, acetamiprid, amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45), chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos, halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, trichlorfon and triflumuron; fungicides such as acibenzolar, aldimorph, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl, benodanil, benomyl, benthiavalicarb, benthiavalicarb-isopropyl, binapacryl, biphenyl, bitertanol, bixafen, blasticidin-S, Bordeaux mixture (tribasic copper sulfate), boscalid/nicobifen, bromuconazole, bupirimate, buthiobate, carboxin, carpropamid, captafol, captan, carbendazim, chloroneb, chlorothalonil, 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine, chlozolinate, clotrimazole, copper oxychloride, copper salts such as copper sulfate and copper hydroxide, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirimol, N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazol-4-carboxamide, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinocap, discostrobin, dithianon, dodemorph, dodine, econazole, edifenphos, enestroburin, epoxiconazole, etaconazole, ethaboxam, ethirimol, ethridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fencaramid, fenfuram, fenhexamide, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferfurazoate, ferimzone, fluazinam, fludioxonil, flumetover, flumorph, fluopicolide, fluopyram, fluoxastrobin, fluquinconazole, fluquinconazole, flusilazole, flusulfamide, flutolanil, flutriafol, folpet, fosetyl-aluminum, fuberidazole, furalaxyl, furametapyr, hexaconazole, hymexazole, guazatine, imazalil, imibenconazole, iminoctadine, iodicarb, ipconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isoprothiolane, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandipropamid, maneb, mapanipyrin, mefenoxam, mepronil, meptyldinocap, metalaxyl, metconazole, methasulfocarb, metiram, metominostrobin, mepanipyrim, metiram, metrafenone, miconazole, myclobutanil, naftifine, neo-asozin (ferric methanearsonate), nuarimol, octhilinone, ofurace, orysastrobin, oxadixyl, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, paclobutrazol, penconazole, pencycuron, penthiopyrad, perfurazoate, phosphonic acid, phthalide, picobenzamid, picoxystrobin, piperalin, polyoxin, probenazole, prochloraz, procymidone, propamocarb, propamocarb-hydrochloride, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pyraclostrobin, pryazophos, pyribencarb, pyrifenox, pyrimethanil, pyrifenox, pyrolnitrine, pyroquilon, quinconazole, quinoxyfen, quintozene, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, techrazene, tecloftalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolyfluanid, triadimefon, triadimenol, triarimol, triazoxide, tricyclazole, tridemorph, triflumizole, trimoprhamide tricyclazole, trifloxystrobin, triforine, triticonazole, uniconazole, validamycin, vinclozolin, zineb, ziram and zoxamide; nematocides such as aldicarb, aldoxycarb, fenamiphos, imicyafos and oxamyl; bactericides such as streptomycin; acaricides such as amitraz, chinomethionat, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, fenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridaben and tebufenpyrad; and biological agents such as Bacillus thuringiensis, Bacillus thuringiensis delta endotoxin, baculovirus, and entomopathogenic bacteria, virus and fungi. Descriptions of various commercially available compounds listed above may be found in The Pesticide Manual, Thirteenth Edition, C. D. S. Thomlin, ed., British Crop Protection Council, 2003. For embodiments where one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) to the compound of Formula 1 is typically between about 1:100 and about 3000:1. Of note are weight ratios between about 1:30 and about 300:1 (for example ratios between about 1:1 and about 30:1). It will be evident that including these additional components may expand the spectrum of diseases controlled beyond the spectrum controlled by the compound of Formula 1 alone.

In one mixture embodiment, granules of a solid composition comprising a compound of Formula 1 is mixed with granules of a solid composition comprising another agricultural protectant. These granule mixtures can be in accordance with the general granule mixture disclosure of PCT Patent Publication WO 94/24861 or more preferably the homogenous granule mixture teaching of U.S. Pat. No. 6,022,552.

Of note are combinations (e.g., in the form of compositions) of a compound of Formula 1 with at least one other fungicide. Of particular note are such combinations where the other fungicide has different site of action from the compound of Formula 1. In certain instances, combinations with other fungicides having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Of particular note are compositions which in addition to compound of Formula 1 include at least one compound selected from the group consisting of (1) alkylenebis(dithiocarbamate) fungicides; (2) cymoxanil; (3) phenylamide fungicides; (4) pyrimidinone fungicides; (5) chlorothalonil; (6) carboxamides acting at complex II of the fungal mitochondrial respiratory electron transfer site; (7) quinoxyfen; (8) metrafenone; (9) cyflufenamid; (10) cyprodinil; (11) copper compounds; (12) phthalimide fungicides; (13) fosetyl-aluminum; (14) benzimidazole fungicides; (15) cyazofamid; (16) fluazinam; (17) iprovalicarb; (18) propamocarb; (19) validomycin; (20) dichlorophenyl dicarboximide fungicides; (21) zoxamide; (22) fluopicolide; (23) mandipropamid; (24) carboxylic acid amides acting on phospholipid biosynthesis and cell wall deposition; (25) dimethomorph; (26) non-DMI sterol biosynthesis inhibitors; (27) inhibitors of demethylase in sterol biosynthesis; (28) bc₁ complex fungicides; and salts of compounds of (1) through (28).

Further descriptions of classes of fungicidal compounds are provided below.

Pyrimidinone fungicides (group (4)) include compounds of Formula A1

wherein M forms a fused phenyl, thiophene or pyridine ring; R¹¹ is C₁-C₆ alkyl; R¹² is C₁-C₆ alkyl or C₁-C₆ alkoxy; R¹³ is halogen; and R¹⁴ is hydrogen or halogen.

Pyrimidinone fungicides are described in PCT Patent Application Publication WO 94/26722 and U.S. Pat. Nos. 6,066,638, 6,245,770, 6,262,058 and 6,277,858. Of note are pyrimidinone fungicides selected from the group: 6-bromo-3-propyl-2-propyloxy-4(3H)-quinazolinone, 6,8-diiodo-3-propyl-2-propyloxy-4(31H)-quinazolinone, 6-iodo-3-propyl-2-propyloxy-4(3H)-quinazolinone (proquinazid), 6-chloro-2-propoxy-3-propylthieno[2,3-d]pyrimidin-4(3H)-one, 6-bromo-2-propoxy-3-propylthieno[2,3-d]pyrimidin-4(3H)-one, 7-bromo-2-propoxy-3-propylthieno[3,2-d]pyrimidin-4(3H)-one, 6-bromo-2-propoxy-3-propylpyrido[2,3-d]pyrimidin-4(3H)-one, 6,7-dibromo-2-propoxy-3-propylthieno[3,2-d]pyrimidin-4(3H)-one, and 3-(cyclopropylmethyl)-6-iodo-2-(propylthio)pyrido-[2,3-d]pyrimidin-4(3H)-one.

Sterol biosynthesis inhibitors (group (27)) control fungi by inhibiting enzymes in the sterol biosynthesis pathway. Demethylase-inhibiting fungicides have a common site of action within the fungal sterol biosynthesis pathway, involving inhibition of demethylation at position 14 of lanosterol or 24-methylene dihydrolanosterol, which are precursors to sterols in fungi. Compounds acting at this site are often referred to as demethylase inhibitors, DMI fungicides, or DMIs. The demethylase enzyme is sometimes referred to by other names in the biochemical literature, including cytochrome P-450 (14DM). The demethylase enzyme is described in, for example, J. Biol. Chem. 1992, 267, 13175-79 and references cited therein. DMI fungicides are divided between several chemical classes: azoles (including triazoles and imidazoles), pyrimidines, piperazines and pyridines. The triazoles include azaconazole, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole and uniconazole. The imidazoles include clotrimazole, econazole, imazalil, isoconazole, miconazole, oxpoconazole, prochloraz and triflumizole. The pyrimidines include fenarimol, nuarimol and triarimol. The piperazines include triforine. The pyridines include buthiobate and pyrifenox. Biochemical investigations have shown that all of the above mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in Modern Selective Fungicides—Properties, Applications and Mechanisms of Action, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205-258.

bc₁ Complex Fungicides (group 28) have a fungicidal mode of action which inhibits the bc₁ complex in the mitochondrial respiration chain. The bc₁ complex is sometimes referred to by other names in the biochemical literature, including complex III of the electron transfer chain, and ubihydroquinone:cytochrome c oxidoreductase. This complex is uniquely identified by Enzyme Commission number EC1.10.2.2. The bc₁ complex is described in, for example, J. Biol. Chem. 1989, 264, 14543-48; Methods Enzymol. 1986, 126, 253-71; and references cited therein. Strobilurin fungicides such as azoxystrobin, dimoxystrobin, enestroburin (SYP-Z071), fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin and trifloxystrobin are known to have this mode of action (H. Sauter et al., Angew. Chem. Int. Ed. 1999, 38, 1328-1349). Other fungicidal compounds that inhibit the bc₁ complex in the mitochondrial respiration chain include famoxadone and fenamidone.

Alkylenebis(dithiocarbamate) fungicides (group (1)) include compounds such as mancozeb, maneb, propineb and zineb. Phenylamide fungicides (group (3)) include compounds such as metalaxyl, benalaxyl, furalaxyl and oxadixyl. Carboxamides (group (6)) include compounds such as boscalid, carboxin, fenfuram, flutolanil, furametpyr, mepronil, oxycarboxin, thifluzamide, penthiopyrad and N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (PCT Patent Publication WO 2003/010149), and are known to inhibit mitochondrial function by disrupting complex II (succinate dehydrogenase) in the respiratory electron transport chain. Copper compounds (group (11)) include compounds such as copper oxychloride, copper sulfate and copper hydroxide, including compositions such as Bordeaux mixture (tribasic copper sulfate). Phthalimide fungicides (group (12)) include compounds such as folpet and captan. Benzimidazole fungicides (group (14)) include benomyl and carbendazim. Dichlorophenyl dicarboximide fungicides (group (20)) include chlozolinate, dichlozoline, iprodione, isovaledione, myclozolin, procymidone and vinclozolin.

Non-DMI sterol biosynthesis inhibitors (group (26)) include morpholine and piperidine fungicides. The morpholines and piperidines are sterol biosynthesis inhibitors that have been shown to inhibit steps in the sterol biosynthesis pathway at a point later than the inhibitions achieved by the DMI sterol biosynthesis (group (27)). The morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. The piperidines include fenpropidin.

Of note are these methods where plant diseases caused by Oomycete fungal plant pathogens are controlled.

The discussion above relating to the use of compounds of Formula 1 in compositions (e.g., certain compositions comprising surfactants, solid diluents, liquid diluents and/or biologically active compounds) and in methods for controlling plant diseases (e.g., controlling plant diseases caused by Oomycete fungal plant pathogens) also applies to compounds within the scope of exclusion of proviso (a) of Formula 1.

The following Tests demonstrate the control efficacy of compounds of this invention on specific pathogens. The pathogen control protection afforded by the compounds is not limited, however, to these species. See Index Tables A for compound descriptions. The stereocenters labeled as “R” (rectus) and “S” (sinister) are based on the Cahn-Ingold-Prelog system as used by Chemical Abstracts; a stereocenter label followed by an asterisks “**” means the stereochemical description is relative to other stereocenters, and the compound is racemic. The abbreviation “Ex.” stands for “Example” and is followed by a number indicating in which example the compound is prepared. Index Table A lists the molecular weight of the highest isotopic abundance parent ion (M+1) formed by addition of H⁺(molecular weight of 1) to the molecule, observed by mass spectrometry using atmospheric pressure chemical ionization (AP⁺). Chiral separation of Compound 1 into Compounds 3 and 4 was accomplished using a preparative CHIRALPAK® AD-RH column (Chiral Technologies, Inc., West Chester, Pa., U.S.A.) containing silica gel coated with amylose-tris(3,5-dimethylphenyl carbamate) and eluted with a water-methanol gradient. Specific rotation ([α]_(D)) was measured in ethanol solution at 25° C. using a 100-mm path cell.

INDEX TABLE A

G is as defined in Exhibit 2; R^(3a) in G is H. L groups are defined as illustrated below.

L-1

L-2

L-3

L-4

L-5

L-6

L-7

L-8

L-9

L-10

L-11

L-12

L-13

L-14

L-15

L-16

L-17

L-18

L-19

L-20

L-21

L-22

L-23

L-24

L-25

L-26

L-27

L-28

L-29

L-30

L-31

L-32

L-33 AP⁺ Cmpd. L X G Z₁—J (M + 1) 1 (Ex. 1) L-1 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 504 2 (Ex. 2) L-1 X¹ G-1 5-phenyl-3-isoxazolyl 502 3 (Ex. 12) L-1 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl [Note 1] 504   4 L-1 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl [Note 2] 504   5 L-1 X¹ G-1 5,6-dihydro-6-phenyl-4H-1,2-oxazin-3-yl 518 6 (Ex. 4) L-1 X¹ G-1 4,5-dihydro-3-phenyl-5-isoxazolyl 504 7 (Ex. 3) L-1 X¹ G-1 (5S)-4,5-dihydro-1-methyl-5-phenyl-1H-imidazol-2-yl 517 8 (Ex. 5) L-1 X¹ G-1 5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl 538   9 L-1 X¹ G-1 5-(4-chlorophenyl)-4,5-dihydro-3-isoxazolyl 538  10 L-1 X¹ G-1 4,5-dihydro-5-(4-methylphenyl)-3-isoxazolyl 518  11 L-1 X¹ G-1 (4R**,5R**)-4,5-dihydro-4-methyl-5-phenyl-3-isoxazolyl 518  12 L-1 X¹ G-27 3-phenyl-1H-pyrazol-1-yl 483  13 L-1 X¹ G-1 4-phenyl-2-oxazolidinyl 506  14 L-1 X¹ G-1 3-acetyl-4-phenyl-2-oxazolidinyl 548 15 (Ex. 8) L-1 X¹ G-1 4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl 518 16 (Ex. 8) L-1 X¹ G-1 3a,4,5,9b-tetrahydronaphth[2,1-d]isoxazol-3-yl 530  17 L-1 X¹ G-1 5-(3-chlorophenyl)-4,5-dihydro-3-isoxazolyl 538 18 (Ex. 8) L-1 X¹ G-1 4,5-dihydro-5-(4-methoxyphenyl)-3-isoxazolyl 534 19 (Ex. 1) L-2 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 518  20 L-3 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 504  21 L-4 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 491 22 (Ex. 1) L-5 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 558  23 L-6 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 460  24 L-1 X¹ G-1 4,5-dihydro-5-(phenylmethyl)-3-isoxazolyl 518  25 L-1 X¹ G-1 (4R**,5S**)-4,5-dihydro-4-methyl-5-phenyl-3-isoxazolyl 518  26 L-1 X¹ G-1 4-biphenyl 511  27 L-1 X¹ G-1 4,5-dihydro-5-(3-methylbutyl)-3-isoxazolyl 498  28 L-1 X¹ G-1 4,5-dihydro-5-(2,2-dimethylpropyl)-3-isoxazolyl 498  29 L-1 X¹ G-1 5,6-dihydro-6-methyl-6-phenyl-4H-1,2-oxazin-3-yl 532  30 L-1 X¹ G-1 3-phenyl-5-isoxazolyl 502  31 L-1 X¹ G-1 4,5-dihydro-4-phenyl-2-oxazolyl 504  32 L-1 X¹ G-1 4,5-dihydro-1-(phenylmethyl)-1H-imidazol-2-yl 517  33 L-1 X¹ G-27 3-biphenyl 494  34 L-1 X¹ G-27 6-phenyl-2-pyridyl 495  35 L-1 X¹ G-1 4,5-dihydro-5-phenyl-5-(trifluoromethyl)-3-isoxazolyl 572  36 L-1 X¹ G-1 5-[3-(trifluoromethyl)phenyl]-3-isoxazolyl 570 37 (Ex. 8) L-1 X¹ G-1

544  38 L-1 X¹ G-1 5-(4-biphenyl)-3-isoxazolyl 578  39 L-1 X¹ G-1 4,5-dihydro-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-3- 640 isoxazolyl  40 L-1 X¹ G-1 5-phenyl-1,3,4-oxadiazol-2-yl 503  41 L-1 X¹ G-1 4,5-dihydro-5-phenyl-2-oxazolyl 504  42 L-1 X¹ G-1 5-phenyl-2-oxazolyl 502  43 L-1 X¹ G-1 2-benzothiazolyl 492 44 (Ex. 8) L-1 X¹ G-1

530  45 L-1 X¹ G-1

511  46 L-1 X¹ G-1 (4R)-4,5-dihydro-4-phenyl-2-oxazolyl 504  47 L-1 X¹ G-1 (5S)-4,5-dihydro-5-phenyl-2-oxazolyl 504  48 L-1 X¹ G-1 5,6-dihydro-6-phenyl-4H-1,3-oxazin-2-yl 518  49 L-1 X¹ G-1 (4S)-4,5-dihydro-4-phenyl-2-oxazolyl 504  50 L-1 X¹ G-1 (5R)-4,5-dihydro-5-phenyl-2-oxazolyl 504  51 L-1 X¹ G-1

516  52 L-1 X¹ G-1 2-benzoxazolyl 475  53 L-1 X¹ G-1 5,6-dihydro-5-phenyl-4H-1,3-oxazin-2-yl 518  54 L-1 X¹ G-1 5,6-dihydro-4-phenyl-4H-1,3-oxazin-2-yl 518  55 L-1 X¹ G-1 4,5-dihydro-5-(methoxycarbonyl)-3-isoxazolyl 486  56 L-1 X¹ G-1 4,5-dihydro-5-(1,1-dimethylethyl)-3-isoxazolyl 484  57 L-1 X¹ G-1 4,5-dihydro-5-(2-bromoethyl)-3-isoxazolyl 534  58 L-1 X¹ G-1 2-benzimidazolyl 475  59 L-1 X¹ G-1 5-(2-fluorophenyl)-3-isoxazolyl 520  60 L-1 X¹ G-1 5-(2-trifluoromethylphenyl)-3-isoxazolyl 570  61 L-1 X¹ G-1 2-naphthalenyl 485  62 L-1 X¹ G-1 phenyl 435  63 L-7 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 518  64 L-1 X¹ G-1 5-(2,4-difluorophenyl)-3-isoxazolyl 538  65 L-1 X¹ G-1 1-phenyl-2-pyrrolidon-4-yl 518  66 L-1 X¹ G-1 4,5-dihydro-5-cyano-3-isoxazolyl 453  67 L-1 X¹ G-1

482  68 L-1 X¹ G-1 3-phenyl-1,2,4-oxadiazol-5-yl 503  69 L-15 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 532  70 L-16 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 478  71 L-17 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 500  72 L-1 X¹ G-1 4-phenoxyphenyl 577  73 L-1 X¹ G-1 1-naphthalenyl 485  74 L-1 X¹ G-1 3-biphenyl 511  75 L-1 X¹ G-1 3-phenoxyphenyl 527  76 L-1 X¹ G-1 1-phenylpyrazol-3-yl 501  77 L-1 X¹ G-1 1-(4-methylphenyl)-1,2,3-triazol-4-yl 516  78 L-1 X¹ G-1 1-phenylpyrazol-5-yl 501  79 L-1 X¹ G-1 4,5-dihydro-5-(2-fluorophenyl)-3-isoxazolyl 522  80 L-17 X¹ G-1 4,5-dihydro-5-(2-fluorophenyl)-3-isoxazolyl 518  81 L-1 X¹ G-1 5,6-dihydro-5-phenyl-6-methoxy-4H-1,2-oxazin-3-yl 548  82 L-1 X¹ G-1

518  83 L-1 X¹ G-1 5-phenyl-2-furanyl 501  84 L-1 X¹ G-1 2-phenyl-4-thiazoyl 518  85 L-1 X¹ G-1 5-phenyl-2-thienyl 517  86 L-1 X¹ G-1 3-(2,4-dichlorophenyl)-5-isoxazoyl 570  87 L-1 X¹ G-1 3-(3,4-dichlorophenyl)-5-isoxazoyl 570  88 L-1 X¹ G-1 4,5-dihydro-5-(naphthalen-2-yl)-3-isoxazolyl 554  89 L-18 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 462  90 L-19 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 468  91 L-1 X¹ G-1 4,5-dihydro-5-(4-t-butylphenyl)-3-isoxazolyl 560  92 L-1 X¹ G-1 (5R)-4,5-dihydro-5-phenyl-1H-imidazol-2-yl 503  93 L-8 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 450  94 L-9 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 478  95 L-1 X¹ G-1

536  96 L-1 X¹ G-1 4,5-dihydro-5-(4-fluorophenyl)-3-isoxazolyl 522  97 L-1 X¹ G-1 4,5-dihydro-5-(4-trifluoromethylphenyl)-3-isoxazolyl 572 98 (Ex. 9) L-1 X¹ G-1 4,5-dihydro-5-(2-pyridyl)-3-isoxazolyl 505  99 L-1 X¹ G-1

481 100 L-1 X¹ G-1 4,5-dihydro-5-isopropyl-5-phenyl-3-isoxazolyl 546 101 L-1 X¹ G-1 4,5-dilhydro-5-propyl-5-phenyl-3-isoxazolyl 546 102 (Ex. 1) L-1 X¹ G-1

562 103 L-1 X¹ G-1 4,5-dihydro-5-cyclopropyl-5-phenyl-3-isoxazolyl 544 104 L-1 X¹ G-1

572 105 L-1 X¹ G-1 4,5-dihydro-5-ethyl-5-phenyl-3-isoxazolyl 532 106 L-1 X¹ G-1 4,5-dihydro-5-(4-biphenyl)-3-isoxazolyl 580 107 (Ex. 10) L-10 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 524 108 L-1 X¹ G-1 (4R,5R)-4,5-dihydro-4,5-diphenyl-1H-imidazol-2-yl 579 109 L-1 X¹ G-1

550 110 L-1 X¹ G-1 4,5-dihydro-5-(4-hydroxyphenyl)-3-isoxazolyl 520 111 L-1 X¹ G-1 4,5-dihydro-5-(2-pyrazinyl)-3-isoxazolyl 506 112 L-1 X¹ G-1

643 113 L-1 X¹ G-1 4,5-dihydro-5-(4-acetoxyphenyl)-3-isoxazolyl 562 114 L-1 X¹ G-1 4,5-dihydro-5-(2-trifluoromethylphenyl)-3-isoxazolyl 572 115 L-1 X¹ G-1 4,5-dihydro-5-(3-trifluoromethylphenyl)-3-isoxazolyl 572 116 L-1 X¹ G-1 4,5-dihydro-5-(methoxycarbonylmethyl)-3-isoxazolyl 500 117 L-1 X¹ G-1 4,5-dihydro-5-(phenylsulfonyl)-3-isoxazolyl 568 118 L-1 X¹ G-1 (5R)-4,5-dihydro-1-methyl-5-phenyl-1H-imidazol-2-yl 517 119 L-1 X¹ G-1 (4S,5R)-4,5-dihydro-4,5-diphenyl-1H-imidazol-2-yl 579 120 L-1 X¹ G-1 4-chlorophenyl 469 121 L-1 X¹ G-1 2-chlorophenyl 469 122 L-1 X¹ G-1 4-(trifluoromethyl)phenyl 503 123 L-1 X¹ G-1 3-chlorophenyl 469 124 L-1 X¹ G-1 3-pyridyl 436 125 L-1 X¹ G-1 4,5-dihydro-5-(3,4-dihydroxyphenyl)-3-isoxazolyl 536 126 (Ex. 11) L-11 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 568 127 L-12 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 658 128 (Ex. 1) L-13 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 504 129 L-1 X¹ G-1

573 130 (Ex. 6) L-14 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 520 131 L-1 X¹ G-1 4,5-dihydro-5-(2-methoxyphenyl)-3-isoxazolyl 534 132 L-1 X¹ G-1 4,5-dihydro-5-methyl-5-(2,5-dichloro-3-thienyl)-3-isoxazolyl 592 133 L-1 X¹ G-1 4,5-dihydro-5-(2,5-dimethylphenyl)-3-isoxazolyl 532 134 L-1 X¹ G-1 4,5-dihydro-5-(4-methoxycarbonylphenyl)-3-isoxazolyl 562 135 L-1 X¹ G-1 4,5-dihydro-5-(2,6-dichlorophenyl)-3-isoxazolyl 572 136 L-1 X¹ G-1 4,5-dihydro-5-(2,4-dimethylphenyl)-3-isoxazolyl 532 137 (Ex. 1) L-1 X¹ G-1

546 138 L-1 X¹ G-1

552 139 L-1 X¹ G-1 4,5-dihydro-5,5-diphenyl-3-isoxazolyl 580 140 L-1 X¹ G-1 4,5-dihydro-5-(2-methoxyphenyl)-5-methyl-3-isoxazolyl 548 141 L-1 X¹ G-1 4,5-dihydro-5-(methoxymethyl)-5-phenyl-3-isoxazolyl 548 142 L-1 X¹ G-1 4,5-dihydro-5-(methylthiomethyl)-5-phenyl-3-isoxazolyl 564 143 L-1 X¹ G-1 4,5-dihydro-5-(methylsulfonylmethyl)-5-phenyl-3-isoxazolyl 596 144 L-1 X¹ G-1 4,5-dihydro-5-(methylsulfinylmethyl)-5-phenyl-3-isoxazolyl 580 145 L-1 X¹ G-1

531 146 L-1 X¹ G-1

622 147 L-1 X¹ G-1

574 148 L-1 X¹ G-1 4,5-dihydro-5-(3-thienyl)-3-isoxazolyl 510 149 L-1 X¹ G-1 3-methylphenyl 449 150 L-1 X¹ G-1 4-methoxyphenyl 465 151 L-1 X¹ G-1 4-methylphenyl 449 152 L-1 X¹ G-1 3-methoxyphenyl 465 153 L-1 X¹ G-1 2-methoxyphenyl 465 154 (Ex. 7) L-1 X² G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 505 155 L-1 X¹ G-1 4,5-dihydro-5-(2,4,6-trimethoxyphenyl)-3-isoxazolyl 594 156 L-1 X¹ G-1 4,5-dihydro-5-acetoxymethyl-5-phenyl-3-isoxazolyl 576 157 L-1 X¹ G-1

558 158 L-1 X¹ G-1

558 159 L-1 X¹ G-1 4,5-dihydro-5-hydroxymethyl-5-phenyl-3-isoxazolyl 534 160 L-1 X¹ G-1

515 161 L-1 X¹ G-1 4,5-dihydro-5-(2-methylphenyl)-3-isoxazolyl 518 162 L-1 X¹ G-1 4,5-dihydro-5-thien-2-yl-3-isoxazolyl 510 163 L-8 X¹ G-1 4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl 464 164 L-8 X¹ G-1

490 165 L-8 X¹ G-1

476 166 L-20 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 490 167 L-21 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 647 168 L-23 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 579 169 L-1 X¹ G-1

496 170 L-1 X¹ G-1

572 171 L-1 X¹ G-1

572 172 L-24 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 562 173 L-1 X¹ G-1

498 174 L-1 X¹ G-1

510 175 L-1 X¹ G-1

576 176 L-1 X¹ G-1

576 177 L-1 X¹ G-1

587 178 L-1 X¹ G-1 4,5-dihydro-5-(2,6-dimethylphenyl)-3-isoxazolyl 532 179 L-1 X¹ G-1 4,5-dihydro-5-(2,4,6-trimethylphenyl)-3-isoxazolyl 546 180 L-1 X¹ G-1 4,5-dihydro-5-pyridin-4-yl-3-isoxazolyl 505 181 L-1 X¹ G-1

547 182 L-1 X¹ G-1

561 183 L-1 X¹ G-1 4,5-dihydro-5-phenyl-1H-pyrazol-3-yl 503 184 L-1 X¹ G-1 4,5-dihydro-5-phenyl-(1-methyl-1H-pyrazol-3-yl) 517 185 L-1 X¹ G-1

532 186 L-1 X¹ G-1

586 187 L-1 X¹ G-1

586 188 L-1 X¹ G-1

511 189 L-1 X¹ G-1 4,5-dihydro-5-(2-bromo-phenyl)-3-isoxazolyl 582 190 L-26 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 524 191 L-1 X¹ G-1

518 192 L-1 X¹ G-1

558 193 L-1 X¹ G-1

468 194 L-1 X¹ G-1

597 195 L-1 X¹ G-1

497 196 L-1 X¹ G-1

539 197 L-1 X¹ G-1 4,5-dihydro-5-phenyl-(1-acetyl-1H-pyrazol-3-yl) 545 198 L-28 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 524 199 L-1 X¹ G-1

500 200 L-1 X¹ G-1

484 201 L-1 X¹ G-1 4,5-dihydro-5-(4-methylthiazol-5-yl)-3-isoxazolyl 525 202 L-1 X¹ G-1

566 203 L-1 X¹ G-1 3-isoxazolyl 425 204 L-1 X¹ G-1 4,5-dihydro-5-phenoxy-3-isoxazolyl 520 205 L-1 X¹ G-1 4,5-dihydro-5-methyl-5-(2-methylphenyl)-3-isoxazolyl 532 206 L-1 X¹ G-1 4,5-dihydro-5-(2,6-dimethoxyphenyl)-3-isoxazolyl 564 207 L-1 X¹ G-1

469 208 L-1 X¹ G-1

500 209 L-1 X¹ G-1

558 210 L-1 X¹ G-1 5-(2-hydroxycarbonylphenyl)-3-isoxazolyl 546 211 L-1 X¹ G-1 4,5-dihydro-5-(1,1-dimethylethoxy)-3-isoxazolyl 500 212 L-1 X¹ G-1

573 213 L-1 X¹ G-1

513 214 L-1 X¹ G-1 4,5-dihydro-5-(2,6-difluorophenyl-3-isoxazolyl 540 215 L-1 X¹ G-1

525 216 L-1 X¹ G-1

613 217 (Ex. 13) L-1 X³ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 502 218 L-1 X¹ G-1

572 219 L-1 X¹ G-1 4,5-dihydro-5-(1-methylbenzimidazol-2-yl)-3-isoxazolyl 58 220 L-1 X¹ G-1 4,5-dihydro-5-(2-cyanophenyl)-3-isoxazolyl 529 221 L-1 X¹ G-1 4,5-dihydro-5-2-methoxycarbonylphenyl)-3-isoxazolyl 562 222 L-1 X¹ G-1

573 223 L-1 X¹ G-1

555 224 L-1 X¹ G-1

523 225 L-1 X¹ G-1

561 226 L-1 X¹ G-1

541 227 L-1 X¹ G-1

601 228 L-1 X¹ G-1

615 229 L-5 X¹ G-1

598 230 L-10 X¹ G-1

564 231 L-5 X¹ G-1

584 232 L-10 X¹ G-1

550 233 L-1 X¹ G-1

559 234 L-1 X¹ G-1

540 235 L-1 X¹ G-1

568 236 L-1 X¹ G-1

609 237 L-29 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 508 238 L-30 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 508 239 L-31 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 566 240 L-32 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 562 241 L-33 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 534 242 L-1 X¹ G-1

520 243 L-1 X¹ G-1

539 244 L-1 X¹ G-1

570 245 L-1 X¹ G-1 4-fluorophenyl 453 246 L-1 X¹ G-1 4-t-butylphenyl 491 247 L-1 X¹ G-1 4-cyanophenyl 460 248 L-1 X¹ G-1 4-nitrophenyl 480 249 L-1 X¹ G-1 4-bromophenyl 513 250 L-1 X¹ G-1 4-iodophenyl 561 251 L-1 X¹ G-1

569 252 L-1 X¹ G-1

587 253 L-1 X¹ G-1

521 254 L-1 X¹ G-1

521 255 L-1 X¹ G-1

521 256 L-1 X¹ G-1

521 257 L-22 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 506 258 L-25 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 556 259 L-27 X¹ G-1 4,5-dihydro-5-phenyl-3-isoxazolyl 520 260 L-5 X¹ G-1 4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl 572 261 L-10 X¹ G-1 4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl 538 262 L-1 X¹ G-1 4,5-dihydro-5-(2-aminosulfonylbenzyl)-3-isoxazolyl 597 263 L-1 X¹ G-1 4,5-dihydro-5-(2-acetoxyphenyl)-3-isoxazolyl 562 264 L-1 X¹ G-1 4,5-dihydro-5-(N-methyl-N-phenylcarbonylamino)-3- 561 isoxazolyl 265 L-1 X¹ G-1 4,5-dihydro-5-cyano-5-phenyl-3-isoxazolyl 529 266 L-8 X¹ G-1

478 267 L-1 X¹ G-1

525 268 L-1 X¹ G-1 4-ethylphenyl 463 769 L-1 X¹ G-1 4-trifluoromethoxyphenyl 519 270 L-1 X¹ G-1 4-methoxycarbonylphenyl 493 271 L-1 X¹ G-1 4-propylphenyl 477 272 L-1 X¹ G-1 4-methylthiophenyl 481 273 L-1 X¹ G-1 4-isopropylphenyl 477 274 L-1 X¹ G-1 4-isobutylphenyl 491 275 L-1 X¹ G-1

574 276 L-5 X¹ G-1

677 277 L-8 X¹ G-1 4,5-dihydro-5-(2,4,6-trimethoxyphenyl)-3-isoxazolyl 540 278 L-1 X¹ G-1

587 279 L-1 X¹ G-1

596 280 L-1 X¹ G-1

611 281 L-1 X¹ G-1

595 282 L-1 X¹ G-1

583 283 L-1 X¹ G-1

583 284 L-8 X¹ G-1

519 [Note 1]: Faster eluting enantiomer from the CHIRALPAK ® AD-RH column using methanol in water as eluant, specific rotation = −98.8°. Analysis using analytical CHIRALPAK ® AD-RH column indicated about 100% optical purity. [Note 2]: Slower eluting enantiomer from the CHIRALPAK ® AD-RH reverse phase column using methanol in water as eluant, specific rotation = +88°. Analysis using analytical CHIRALPAK ® AD-RH column indicated about 93% optical purity. [Note 3]: Diastereomer A. [Note 4]: Diastereomer B. [Note 5]: Mixture of isomers.

Biological Examples of the Invention

General protocol for preparing test suspensions for Test A-C: The test compounds were first dissolved in acetone in an amount equal to 3% of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water (50/50 mix by volume) containing 250 ppm of the surfactant Trem® 014 (polyhydric alcohol esters). The resulting test suspensions were then used in Tests A-C. Spraying a 200 ppm test suspension to the point of run-off on the test plants was equivalent to a rate of 500 g/ha.

Test A

Grape seedlings were inoculated with a spore suspension of Plasmopara vilicola (the causal agent of grape downy mildew) and incubated in a saturated atmosphere at 20° C. for 24 h. After a short drying period, the test suspension was sprayed to the point of run-off on the grape seedlings, which were then moved to a growth chamber at 20° C. for 5 days, after which time the grape seedling were placed back into a saturated atmosphere at 20° C. for 24 h. Upon removal, visual disease ratings were made.

Test B

The test suspension was sprayed to the point of run-off on tomato seedlings. The following day the seedlings were inoculated with a spore suspension of Phytophthora infestans (the causal agent of tomato late blight) and incubated in a saturated atmosphere at 20° C. for 24 h, and then moved to a growth chamber at 20° C. for 5 days, after which time visual disease ratings were made.

Test C

Tomato seedlings were inoculated with a spore suspension of Phytophthora infestans (the causal agent of tomato late blight) and incubated in a saturated atmosphere at 20° C. for 17 h. After a short drying period, the test suspension was sprayed to the point of run-off on the tomato seedlings, which were then moved to a growth chamber at 20° C. for 4 days, after which time visual disease ratings were made.

In addition to Tests A-C, the compounds were also sprayed on 2 separate sets of tomato plants, which were inoculated with Botrytis cinerea or Alternaria solani 24 h after treatment, bluegrass plants, which were inoculated with Pythium aphanidermatum 24 h after treatment and 3 separate sets of wheat plants, which were inoculated with Erysiphe graminis f. sp. tritici, Puccinia recondita or Septoria nodorum 24 h after treatment. Test compounds did not show noticeable activity against these additional pathogens under the test conditions at the application rates tested.

Results for Tests A-C are given in Table A. In the table, a rating of 100 indicates 100% disease control and a rating of 0 indicates no disease control (relative to the controls). A dash (-) indicates no test results.

TABLE A RESULTS OF BIOLOGICAL TESTS Percent Disease Control Compound Test A Test B Test C  1 100 100 99  2 100 99 99  3** 100 100 99  4** 100 100 99  5 96 100 99  6* 95 100 99  7 0 93 59  8 100 100 99  9 99 100 99  10 97 100 99  11 99 100 99  12 52 47 0  13 0 95 86  14 25 99 99  15 100 100 98  16 99 100 99  17* 100 99 99  18* 100 100 99  19* 100 100 99  20* 96 99 99  21* 46 50 7  22* 100 100 99  23* 99 100 99  24 99 100 93  25* 100 100 99  26 76 83 33  27 100 100 98  28 99 100 94  29 99 100 99  30** 31 57 50  31** 84 83 60  32 0 26 0  33 15 9 0  34 0 40 0 * 100 100 96  36 58 57 24  37* 100 100 99  38 0 9 0  39 8 67 0  40 47 100 99  41 0 100 99  42 62 100 96  43 0 43 0  44* 100 100 99  45 30 26 0  46 0 99 53  47 0 85 47  48 0 85 0  49 0 100 96  50 0 100 99  51 99 100 99  52 85 100 67  53* 24 68 26  54 16 73 0  55 17 26 0  56 99 100 99  57 99 100 99  58 0 99 0  59* 97 100 91  60 100 95 94  61 80 77 0  62 73 73 26  63 80 100 98  64 90 99 88  65 46 100 83  66 48 63 73  67* 100 100 99  68 96 95 88  69 40 9 0  70 8 24 0  71 — 99 33  72 72 100 52  73 27 40 0  74 50 40 0  75 72 24 0  76 72 92 67  77 87 100 99  78 0 0 0  79 100 100 66  80 99 100 57  81 93 92 77  82 0 88 26  83 46 92 0  84 67 33 0  85 85 70 0  86 83 79 14  87 76 44 0  88* 99 100 99  89 49 73 0  90 66 57 0  91* 99 100 91  92* 13 33 9  93* 78 100 99  94* 99 100 99  95* 100 100 95  96* 100 100 99  97* 99 100 95  98* 77 100 99  99 31 33 0 100* 100 100 99 101* 100 100 99 102* 100 100 99 103* 100 100 99 104 100 100 99 105* 100 100 99 106* 80 85 24 107* 100 100 99 108 0 58 0 109* 100 100 98 110* 97 100 99 111* 97 100 97 112* 76 100 68 113* 99 100 99 114* 100 100 99 115* 100 100 99 116 46 100 79 117* 93 100 99 118* 0 87 16 119 0 82 0 120 99 88 0 121 83 47 0 122 99 46 0 123 95 68 0 124 8 98 26 125 31 53 0 126 100 100 99 127 73 40 0 128* 100 100 99 129* 99 100 99 130** 100 100 99 131* 100 100 99 132* 85 100 91 133* 100 100 99 134* 90 100 66 135* 100 100 99 136* 99 100 99 137* 100 100 99 138* 93 100 99 139* 87 98 87 140* 98 100 57 141* 99 100 99 142* 97 100 98 143* 99 100 99 144* 99 100 93 145 17 58 0 146 83 100 53 147* 100 100 95 148** 100 100 99 149 99 97 — 150 99 100 — 151 100 99 — 152 91 89 — 153 73 0 — 154* 90 100 99 155* 100 100 99 156* 100 100 99 157* 100 100 94 158 96 100 99 159 94 100 99 160 68 80 17 161* 100 100 99 162* 100 100 99 163** 99 100 98 164** 99 100 99 165** 99 100 99 166** 100 100 98 167 67 64 24 168** 100 100 99 169 100 100 99 170* 99 100 93 171* 99 100 98 172* 91 63 0 173* 100 100 99 174* 100 100 99 175 68 100 33 176 68 100 63 177* 93 100 99 178* 100 100 99 179* 99 100 98 180 50 100 99 181 80 100 97 182 99 100 97 183* 92 92 33 184* 99 95 73 185* 100 100 98 186* 95 100 86 187* 99 100 93 188* 99 100 99 189* 100 100 99 190 80 68 17 191 99 100 99 192* 99 100 99 193* 100 100 99 194* 94 100 99 195 48 92 80 196* 99 100 99 197* 89 100 90 198* 100 100 99 199 91 99 98 200 80 100 90 201* 99 100 99 202 95 100 98 203* 99 100 92 204* 99 100 99 205* 99 100 99 206* 99 100 99 207 40 83 0 208 79 64 0 209* 99 100 90 210 91 100 83 211* 100 100 99 212* 98 100 99 213* 94 100 98 214* 100 100 99 215* 99 100 99 216* 100 100 99 217* 95 100 99 218* 73 63 47 219 100 100 99 220 100 100 99 221 100 100 99 222 100 100 100 223 100 100 100 224 0 63 0 225 100 100 100 226 83 100 99 227 100 100 100 228 99 100 100 229** 100 100 100 230** 100 100 100 231** 100 100 100 232** 100 100 100 233* 100 100 100 234* 99 100 100 235* 99 100 100 236* 100 100 100 237* 22 47 16 238* 100 100 100 239* 14 0 0 240* 100 100 100 241* 100 100 100 242* 99 100 85 243** 99 100 100 244* 98 100 99 245* 99 74 0 246* 99 79 40 247* 99 100 88 248* 90 73 26 249* 99 64 0 250* 86 58 0 251* 99 100 99 252* 88 91 97 253* 100 100 95 254* 100 100 93 255* 95 100 93 256* 100 100 99 257* 17 0 0 258** 100 100 98 259* 100 100 99 260** 100 100 96 261** 100 100 93 262* 79 100 91 263* 99 84 83 264* 99 100 88 265** 100 100 98 266* 100 100 100 267 100 100 100 268 100 100 88 269 100 100 0 270 99 83 0 271 100 100 72 272 100 100 100 273 100 100 90 274 99 100 100 275** 99 100 98 276** 100 100 97 277* 86 100 99 278* 94 100 99 279* 100 100 99 280** 92 100 98 281** 100 100 99 282 — — — 283 — — — 284 — — — *indicates compounds tested at 40 ppm. **indicates compounds tested at 10 ppm. 

1-16. (canceled)
 17. A compound selected from Formula 1B, an N-oxide and salt thereof

wherein each R^(4a1) and R^(4a2) is independently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃ haloalkenyl, C₂-C₃ haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C₁-C₂ alkoxy, C₁-C₂ haloalkoxy, C₁-C₂ alkylthio, C₁-C₂ haloalkylthio, C₂-C₃ alkoxyalkyl, C₂-C₃ alkylcarbonyl, C₂-C₃ alkoxycarbonyl, C₂-C₃ alkylaminocarbonyl or C₃-C₄ dialkylaminocarbonyl; and Z³ is CN or C(═S)NH₂.
 18. A compound of claim 17 wherein each R^(4a1) and R^(4a2) is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl, halogen, cyano, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.
 19. A compound of claim 17 selected from the group consisting of: 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide, 1-[2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide, 1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile, and 1-[2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile. 20-23. (canceled)
 24. A compound selected from: 1-(2-chloroacetyl)-4-piperidinecarbonitrile and 1-(2-chloroacetyl)-N-(1,1-dimethylethyl)-4-piperidinecarboxamide. 